



(51) International Patent Classification:

A61P 35/00 (2006.01)

A61K 39/00 (2006.01)

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2022/077749

(22) International Filing Date:

05 October 2022 (05.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/253,106

06 October 2021 (06.10.2021)

US

63/257,901

20 October 2021 (20.10.2021)

US

(71) Applicants: GENMAB A/S [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK). BIONTECH SE [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). MSD INTERNATIONAL BUSINESS GMBH [CH/CH]; Tribschenstrasse 60, 6005 Luzern (CH).

(72) Inventors: MUIK, Alexander; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). SCHÖDEL, Kristina; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). PENICHEVA, Nora; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). JURE-KUNKEL, Maria,N.; c/o Genmab Inc, 777 Scudders Mill Road, Plainsboro, 08536 (US). SAHIN, Ugur; c/o BioNTech SE, An der Goldgrube 12, 55116 Mainz (DE).

(74) Agent: GENMAB A/S; IPR, Kalvebod Brygge 43, 1560 Copenhagen V (DK).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


(54) Title: MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTI-BODIES FOR TREATING CANCERS

Figure 1

A. PD1-mediated T cell inhibition



B. PD-L1-blockade + T cell co-stimulation



(57) Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN
COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS

Technical Field

5 The present invention relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD137 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

Background

10

CD137 (4-1BB) is a member of the TNFR family and is a co-stimulatory molecule on CD8⁺ and CD4⁺ T cells, regulatory T cells (Tregs), Natural Killer T cells (NK(T) cells), B cells and neutrophils. On T cells, CD137 is not constitutively expressed, but induced upon T-cell receptor (TCR) activation (for example, on tumor infiltrating lymphocytes (TILs) (Gros et al., J. Clin Invest 2014;124(5):2246-59)).

15 Stimulation via its natural ligand 4-1BBL or agonist antibodies leads to signaling using TRAF-2 and TRAF-1 as adaptors. Early signaling by CD137 involves K-63 poly-ubiquitination reactions that ultimately result in activation of the nuclear factor (NF)- κ B and mitogen-activated protein (MAP)-kinase pathways. Signaling leads to increased T cell co-stimulation, proliferation, cytokine production, maturation and prolonged CD8⁺ T-cell survival. Agonistic antibodies against CD137 have been shown
20 to promote anti-tumor control by T cells in various pre-clinical models (Murillo et al., Clin Cancer Res 2008;14(21):6895-906). Antibodies stimulating CD137 can induce survival and proliferation of T cells, thereby enhancing the anti-tumor immune response. Antibodies stimulating CD137 have been disclosed in the prior art, and include urelumab, a human IgG4 antibody (AU 2004279877) and utomilumab, a human IgG2 antibody (Fisher et al., 2012, Cancer Immunol. Immunother. 61: 1721-1733).

25 Programmed death ligand 1 (PD-L1, PDL1, CD274, B7H1) is a 33 kDa, single-pass type I membrane protein. Three isoforms of PD-L1 have been described, based on alternative splicing. PD-L1 belongs to the immunoglobulin (Ig) superfamily and contains one Ig-like C2-type domain and one Ig-like V-type domain. Freshly isolated T and B cells express negligible amounts of PD-L1 and a fraction (about 16%) of CD14⁺ monocytes constitutively express PD-L1. However, interferon- γ (IFN γ) is known to
30 upregulate PD-L1 on tumor cells.

PD-L1 obstructs anti-tumor immunity by 1) tolerizing tumor-reactive T cells by binding to its receptor, programmed cell death protein 1 (PD-1) (CD279) on activated T cells; 2) rendering tumor cells resistant to CD8⁺ T cell and Fas ligand-mediated lysis by PD-1 signaling through tumor cell-expressed PD-L1; 3) tolerizing T cells by reverse signaling through T cell-expressed CD80 (B7.1); and 4) promoting the
35 development and maintenance of induced T regulatory cells. PD-L1 is expressed in many human cancers, including melanoma, ovarian, lung and colon cancer (Latchman et al., 2004 Proc Natl Acad Sci USA 101, 10691-6).

PD-L1 blocking antibodies have shown clinical activity in several cancers known to overexpress PD-L1 (incl. melanoma, NSCLC). For example, atezolizumab is a humanized IgG1 monoclonal antibody against PD-L1. It is currently in clinical trials as an immunotherapy for several indications including various types of solid tumors (see e.g. Rittmeyer et al., 2017 Lancet 389:255-265) and is approved for non-small-cell lung cancer and bladder cancer indications. Avelumab, a PD-L1 antibody, (Kaufman et al Lancet Oncol. 2016;17(10):1374-1385) has been approved by the FDA for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, and is currently in clinical trials in several cancer indications, including bladder cancer, gastric cancer, head and neck cancer, mesothelioma, NSCLC, ovarian cancer and renal cancer. Durvalumab, a PD-L1 antibody, is approved for locally advanced or metastatic urothelial carcinoma indications, and is in clinical development in multiple solid tumors and blood cancers (see e.g. Massard et al., 2016 J Clin Oncol. 34(26):3119-25). Further anti-PD-L1 antibodies have been described e.g. in WO2004004771.

Horton et al (J Immunother Cancer. 2015; 3(Suppl 2): O10) discloses combination of an agonistic 4-1BB antibody with a neutralizing PD-L1 antibody. WO 2019/025545 provides binding agents, such as bispecific antibodies, binding human PD-L1 and binding human CD137.

However, despite these advances in the art there is a considerable need for improved therapies to prevent progression of a tumor or treating cancer.

Summary

The present inventors have surprisingly found that a combination of (i) stimulation with a binding agent binding human PD-L1 and binding human CD137 and (ii) an antibody binding to Programmed Death-1 (PD-1) amplifies the immune response.

Thus, in a first aspect, the present disclosure provides a binding agent for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject the binding agent prior to, simultaneously with, or after administration of an antibody binding to Programmed Death-1 (PD-1), or an antigen-binding fragment thereof, wherein the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1;

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively;

and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a

light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in:
SEQ ID NO: 16, 17, and 18, respectively,

and, wherein the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 43, 44 and 45, respectively, and a
5 light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 46, 47 and 48, respectively, or the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 65, 66 and 67, respectively.

10 In a second aspect, the present disclosure provides a kit comprising

(i) a binding agent comprising a first binding region binding to CD137 and a second binding region binding to PD-L1

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1,
15 CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively,

and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the
20 CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively,

and

(ii) an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the antibody
25 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the
30 CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

In a third aspect, the present disclosure provides a kit of the second aspect for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject.

35 In a fourth aspect, the present disclosure provides a method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject a binding agent comprising a first binding region binding to CD137 and a second binding region binding to PD-L1

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively;

5 and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively,

10 prior to, simultaneously with, or after administration of an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody comprises a heavy
15 chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

Brief description of the Figures

Fig. 1 shows a schematic representation of the anticipated mode of action of CD137xPD-L1 bispecific antibodies. (A) PD-L1 is expressed on antigen-presenting cells (APCs) as well as on tumor cells. PD-L1 binding to T cells expressing the negative regulatory molecule PD-1 effectively overrides T cell activation signals and eventually leads to T cell inhibition. (B) Upon addition of a CD137xPD-L1 bispecific antibody, the inhibitory PD-1:PD-L1 interaction is blocked via the PD-L1-specific arm and at the same time, the bispecific antibody, through the cell-cell interaction provides agonistic signaling to CD137 expressed on the T cells resulting in strong T cell costimulation.

Fig. 2 shows IL-2 production induced by GEN1046 in combination with pembrolizumab in a MLR assay of LPS-matured mDCs and purified CD8⁺ T-cells. Purified CD8⁺ T cells were co-cultured with allogeneic mDCs for 5 days in the presence of GEN1046 (0.001 - 30 µg/mL), pembrolizumab (0.01 - 100 µg/mL) either alone or in combination, control antibodies, or in the absence of any antibodies (No Tx). IL-2 secretion was analyzed by Luminex. Data shown are mean IL-2 ± SD of duplicate wells. Each individual graph represents one of three donor pairs.

Fig. 3 shows IFN γ production induced by GEN1046 in combination with pembrolizumab in a mixed lymphocyte reaction (MLR) of LPS-matured dendritic cells (mDCs) and purified CD8⁺ T cells. Purified CD8⁺ T cells were co-cultured with allogeneic mDCs for 5 days in the presence of GEN1046 (0.001 - 30 µg/mL), pembrolizumab (0.01 - 100 µg/mL) either alone or in combination, control antibodies, or in the absence of any antibodies (No Tx). IFN γ secretion was analysed by ELISA. Data shown are mean IFN γ ± standard deviation (SD) of duplicate wells. Each individual graph represents one of three DC/T-cell donor pairs.

Fig. 4 shows TNF α production induced by GEN1046 in combination with pembrolizumab in a MLR assay of LPS-matured mDCs and purified CD8⁺ T-cells. Purified CD8⁺ T cells were co-cultured with allogeneic mDCs for 5 days in the presence of GEN1046 (0.001 - 30 µg/mL), pembrolizumab (0.01 - 100 µg/mL) either alone or in combination, control antibodies, or in the absence of any antibodies (No Tx). TNF α secretion was analysed by Luminex. Data shown are mean TNF α ± SD of duplicate wells. Each individual graph represents one of three donor pairs.

Fig. 5 shows the MC38 syngeneic tumor model that was established by subcutaneous inoculation of 1 × 10⁶ MC38 cells into C57BL/6 mice. When tumors reached an average volume of 64 mm³, mice were randomized and treated with mbsIgG2a-PD-L1 $\times$ 4-1BB (5 mg/kg), an anti-mouse PD-1 antibody (anti-mPD-1; 10 mg/kg), either alone or in combination, or PBS (all 2QW $\times$ 3). A. Data shown are the median tumor volume per treatment group (n=10) with data carried forward for animals that reached termination criteria. Growth curves were discontinued when <50% of the animals within a treatment group remained

alive (PBS, mbsIgG2a-PD-L1x4-1BB, anti-mPD-1) or until Day 35 (combination of mbsIgG2a-PD-L1x4-1BB with anti-mPD-1). Arrows indicate days of treatment. B. Progression-free survival, defined as the percentage of mice with tumor volume smaller than 500 mm³, is shown as Kaplan Meier curve. Mantel Cox analysis was used to compare survival between treatment groups on Day 45 (Table Y).

5

Fig. 6 shows analysis of the proliferation dose-response of GEN1046 (DuoBody-PD-L1x4-1BB) and anti-PD-1 antibody Pembrolizumab in an antigen-specific T cell assay with active PD1/PD-L1 axis. Carboxyfluorescein succinimidyl ester (CFSE)-labeled T cells electroporated with a claudin-6-specific T-cell receptor (TCR)- and PD-1- in vitro translated (IVT)-RNA were incubated with claudin-6-IVT-RNA-electroporated immature dendritic cells in the presence of **(A)** GEN1046 (at 3-fold serial dilutions from 1 to 0.00015 µg/mL) or **(B)** Pembrolizumab (at 4-fold serial dilutions from 0.8 to 0.00005 µg/mL) for five days. CD8⁺ T cell proliferation was measured by flow cytometry. Data shown are expansion indices calculated using FlowJo software v10.7.1 as a function of the antibody concentration. Error bars (SD) indicate variation within the experiment (n=3 replicates in (A); n=2 duplicates in (B), using cells from one representative donor). Curves were fitted by 4-parameter logarithmic fit and EC₅₀ values and Hill-Slopes (shown in Table 1 and 2) were determined using GraphPad Prism software v9.0.

10

15

Fig. 7 shows release of the PD-1/PD-L1-mediated T cell inhibition and additional co-stimulation of CD8⁺ T cell proliferation by GEN1046 in the absence or presence of anti-PD-1 antibody Pembrolizumab. CFSE-labelled T cells electroporated with a claudin-6-specific TCR- and PD-1-in vitro translated (IVT)-RNA were incubated with claudin-6-IVT-RNA-electroporated immature dendritic cells in the presence of 0.2 µg/mL, 0.0067 µg/mL or 0.0022 µg/mL GEN1046 in combination with a fixed concentration of 0.8 µg/mL Pembrolizumab or isotype control antibody IgG1-ctrl or five days (n=2 technical replicates per condition, using cells from n=3 individual donors). Medium only, 0.8 µg/mL IgG1-ctrl only and 0.8 µg/mL Pembrolizumab only were used to determine baseline proliferation in the absence of GEN1046. CD8⁺ T cell proliferation was measured by flow cytometry. Bar graphs represent the mean±SD of expansion indices per indicated condition calculated using FlowJo software v10.7.1. The dashed line represents baseline proliferation in the presence of the anti-PD-1 antibody Pembrolizumab.

25

30

Fig. 8 is a schematic representation of a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors.

Fig. 9 is a waterfall plot showing progression-free survival in subjects having received prior therapy with a checkpoint inhibitor (gray line) and checkpoint inhibitor naive patients (black line).

35

Fig. 10 compares time since last prior anti-PD-(L)1 in subjects across CPI-experienced expansion cohorts (GEN1046 monotherapy) with clinical response (PR), compared to those with stable disease

(SD) or progressive disease (PD). Response groups were compared using a Wilcoxon test. PR vs. PD: $p=0.0017$; PR vs. SD: $p=0.034$.

Fig. 11 shows predicted partial response (PR) and complete (CR) rates for GEN1046 given as 100 mg Q3W or Q6W in combination with Pembrolizumab in an integrated quantitative systems pharmacology (QSP) model.

Fig. 12 shows characterization of the exhausted phenotype of $CD3^+$ T cells after two rounds of CD3/CD28 stimulation. (A) *In vitro* exhausted $CD3^+$ T cells or naïve T cells were stimulated with CD3/CD28 beads. Secretion of IFN γ was analyzed by ELISA. Data shown are mean + standard deviation (SD) of duplicate wells of one representative donor pair. (B) Expression of TIM3, LAG3, PD-1 and 4-1BB on naïve and *in vitro* exhausted $CD3^+$ T cells was determined by flow cytometry. Data shown are the median fluorescence intensity corrected for background fluorescence (Δ MFI). (C) Expression of Ki67 on naïve and *in vitro* exhausted $CD3^+$ T cells was determined by flow cytometry.

Fig. 13 shows secretion of IFN γ induced by GEN1046 in combination with pembrolizumab in a mixed lymphocyte reaction (MLR) of mature dendritic cells (mDCs) and *in vitro* exhausted $CD3^+$ T cells (Tex). Tex were co-cultured with allogeneic LPS-matured DCs (at a DC:T cell ratio of 1:4) in the presence of GEN1046 (0.001 - 30 μ g/mL) or pembrolizumab (1 μ g/mL) alone or in combination for 5 days. Co-cultures without antibody treatment (w/o antibody) or treated with bsIgG1-PD-L1 $\times$ ctrl (30 μ g/mL), bsIgG1-ctrl $\times$ 4-1BB (30 μ g/mL), IgG4 isotype control (1 μ g/mL) or IgG1-ctrl-FEAL (30 μ g/mL) were included as controls. Secretion of IFN γ was analyzed by ELISA. Data shown are mean + standard deviation (SD) of duplicate wells of one representative donor pair out of four donor pairs tested.

Fig 14 shows the Highest single agent (HSA) synergy scores for the combination of GEN1046 with pembrolizumab in a MLR of mDCs and Tex. Tex were co-cultured with allogeneic LPS-matured DCs (at a DC:T cell ratio of 1:4) in the presence of GEN1046 (0.001 - 30 μ g/mL) or pembrolizumab (1 μ g/mL) alone or in combination for 5 days. Data shown are HSA synergy scores of one representative donor pair out of four donor pairs tested (same donor as shown in Figure 13). Scores >10 are indicative of synergy in this model.

Fig. 15 shows the MC38 colon cancer model that was established by SC inoculation of 1×10^6 MC38 cells into C57BL/6 mice. When tumors reached an average volume of 60 mm³, mice were randomized and treated with the indicated antibodies or combinations thereof (all 2QW $\times$ 3). A. Data shown are the median tumor volume per treatment group (n=10) with data carried forward for animals that reached termination criteria. Growth curves were discontinued when $<50\%$ of the animals within a treatment group remained alive (mIgG2a-ctrl-AAKR, mbsIgG2a-PD-L1 $\times$ 4-1BB, anti-mouse PD-1 antibody [anti-

mPD-1]) or until Day 60 (combination of mbsIgG2a-PD-L1×4-1BB with anti-mPD-1). Downward facing triangles indicate days of treatment. B. Progression-free survival, defined as the percentage of mice with tumor volume smaller than 500 mm³, is shown as Kaplan Meier curve. Mantel Cox analysis was used to compare survival between treatment groups on Day 69 (Table 19).

5

Fig. 16 shows the (re)challenge of mice with complete tumor regression upon treatment and a control group of tumor-naïve mice. Mice were (re)challenged with 1×10^6 MC38 tumor cells that were SC injected on Day 121 after the treatment with antibodies was initiated. Data shown are mean tumor volumes $\pm$ SEM.

10

Fig. 17 shows quantitative IHC and ISH data on cellular immune and tumor markers expressed in resected tumor tissues from the MC38 colon cancer model. C57BL/6 mice were inoculated with 1×10^6 MC38 cells. When tumors reached an average volume of 50-70 mm³, mice were randomized and treated with mbsIgG2a-PD-L1×4-1BB, anti-mPD-1 or the combination thereof. Tumors were resected on Day 7 (n=5 per treatment group) or Day 14 (n=5 per treatment group) after treatment initiation. Some of the resected tumor samples were too small to perform IHC analysis, resulting in analysis of 4-5 tumors per treatment group. Sections of resected tumors (4 μ m) were stained using anti-CD3, anti-CD4, anti-CD8 or anti-PD-L1 antibodies by immunohistochemistry (IHC), or were stained for 4-1BB or PD-L2 by in situ hybridization (ISH). Data from IHC are depicted as % marker positive cells of the total cells counted in the slide as well as mean $\pm$ SEM per treatment group. Data from ISH are depicted as RNAscope H-score per slide as well as mean $\pm$ SEM per treatment group.

15

20

25

Fig. 18 shows GzmB and Ki67 expression in CD8 T-cell subsets from dissociated tumor tissue from the MC38 colon cancer model. C57BL/6 mice were inoculated with 1×10^6 MC38 cells. When tumors reached an average volume of 50-70 mm³, mice were randomized and treated with mbsIgG2a-PD-L1×4-1BB, anti-mPD-1 or the combination thereof. Tumors were resected on Day 7 (n=5 per treatment group) after treatment initiation, dissociated to single cells suspensions and analyzed by flow cytometry. Data shown are the percentage of GzmB⁺ (A) or Ki67⁺ cells (B) within the CD8⁺ T-cell population of individual mice and the mean $\pm$ SEM per treatment group. Mann-Whitney statistical analysis was performed to compare the percentage of GzmB⁺ or Ki67⁺ cells within the CD8⁺ T-cell population between treatment groups, with * p < 0.05 and **p < 0.01.

30

35

Fig. 19 shows the cytokine levels in peripheral blood of MC38-tumor bearing C57BL/6 mice treated with mbsIgG2a-PD-L1×4-1BB, an anti-mPD-1 antibody either as single agents or in combination, or nonbinding control antibody IgG2a-ctrl-AAKR. Peripheral blood samples were taken at baseline (one day before treatment [Day -1], dotted line) and two days after each treatment (Day 2 and Day 5). Cytokine analysis was performed by ECLIA.

Table 1 – Sequences: Bold and underlined are F; E; A; L and R, corresponding with positions 234 and 235; 265; 405 and 409, respectively, said positions being in accordance with EU-numbering. IN SEQ ID Nos.: 63 and 64 bold amino acids represent the –AAKR or –AALT mutations required for

5 controlled Fab-arm exchange. In variable regions, said CDR regions that were annotated in accordance with IMGT definitions (unless otherwise stated or contradicted by context), are underlined.

SEQ ID	NAME	SEQUENCE	Organism
1	VH_CD137-009-H7	EVQLVESGGGLVQPGRSLRLSCTASGFSLN <u>NDYW</u> MSWVRQAPGKGLEWVG <u>YIDVGGSL</u> YYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYC <u>ARGGLTYGFDL</u> WGQGTTLTVSS	synthetic construct
2	VH_CD137-009-H7_CDR1	GFSLN <u>DYW</u>	synthetic construct
3	VH_CD137-009-H7_CDR2	IDVGG <u>SL</u>	synthetic construct
4	VH_CD137-009-H7_CDR3	ARGGLTYGFDL	synthetic construct
5	VL_CD137-009-L2	DIVMTQSPSSLSASVGDRTITCQASE <u>DISSYLAWYQ</u> QKPGKAPKRLIYG <u>ASDL</u> ASGVPSRFSASGSGTDYFTFTISSLQPEDATYYCHYYATISGLGVA <u>FGGGTKVEIK</u>	synthetic construct
6	VL_CD137-009-L2_CDR1	EDISS <u>Y</u>	synthetic construct
7	VL_CD137-009-L2_CDR2	GAS	synthetic construct
8	VL_CD137-009-L2_CDR3	HYYATISGLGVA	synthetic construct
9	VH_CD137-009	QSLEESGGRLVTPGTPLTCTVSGFSLN <u>DYW</u> MSWVRQAPGKGLEWIG <u>YIDVGGSL</u> YYASWAKGRFTISRSTTVDLKMTSLTTEDTATYFC <u>ARGGLTYGFDL</u> WGPGTLTVSS	synthetic construct
10	VL_CD137-009	DIVMTQTPASVSEPVGGTVTINCQASEDISSYLAWYQKPGQRPKRLIYGASDLASGVPSRFSASGSGTEYALTISDLESADAATYYCHYYATISGLGVA <u>FGGGTEVVV</u> K	synthetic construct
11	VH-PD-L1-547	EVQLLEPGGGLVQPGGSLRLSCEAS <u>GSTFSTYAMS</u> WVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTISRDSKNTLFLQMSSLRAEDTAVYYCA <u>AIPARGYNYG</u> SFQHWGQGTTLTVSS	synthetic construct
12	VH- PD-L1-547-CDR1	GSTFSTYA	synthetic construct
13	VH- PD-L1-547-CDR2	FSGSGGFT	synthetic construct
14	VH- PD-L1-547-CDR3	AIPARGYNYGSFQH	synthetic construct
15	VL- PD-L1-547	SYVLTQPPSVSVAPGQTARITCGGNN <u>IGSKSVHWY</u> QKPGQAPVLV <u>VYDDN</u> DRPSGLPERFSGSNSGNTATLTISRVEAGDEADYYC <u>QVWDSSDHVV</u> FGGGTKLTVL	synthetic construct

16	VL- PD-L1-547-CDR1	NIGSKS	synthetic construct
17	VL- PD-L1-547-CDR2	DDN	synthetic construct
18	VL- PD-L1-547-CDR3	QVWDSSSDHVV	synthetic construct
19	IgG1-Fc	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK	synthetic construct
20	IgG1-Fc_F405L	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK	synthetic construct
21	IgG1-Fc_K409R	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK	synthetic construct
22	IgG1-Fc_FEA	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHTC PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVV VAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK	synthetic construct
23	IgG1-FEAR-Fc	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHTC PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVV VAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE	synthetic construct

		KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK	
24	IgG1-FEAL-Fc	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVKPKCDKTHTC PPCPAPEFE ~~EG~~ GPSVFLFPPKPKDTLMISRTPEVTCVV VAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK	synthetic construct
25	IgG1-Fc without C-terminal Lysine	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVKPKCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPG	synthetic construct
26	IgG1-Fc_F405L without C-terminal Lysine	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVKPKCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPG	synthetic construct
27	IgG1-Fc_K409R without C-terminal Lysine	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVKPKCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPG	synthetic construct
28	IgG1-Fc_FEA without C-terminal Lysine	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVKPKCDKTHTC PPCPAPEFE ~~EG~~ GPSVFLFPPKPKDTLMISRTPEVTCVV VAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF	synthetic construct

		LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQK SLSLSPG	
29	IgG1-FEAR-Fc without C-terminal Lysine	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHC PPCPAPEFE ~~EG~~ GPSVFLFPPKPKDTLMISRTPEVTCVV VAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFF LYSRLTVDKSRWQQGNVFSCSV MHEALHNHYTQK SLSLSPG	synthetic construct
30	IgG1-FEAL-Fc without C-terminal Lysine	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHC PPCPAPEFE ~~EG~~ GPSVFLFPPKPKDTLMISRTPEVTCVV VAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFL LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQK SLSLSPG	synthetic construct
31	CD137-009 heavy chain	EVQLVESGGGLVQPGRSLRLSCTASGFSNDYWMMS WVRQAPGKGLEWVGIDVGGSLYYAASVKGRFTIS RDDSISAIYLMNSLKTEDTAVYYCARGGLTYGFDL WGQGT ~~LV~~ TVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVT ~~TV~~ SWNSGALTSGVHTFPAVLQSS GLYSLSSVTVPS ~~SSL~~ GTQTYICNVNHKPSNTKVDKR VEPKSCDKTHC ~~PP~~ CPAPEFE ~~EG~~ GPSVFLFPPKPKDTL MISRTPEVTCVVAVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPG	synthetic construct
32	CD137-009 light chain	DIVMTQSPSSLSASVGRVTITCQASEDISSYLAWYQ QKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYFT ISLQPED ~~IAT~~ YYCHYYATISGLGVAFGGGTKEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV QWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLS KADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC	synthetic construct
33	PD-L1-547 heavy chain	EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMS WVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTI SRDSSKNTLFLQMSSLRAED TAVYYCAIPARGYNYGSFQHWGQGT ~~LV~~ TVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS ~~SSL~~ GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHC ~~PP~~ C PAPEFE ~~EG~~ GPSVFLFPPKPKDTLMISRTPEVTCVVAV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP	synthetic construct

		SDIAVEWESNGQPENNYKTTTPVLSDSGSFLLYSKL TVDKSRWQQGNVFSQVMHEALHNHYTQKSLSLS PG	
34	PD-L1-547 light chain	SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWY QQKPGQAPVLVYDDNDRPSGLPERFSGSNSGNTA TLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKL TVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYP GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASS YLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	synthetic construct
35	Kappa-C	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA KVQWKVDNALQSGNSQESVTEQDSKSTYLSSTL TLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	synthetic construct
36	Lambda-C	GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLS LTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	synthetic construct
37	Human CD137 (UniProtKB - Q07011; incl. signal peptide sequence: aa 1-23)	MGNSCYNIVALLVLNFERTRSLQDPCSNCPAGTFC DNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVF RTRKECSSTSNAECDCTPGFHC LGAGCSMCEQDCK QGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLD GKSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPA REPGHSPQIISFFLALTSTALLFLLFLLTLRFSVVKRGR KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC EL	Homo sapiens
38	Human CD137 (UniProtKB - Q07011; mature sequence)	LQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGG QRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHC LGAGCSMCEQDCKQGQELTKKGCKDCCFGTFNDQ KRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPA DLSPGASSVTPPAPAREPGHSPQIISFFLALTSTALLFL LFFLLTLRFSVVKRGRKKLLYIFKQPFMRPVQTTQEED GCSCRFPEEEEGGCEL	Homo sapiens
39	Human PD-L1 (UniProtKB - Q9NZQ7; incl. signal peptide sequence: aa 1-18)	MRIFAVFIFMTYWHLNAFTVTPKDLVVEYGSN MTIECFPVEKQLDLAALIVYWEMEDKNIIQFVHGEE DLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQD AGVYRCMISYGGADYKRITVKVNAPYNKINQRILVV DPVTSEHELTCAEGYPKAEVIWTSSDHQVLSGKTT TTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEE NHTAELVPELPLAHPNERTHLVILGAILLCLGVALT FIFRLRKGRMMDVKKCGIQDTSKKQSDTHLEET	Homo sapiens
40	Human PD-L1 (UniProtKB - Q9NZQ7; mature sequence)	FTVTPKDLVVEYGSNMTIECKFPVEKQLDLAALIV YWEMEDKNIIQFVHGEE DLKVQHSSYRQRARLLKD QLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRI TVKVNAPYNKINQRILVDPVTSEHELTCAEGYPK AEVIWTSSDHQVLSGKTTTNSKREEKLFNVTSTLR INTTTNEIFYCTFRRLDPEENHTAELVPELPLAHPNE RTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGI QDTSKKQSDTHLEET	Homo sapiens
41	Human PD-1	MQIPQAPWPVWVAVLQLGWRPGWFLDSPDRPW NPPTFSPALLVTEGDNATFTCSFSNTSESVLNWY RMSPSNQTDKLAAPEDRSQPGQDCFRVTQLPN GRDFHMSVVRARRNDSGTLYCGAISLAPKAQIKESL RAELRVTERRAEVPTAHPSPSPRAGQFQTLVVGVV GGLLGSLLVWVLAIVCSRAARGTIGARRTGQPLK	Homo sapiens

			EDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQ TEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPED GHCSWPL	
42	CTLA-4		MACLGFRHKAQLNLATRTWPCTLLFFLLFIPVFCK AMHVAQPAVVLASSRGIAFVCEYASPGKATEVRVT VLRQADSQVTEVCAATYMMGNELTFLDDSICTGTS SGNQVNLTIQGLRAMDTGLYICKVELMYPPPYLGI GNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFLL TAVSLSKMLKKRSPLTGTVYVKMPPEPECEKQFQP YFIPIN	Homo sapiens
43	Pembrolizumab CDR1	VH	GYTFTNYY	synthetic construct
44	Pembrolizumab CDR2	VH	INPSNGGT	synthetic construct
45	Pembrolizumab CDR3	VH	ARRDYRFDMGFDY	synthetic construct
46	Pembrolizumab CDR1	VL	KGVSTSGYSY	synthetic construct
47	Pembrolizumab CDR2	VL	LAS	synthetic construct
48	Pembrolizumab CDR3	VL	QHSRDLPLT	synthetic construct
49	Pembrolizumab VH		QVQLVQSGVEVKKPGASVKVSCASGYTFTNYYMY WVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRV TLTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFD MGFDYWGQGTTTVTVSS	synthetic construct
50	Pembrolizumab VL		EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLH WYQQKPGQAPRLLIYLAYLESGVPAFSGSGSGTD FTLTISSELPEDFAVYYCQHSRDLPLTFGGGKVEIK	synthetic construct
51	Pembrolizumab Heavy chain	Heavy	QVQLVQSGVEVKKPGASVKVSCASGYTFTNYYMY WVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRV TLTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFD MGFDYWGQGTTTVTVSSASTKGPSVFPLAPCSRSTS ESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVTVPSSSLGKTYTCNVDPKPSNT KVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKD TLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKGLPSSIEKISKAKGQPREPQVYTLPPSQEE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLGLK	synthetic construct
52	Pembrolizumab Light chain	Light	EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLH WYQQKPGQAPRLLIYLAYLESGVPAFSGSGSGTD FTLTISSELPEDFAVYYCQHSRDLPLTFGGGKVEIKR TVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLT SKADYEKHKVYACEVTHQGLSPVTKSFNRGEC	synthetic construct
53	VH_ IgG1-b12		QVQLVQSGAEVKKPGASVKVSCQASGYRFSNFVIH WVRQAPGQRFWMGWINPYNGNKEFSAKFQDR	synthetic construct

		VTFTADTSANTAYMELRSLRSADTAVYYC <u>ARVGPYS</u> <u>WDDSPQDNYYMDVWGKGTIVVSS</u>	
54	VL_IgG1-b12	EIVLTQSPGTLSPGERATFSCRSSH <u>HSIRRR</u> VAWY QHKGPGQAPRLVIHGVSNRASGISDRFSGSGSGTDFT LTITRVEPEDFALYYCQVYGASSYTFGQGTKLERK	synthetic construct
55	m4-1BB-3H3 VH	EMQLVESGGGLVQPGRSMKLSCAGSGFTLSDYGVVA WVRQAPKKGLEWVAYISYAGGTTYRESVKGRFTIS RDNAKSTLYLQMDSLRSEDATYYCTIDYGGYSGS <u>HWYFDFWGP</u> MTMTVSS	synthetic construct
56	m4-1BB-3H3 VL	DIQMTQSPSLLSASVGDRTVLTNCRSTQNVYKNLAW YQQKLGEAPKLLIYNANSLQAGIPSRFSGSGSGTDFT LTISSLQPEDVATYFCQQYYSGNTFGAGTNLELK	synthetic construct
57	AALT	AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPV TLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCK CPAPNAAGGPSVFIFPPKIKDVLMISSPMVTCVVV DVSEDDPDVQISWVFNNEVLTAQTQTHREDYNST LRVVSALPIQHQQDWMSGKEFKCKVNNKALPAPIER TISKPKGVRAPQVYVLPPEEEMTKKQVTLTCMVT DFMPEDIYVEWTNNGKTELNYKNTEPVLDSGSYL MYSKLTVEKKNWVERNSYSCSVVHEGLHNHHTTKS FSRTPGK	synthetic construct
58	AAKR	AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPV TLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCK CPAPNAAGGPSVFIFPPKIKDVLMISSPMVTCVVV DVSEDDPDVQISWVFNNEVLTAQTQTHREDYNST LRVVSALPIQHQQDWMSGKEFKCKVNNKALPAPIER TISKPKGVRAPQVYVLPPEEEMTKKQVTLTCMVK DFMPEDIYVEWTNNGKTELNYKNTEPVLDSGSYF MYSRLRVEKKNWVERNSYSCSVVHEGLHNHHTTKS FSRTPGK	synthetic construct
59	constant region mouse kappa LC	RADAAPTVISFPPSSEQLTSGGASVVCFLNNFYPKDI NVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSST LTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC	synthetic construct
60	MPDL3280A VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIH WYRQAPGKGLEWYAWISPYGGSTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGG <u>FDYWGQGT</u> LTVSS	synthetic construct
61	MPDL3280A VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK	synthetic construct
62	Pembrolizumab VH (Kabat numbering)	NYYMY	synthetic construct
63	Pembrolizumab VH (Kabat numbering)	GINPSNGGTNFNEKFKN	synthetic construct
64	Pembrolizumab VH (Kabat numbering)	RDYRFDMGFDY	synthetic construct
65	Pembrolizumab VL (Kabat numbering)	RASKGVSTSGYSYLH	synthetic construct

66	Pembrolizumab CDR2 (Kabat numbering)	VL	LASYLES	synthetic construct
67	Pembrolizumab CDR3 (Kabat numbering)	VL	QHSRDLPLT	synthetic construct

Detailed Description of the Invention

Although the present disclosure is further described in more detail below, it is to be understood that this disclosure is not limited to the particular methodologies, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present disclosure which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

In the following, the elements of the present disclosure will be described in more detail. These elements are listed with specific embodiments, however, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The variously described examples and preferred embodiments should not be construed to limit the present disclosure to only the explicitly described embodiments. This description should be understood to support and encompass embodiments which combine the explicitly described embodiments with any number of the disclosed and/or preferred elements. Furthermore, any permutations and combinations of all described elements in this application should be considered disclosed by the description of the present application unless the context indicates otherwise. For example, if in a preferred embodiment of the binding agent used herein the first heavy chain comprises or consists essentially of or consists of an amino acid sequence set forth in SEQ ID NO: 23 or 29 [IgG1-Fc_FEAR] and in another preferred embodiment of the binding agent used herein the second heavy chain comprises or consists essentially of or consists of an amino acid sequence set forth in SEQ ID NO: 24 or 30 [IgG1-Fc_FEAL], then in a further preferred embodiment of the binding agent used herein the first heavy chain comprises or consists essentially of or consists of an amino acid sequence set forth in SEQ ID NO: 23 or 29 [IgG1-Fc_FEAR] and the second heavy chain comprises or consists essentially of or consists of an amino acid sequence set forth in SEQ ID NO: 24 or 30 [IgG1-Fc_FEAL].

Preferably, the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H. Kölbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995).

The practice of the present disclosure will employ, unless otherwise indicated, conventional chemistry, biochemistry, cell biology, immunology, and recombinant DNA techniques which are explained in the

literature in the field (cf., e.g., Organikum, Deutscher Verlag der Wissenschaften, Berlin 1990; Streitwieser/Heathcock, "Organische Chemie", VCH, 1990; Beyer/Walter, "Lehrbuch der Organischen Chemie", S. Hirzel Verlag Stuttgart, 1988; Carey/Sundberg, "Organische Chemie", VCH, 1995; March, "Advanced Organic Chemistry", John Wiley & Sons, 1985; Römpp Chemie Lexikon, Falbe/Regitz (Hrsg.), Georg Thieme Verlag Stuttgart, New York, 1989; Molecular Cloning: A Laboratory Manual, 2nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989.

All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by the context. The use of any and all examples, or exemplary language (e.g., "such as"), provided herein is intended merely to better illustrate the present disclosure and does not pose a limitation on the scope of the present disclosure otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the present disclosure.

Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether *supra* or *infra*, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Definitions

In the following, definitions will be provided which apply to all aspects of the present disclosure. The following terms have the following meanings unless otherwise indicated. Any undefined terms have their art recognized meanings.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated member, integer or step or group of members, integers or steps but not the exclusion of any other member, integer or step or group of members, integers or steps. The term "consisting essentially of" means excluding other members, integers or steps of any essential significance. The term "comprising" encompasses the term "consisting essentially of" which, in turn, encompasses the term "consisting of". Thus, at each occurrence in the present application, the term "comprising" may be

replaced with the term "consisting essentially of" or "consisting of". Likewise, at each occurrence in the present application, the term "consisting essentially of" may be replaced with the term "consisting of".

The terms "a", "an" and "the" and similar references used in the context of describing the present disclosure (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context.

Where used herein, "and/or" is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example, "X and/or Y" is to be taken as specific disclosure of each of (i) X, (ii) Y, and (iii) X and Y, just as if each is set out individually herein.

In the context of the present disclosure, the term "about" denotes an interval of accuracy that the person of ordinary skill will understand to still ensure the technical effect of the feature in question. The term typically indicates deviation from the indicated numerical value by $\pm 5\%$, $\pm 4\%$, $\pm 3\%$, $\pm 2\%$, $\pm 1\%$, $\pm 0.9\%$, $\pm 0.8\%$, $\pm 0.7\%$, $\pm 0.6\%$, $\pm 0.5\%$, $\pm 0.4\%$, $\pm 0.3\%$, $\pm 0.2\%$, $\pm 0.1\%$, $\pm 0.05\%$, and for example $\pm 0.01\%$. As will be appreciated by the person of ordinary skill, the specific such deviation for a numerical value for a given technical effect will depend on the nature of the technical effect. For example, a natural or biological technical effect may generally have a larger such deviation than one for a man-made or engineering technical effect.

The term "binding agent" in the context of the present disclosure refers to any agent capable of binding to desired antigens. In certain embodiments of the present disclosure, the binding agent is an antibody, antibody fragment, or construct thereof. The binding agent may also comprise synthetic, modified or non-naturally occurring moieties, in particular non-peptide moieties. Such moieties may, for example, link desired antigen-binding functionalities or regions such as antibodies or antibody fragments. In one embodiment, the binding agent is a synthetic construct comprising antigen-binding CDRs or variable regions.

As used herein, "immune checkpoint" refers to regulators of the immune system, and, in particular, co-stimulatory and inhibitory signals that regulate the amplitude and quality of T cell receptor recognition of an antigen. In certain embodiments, the immune checkpoint is an inhibitory signal. In certain embodiments, the inhibitory signal is the interaction between PD-1 and PD-L1 and/or PD-L2. In certain embodiments, the inhibitory signal is the interaction between CTLA-4 and CD80 or CD86 to displace CD28 binding. In certain embodiments the inhibitory signal is the interaction between LAG-3 and MHC class II molecules. In certain embodiments, the inhibitory signal is the interaction between TIM-3 and one or more of its ligands, such as galectin 9, PtdSer, HMGB1 and CEACAM1. In certain embodiments, the inhibitory signal is the interaction between one or several KIRs and their ligands. In certain

embodiments, the inhibitory signal is the interaction between TIGIT and one or more of its ligands, PVR, PVRL2 and PVRL3. In certain embodiments, the inhibitory signal is the interaction between CD94/NKG2A and HLA-E. In certain embodiments, the inhibitory signal is the interaction between VISTA and its binding partner(s). In certain embodiments, the inhibitory signal is the interaction between one or more Siglecs and their ligands. In certain embodiments, the inhibitory signal is the interaction between GARP and one or more of its ligands. In certain embodiments, the inhibitory signal is the interaction between CD47 and SIRP α . In certain embodiments, the inhibitory signal is the interaction between PVRL1 and PVRL2. In certain embodiments, the inhibitory signal is the interaction between CSF1R and CSF1. In certain embodiments, the inhibitory signal is the interaction between BTLA and HVEM. In certain embodiments, the inhibitory signal is part of the adenosinergic pathway, e.g., the interaction between A2AR and/or A2BR and adenosine, produced by CD39 and CD73. In certain embodiments, the inhibitory signal is the interaction between B7-H3 and its receptor and/or B7-H4 and its receptor. In certain embodiments, the inhibitory signal is mediated by IDO, CD20, NOX or TDO.

The terms "checkpoint inhibitor" (CPI) and "immune checkpoint (ICP) inhibitor" are used herein synonymously. The terms refer to molecules, such as binding agents, which totally or partially reduce, inhibit, interfere with or negatively modulate one or more checkpoint proteins or that totally or partially reduce, inhibit, interfere with or negatively modulate expression of one or more checkpoint proteins, like molecules, such as binding agents, which inhibit an immune checkpoint, in particular, which inhibit the inhibitory signal of an immune checkpoint. In one embodiment, the immune checkpoint inhibitor binds to one or more checkpoint proteins. In one embodiment, the immune checkpoint inhibitor binds to one or more molecules regulating checkpoint proteins. In one embodiment, the immune checkpoint inhibitor binds to precursors of one or more checkpoint proteins e.g., on DNA- or RNA-level. Any agent that functions as a checkpoint inhibitor according to the present disclosure can be used. The term "partially" as used herein means at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% in the level, e.g., in the level of inhibition of a checkpoint protein.

In one embodiment, the checkpoint inhibitor can be any compound, such as any binding agent, which inhibits the inhibitory signal of an immune checkpoint, wherein the inhibitory signal is selected from the group consisting of: the interaction between PD-1 and PD-L1 and/or PD-L2; the interaction between CTLA-4 and CD80 or CD86 to displace CD28 binding; the interaction between LAG-3 and MHC class II molecules; the interaction between TIM-3 and one or more of its ligands, such as galectin 9, PtdSer, HMGB1 and CEACAM1; the interaction between one or several KIRs and their ligands; the interaction between TIGIT and one or more of its ligands, PVR, PVRL2 and PVRL3; the interaction between CD94/NKG2A and HLA-E; the interaction between VISTA and its binding partner(s); the interaction

between one or more Siglecs and their ligands; the interaction between GARP and one or more of its ligands; the interaction between CD47 and SIRP α ; the interaction between PVRIG and PVRL2; the interaction between CSF1R and CSF1; the interaction between BTLA and HVEM; part of the adenosinergic pathway, e.g., the interaction between A2AR and/or A2BR and adenosine, produced by CD39 and CD73; the interaction between B7-H3 and its receptor and/or B7-H4 and its receptor; an inhibitory signal mediated by IDO, CD20, NOX or TDO. In one embodiment, the checkpoint inhibitor is at least one selected from the group consisting of PD-1 inhibitors, PD-L1 inhibitors, PD-L2 inhibitors, CTLA-4 inhibitors, TIM-3 inhibitors, KIR inhibitors, LAG-3 inhibitors, TIGIT inhibitors, VISTA inhibitors, and GARP inhibitors. In one embodiment, the checkpoint inhibitor may be a blocking antibody, such as a PD-1 blocking antibody, a CTLA4 blocking antibody, a PD-L1 blocking antibody, a PD-L2 blocking antibody, a TIM-3 blocking antibody, a KIR blocking antibody, a LAG-3 blocking antibody, a TIGIT blocking antibody, a VISTA blocking antibody, or a GARP blocking antibody. Examples of a PD-1 blocking antibody include pembrolizumab, nivolumab, cemiplimab, and spartalizumab. Examples of a CTLA4 blocking antibody include ipilimumab and tremelimumab. Examples of a PD-L1 blocking antibody include atezolizumab, durvalumab, and avelumab.

The term "immunoglobulin" relates to proteins of the immunoglobulin superfamily, preferably to antigen receptors such as antibodies or the B cell receptor (BCR). The immunoglobulins are characterized by a structural domain, *i.e.*, the immunoglobulin domain, having a characteristic immunoglobulin (Ig) fold. The term encompasses membrane bound immunoglobulins as well as soluble immunoglobulins. Membrane bound immunoglobulins are also termed surface immunoglobulins or membrane immunoglobulins, which are generally part of the BCR. Soluble immunoglobulins are generally termed antibodies.

The structure of immunoglobulins has been well characterized. See, e.g., Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)). Briefly, immunoglobulins generally comprise several chains, typically two identical heavy chains and two identical light chains which are linked via disulfide bonds. These chains are primarily composed of immunoglobulin domains or regions, such as the V_L or VL (variable light chain) domain/region, C_L or CL (constant light chain) domain/region, V_H or VH (variable heavy chain) domain/region, and the C_H or CH (constant heavy chain) domains/regions C_{H1} (CH1), C_{H2} (CH2), C_{H3} (CH3), and C_{H4} (CH4). The heavy chain constant region typically is comprised of three domains, CH1, CH2, and CH3. The hinge region is the region between the CH1 and CH2 domains of the heavy chain and is highly flexible. Disulfide bonds in the hinge region are part of the interactions between two heavy chains in an IgG molecule. Each light chain typically is comprised of a VL and a CL. The light chain constant region typically is comprised of one domain, CL. The VH and VL regions may be further subdivided into regions of hypervariability (or hypervariable regions which

may be hypervariable in sequence and/or form of structurally defined loops), also termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. Mol. Biol. 196, 901-917 (1987)). Unless otherwise stated or contradicted by context, CDR sequences herein are identified according to IMGT rules using DomainGapAlign (Lefranc MP., Nucleic Acids Research 1999;27:209-212 and Ehrenmann F., Kaas Q. and Lefranc M.-P. Nucleic Acids Res., 38, D301-307 (2010); see also internet http address www.imgt.org. Unless otherwise stated or contradicted by context, reference to amino acid positions in the constant regions in the present disclosure is according to the EU-numbering (Edelman et al., Proc Natl Acad Sci USA. 1969 May;63(1):78-85; Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition. 1991 NIH Publication No. 91-3242).

There are five types of mammalian immunoglobulin heavy chains, *i.e.*, α , δ , ϵ , γ , and μ which account for the different classes of antibodies, *i.e.*, IgA, IgD, IgE, IgG, and IgM. As opposed to the heavy chains of soluble immunoglobulins, the heavy chains of membrane or surface immunoglobulins comprise a transmembrane domain and a short cytoplasmic domain at their carboxy-terminus. In mammals there are two types of light chains, *i.e.*, lambda and kappa. The immunoglobulin chains comprise a variable region and a constant region. The constant region is essentially conserved within the different isotypes of the immunoglobulins, wherein the variable part is highly divers and accounts for antigen recognition.

The term "amino acid" and "amino acid residue" may herein be used interchangeably, and are not to be understood limiting. Amino acids are organic compounds containing amine ($-NH_2$) and carboxyl ($-COOH$) functional groups, along with a side chain (R group) specific to each amino acid. In the context of the present disclosure, amino acids may be classified based on structure and chemical characteristics. Thus, classes of amino acids may be reflected in one or both of the following tables:

Table 2: Main classification based on structure and general chemical characterization of R group

Class	Amino acid
Acidic Residues	D and E
Basic Residues	K, R, and H
Hydrophilic Uncharged Residues	S, T, N, and Q
Aliphatic Uncharged Residues	G, A, V, L, and I
Non-polar Uncharged Residues	C, M, and P
Aromatic Residues	F, Y, and W

Table 3: Alternative Physical and Functional Classifications of Amino Acid Residues

Class	Amino acid
Hydroxyl group containing residues	S and T
Aliphatic residues	I, L, V, and M

Cycloalkenyl-associated residues	F, H, W, and Y
Hydrophobic residues	A, C, F, G, H, I, L, M, R, T, V, W, and Y
Negatively charged residues	D and E
Polar residues	C, D, E, H, K, N, Q, R, S, and T
Positively charged residues	H, K, and R
Small residues	A, C, D, G, N, P, S, T, and V
Very small residues	A, G, and S
Residues involved in turn formation	A, C, D, E, G, H, K, N, Q, R, S, P, and T
Flexible residues	Q, T, K, S, G, P, D, E, and R

For the purposes of the present disclosure, "variants" of an amino acid sequence (peptide, protein or polypeptide) comprise amino acid insertion variants, amino acid addition variants, amino acid deletion variants and/or amino acid substitution variants. The term "variant" includes all mutants, splice variants, posttranslationally modified variants, conformations, isoforms, allelic variants, species variants, and species homologs, in particular those which are naturally occurring. The term "variant" includes, in particular, fragments of an amino acid sequence.

Amino acid insertion variants comprise insertions of single or two or more amino acids in a particular amino acid sequence. In the case of amino acid sequence variants having an insertion, one or more amino acid residues are inserted into a particular site in an amino acid sequence, although random insertion with appropriate screening of the resulting product is also possible.

Amino acid addition variants comprise amino- and/or carboxy-terminal fusions of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids.

Amino acid deletion variants are characterized by the removal of one or more amino acids from the sequence, such as by removal of 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. The deletions may be in any position of the protein. Amino acid deletion variants that comprise the deletion at the N-terminal and/or C-terminal end of the protein are also called N-terminal and/or C-terminal truncation variants.

Amino acid substitution variants are characterized by at least one residue in the sequence being removed and another residue being inserted in its place. Substitution of one amino acid for another may be classified as a conservative or non-conservative substitution. Preference is given to the modifications being in positions in the amino acid sequence which are not conserved between homologous proteins or peptides and/or to replacing amino acids with other ones having similar properties. Preferably, amino acid changes in peptide and protein variants are conservative amino acid changes, *i.e.*, substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains. In the context of the present disclosure, a "conservative substitution" is a substitution of one amino acid with another amino acid having similar structural and/or chemical characteristics, such substitution of one amino acid residue for

another amino acid residue of the same class as defined in any of the two tables above: for example, leucine may be substituted with isoleucine as they are both aliphatic, branched hydrophobes. Similarly, aspartic acid may be substituted with glutamic acid since they are both small, negatively charged residues. Naturally occurring amino acids may also be generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In one embodiment, conservative amino acid substitutions include substitutions within the following groups:

- 10 - glycine, alanine;
- valine, isoleucine, leucine;
- aspartic acid, glutamic acid;
- asparagine, glutamine;
- serine, threonine;
- 15 - lysine, arginine; and
- phenylalanine, tyrosine.

The term "amino acid corresponding to position..." and similar expressions as used herein refer to an amino acid position number in a human IgG1 heavy chain. Corresponding amino acid positions in other immunoglobulins may be found by alignment with human IgG1. Thus, an amino acid or segment in one sequence that "corresponds to" an amino acid or segment in another sequence is one that aligns with the other amino acid or segment using a standard sequence alignment program such as ALIGN, ClustalW or similar, typically at default settings and has at least 50%, at least 80%, at least 90%, or at least 95% identity to a human IgG1 heavy chain. It is considered well-known in the art how to align a sequence or segment in a sequence and thereby determine the corresponding position in a sequence to an amino acid position according to the present disclosure.

The term "antibody" (Ab) in the context of the present disclosure refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or a derivative of either thereof, which has the ability to specifically bind to an antigen (in particular an epitope on an antigen) under typical physiological conditions, preferably with a half-life of significant periods of time, such as at least about 30 minutes, at least about 45 minutes, at least about one hour, at least about two hours, at least about four hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or more days, etc., or any other relevant functionally-defined period (such as a time sufficient to induce, promote, enhance, and/or modulate a physiological response associated with antibody binding to the antigen and/or time sufficient for the antibody to recruit an effector activity). In particular, the term "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L)

chains inter-connected by disulfide bonds. The term "antibody" includes monoclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies and combinations of any of the foregoing. Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (CH). Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL). The variable regions and constant regions are also referred to herein as variable domains and constant domains, respectively. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs of a VH are termed HCDR1, HCDR2 and HCDR3 (or CDR-H1, CDR-H2 and CDR-H3), the CDRs of a VL are termed LCDR1, LCDR2 and LCDR3 (or CDR-L1, CDR-L2 and CDR-L3). The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of an antibody comprise the heavy chain constant region (CH) and the light chain constant region (CL), wherein CH can be further subdivided into constant domain CH1, a hinge region, and constant domains CH2 and CH3 (arranged from amino-terminus to carboxy-terminus in the following order: CH1, CH2, CH3). The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (*e.g.*, effector cells) and components of the complement system such as C1q. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoactive portions of intact immunoglobulins. Antibodies are typically tetramers of immunoglobulin molecules. Antibodies may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)₂, as well as single chain antibodies and humanized antibodies.

The variable regions of the heavy and light chains of the immunoglobulin molecule contain a binding domain that interacts with an antigen. The terms "binding region" and "antigen-binding region" are used herein interchangeably and refer to the region which interacts with the antigen and comprises both a VH region and a VL region. An antibody as used herein comprises not only monospecific antibodies, but also multispecific antibodies which comprise multiple, such as two or more, *e.g.*, three or more, different antigen-binding regions.

As indicated above, the term antibody herein, unless otherwise stated or clearly contradicted by context, includes fragments of an antibody that are antigen-binding fragments, *i.e.*, retain the ability to specifically bind to the antigen. It has been shown that the antigen-binding function of an antibody may be performed by fragments of a full-length antibody. Examples of antigen-binding fragments encompassed within the term "antibody" include (i) a Fab' or Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains, or a monovalent antibody as described in

WO 2007/059782 (Genmab); (ii) F(ab')₂ fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting essentially of the VH and CH1 domains; (iv) a Fv fragment consisting essentially of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment (Ward et al., *Nature* 341, 544-546 (1989)), which consists essentially of a VH domain and also called domain antibodies (Holt et al; *Trends Biotechnol.* 2003 Nov;21(11):484-90); (vi) camelid or Nanobody molecules (Revets et al; *Expert Opin Biol Ther.* 2005 Jan;5(1):111-24); and (vii) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they may be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain antibodies or single chain Fv (scFv), see for instance Bird et al., *Science* 242, 423-426 (1988) and Huston et al., *PNAS USA* 85, 5879-5883 (1988)). Such single chain antibodies are encompassed within the term antibody unless otherwise noted or clearly indicated by context. Although such fragments are generally included within the meaning of antibody, they collectively and each independently are unique features of the present disclosure, exhibiting different biological properties and utility. These and other useful antibody fragments in the context of the present disclosure, as well as bispecific formats of such fragments, are discussed further herein. It also should be understood that the term antibody, unless specified otherwise, also includes polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides, such as chimeric antibodies and humanized antibodies, and antibody fragments retaining the ability to specifically bind to the antigen (antigen-binding fragments) provided by any known technique, such as enzymatic cleavage, peptide synthesis, and recombinant techniques.

An antibody as generated can possess any isotype. As used herein, the term "isotype" refers to the immunoglobulin class (for instance IgG (such as IgG1, IgG2, IgG3, IgG4), IgD, IgA (such as IgA1, IgA2), IgE, IgM, or IgY) that is encoded by heavy chain constant region genes. When a particular isotype, e.g. IgG1, is mentioned herein, the term is not limited to a specific isotype sequence, e.g. a particular IgG1 sequence, but is used to indicate that the antibody is closer in sequence to that isotype, e.g. IgG1, than to other isotypes. Thus, e.g. an IgG1 antibody disclosed herein may be a sequence variant of a naturally-occurring IgG1 antibody, including variations in the constant regions.

IgG1 antibodies can exist in multiple polymorphic variants termed allotypes (reviewed in Jefferis and Lefranc 2009. *mAbs* Vol 1 Issue 4 1-7) any of which are suitable for use in some of the embodiments herein. Common allotypic variants in human populations are those designated by the letters a, f, n, z or combinations thereof. In any of the embodiments herein, the antibody may comprise a heavy chain Fc region comprising a human IgG Fc region. In further embodiments, the human IgG Fc region comprises a human IgG1.

The term "multispecific antibody" in the context of the present disclosure refers to an antibody having at least two different antigen-binding regions defined by different antibody sequences. In some embodiments, said different antigen-binding regions bind different epitopes on the same antigen. However, in preferred embodiments, said different antigen-binding regions bind different target
5 antigens. In one embodiment, the multispecific antibody is a "bispecific antibody" or "bs". A multispecific antibody, such as a bispecific antibody, can be of any format, including any of the bispecific or multispecific antibody formats described herein below.

The term "full-length" when used in the context of an antibody indicates that the antibody is not a
10 fragment, but contains all of the domains of the particular isotype normally found for that isotype in nature, e.g. the VH, CH1, CH2, CH3, hinge, VL and CL domains for an IgG1 antibody.

The term "human antibody", as used herein, is intended to include antibodies having variable and framework regions derived from human germline immunoglobulin sequences and a human
15 immunoglobulin constant domain. The human antibodies disclosed herein may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations, insertions or deletions introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*). However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another non-human species, such as a mouse, have been
20 grafted onto human framework sequences.

The term "chimeric antibody" as used herein, refers to an antibody wherein the variable region is derived from a non-human species (e.g. derived from rodents) and the constant region is derived from a different species, such as human. Chimeric antibodies may be generated by antibody engineering. "Antibody
25 engineering" is a term used generically for different kinds of modifications of antibodies, and processes for antibody engineering are well-known for the skilled person. In particular, a chimeric antibody may be generated by using standard DNA techniques as described in Sambrook et al., 1989, Molecular Cloning: A laboratory Manual, New York: Cold Spring Harbor Laboratory Press, Ch. 15. Thus, the chimeric antibody may be a genetically or an enzymatically engineered recombinant antibody. It is
30 within the knowledge of the skilled person to generate a chimeric antibody, and thus, generation of the chimeric antibody may be performed by other methods than those described herein. Chimeric monoclonal antibodies for therapeutic applications in humans are developed to reduce anticipated antibody immunogenicity of non-human antibodies, e.g. rodent antibodies. They may typically contain non-human (e.g. murine or rabbit) variable regions, which are specific for the antigen of interest, and
35 human constant antibody heavy and light chain domains. The terms "variable region" or "variable domain" as used in the context of chimeric antibodies, refer to a region which comprises the CDRs and framework regions of both the heavy and light chains of an immunoglobulin, as described below.

The term "humanized antibody" as used herein, refers to a genetically engineered non-human antibody, which contains human antibody constant domains and non-human variable domains modified to contain a high level of sequence homology to human variable domains. This can be achieved by grafting of the six non-human antibody complementarity-determining regions (CDRs), which together form the antigen binding site, onto a homologous human acceptor framework region (FR) (see WO 92/22653 and EP 0 629 240). In order to fully reconstitute the binding affinity and specificity of the parental antibody, the substitution of framework residues from the parental antibody (i.e. the non-human antibody) into the human framework regions (back-mutations) may be required. Structural homology modeling may help to identify the amino acid residues in the framework regions that are important for the binding properties of the antibody. Thus, a humanized antibody may comprise non-human CDR sequences, primarily human framework regions optionally comprising one or more amino acid back-mutations to the non-human amino acid sequence, and fully human constant regions. Optionally, additional amino acid modifications, which are not necessarily back-mutations, may be applied to obtain a humanized antibody with preferred characteristics, such as affinity and biochemical properties.

As used herein, a protein which is "derived from" another protein, e.g., a parent protein, means that one or more amino acid sequences of the protein are identical or similar to one or more amino acid sequences in the other or parent protein. For example, in an antibody, binding arm, antigen-binding region, constant region, or the like which is derived from another or a parent antibody, binding arm, antigen-binding region, or constant region, one or more amino acid sequences are identical or similar to those of the other or parent antibody, binding arm, antigen-binding region, or constant region. Examples of such one or more amino acid sequences include, but are not limited to, those of the VH and VL CDRs and/or one or more or all of the framework regions, VH, VL, CL, hinge, or CH regions. For example, a humanized antibody can be described herein as "derived from" a non-human parent antibody, meaning that at least the VL and VH CDR sequences are identical or similar to the VH and VL CDR sequences of said non-human parent antibody. A chimeric antibody can be described herein as being "derived from" a non-human parent antibody, meaning that typically the VH and VL sequences may be identical or similar to those of the non-human parent antibody. Another example is a binding arm or an antigen-binding region which may be described herein as being "derived from" a particular parent antibody, meaning that said binding arm or antigen-binding region typically comprises identical or similar VH and/or VL CDRs, or VH and/or VL sequences to the binding arm or antigen-binding region of said parent antibody. As described elsewhere herein, however, amino acid modifications such as mutations can be made in the CDRs, constant regions or elsewhere in the antibody, binding arm, antigen-binding region or the like, to introduce desired characteristics. When used in the context of one or more sequences derived from a first or parent protein, a "similar" amino acid sequence preferably has a sequence identity of at least

about 50%, such as at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 97%, 98% or 99%.

5 Non-human antibodies can be generated in a number of different species, such as mouse, rabbit, chicken, guinea pig, llama and goat.

Monoclonal antibodies can be produced by a variety of techniques, including conventional monoclonal antibody methodology, e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256: 495 (1975). Other techniques for producing monoclonal antibodies can be employed, e.g.,
10 viral or oncogenic transformation of B-lymphocytes or phage display techniques using libraries of antibody genes, and such methods are well known to a person skilled in the art.

Hybridoma production in such non-human species is a very well-established procedure. Immunization protocols and techniques for isolation of splenocytes of immunized animals/non-human species for
15 fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.

When used herein, unless contradicted by context, the term "Fab-arm" or "arm" refers to one heavy chain-light chain pair and is used interchangeably with "half molecules" herein.
20

The term "binding arm comprising an antigen-binding region" means an antibody molecule or fragment that comprises an antigen-binding region. Thus, a binding arm can comprise, e.g., the six VH and VL CDR sequences, the VH and VL sequences, a Fab or Fab' fragment, or a Fab-arm.

25 When used herein, unless contradicted by context, the term "Fc region" refers to an antibody region consisting of the two Fc sequences of the heavy chains of an immunoglobulin, wherein said Fc sequences comprise at least a hinge region, a CH2 domain, and a CH3 domain. In one embodiment, the term "Fc region", as used herein, refers to a region comprising, in the direction from the N- to C-terminal end of the antibody, at least a hinge region, a CH2 region and a CH3 region. An Fc region of the antibody
30 may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (such as effector cells) and components of the complement system.

In the context of the present disclosure, the term "induce Fc-mediated effector function to a lesser extent" used in relation to an antibody, including a multispecific antibody, means that the antibody induces Fc-mediated effector functions, such function in particular being selected from the list of IgG Fc receptor (FcγR) binding, C1q binding, ADCC or CDC, to a lesser extent compared to a human IgG1 antibody comprising (i) the same CDR sequences, in particular comprising the same first and second
35

antigen-binding regions, as said antibody and (ii) two heavy chains comprising human IgG1 hinge, CH2 and CH3 regions.

5 Fc-mediated effector function may be measured by binding to FcγRs, binding to C1q, or induction of Fc-mediated cross-linking via FcγRs.

10 The term "hinge region" as used herein refers to the hinge region of an immunoglobulin heavy chain. Thus, for example, the hinge region of a human IgG1 antibody corresponds to amino acids 216-230 according to the EU numbering as set forth in Kabat (Kabat, E.A. et al., Sequences of proteins of immunological interest. 5th Edition - US Department of Health and Human Services, NIH publication No. 91-3242, pp 662,680,689 (1991). However, the hinge region may also be any of the other subtypes as described herein.

15 The term "CH1 region" or "CH1 domain" as used herein refers to the CH1 region of an immunoglobulin heavy chain. Thus, for example, the CH1 region of a human IgG1 antibody corresponds to amino acids 118-215 according to the EU numbering as set forth in Kabat (*ibid*). However, the CH1 region may also be any of the other subtypes as described herein.

20 The term "CH2 region" or "CH2 domain" as used herein refers to the CH2 region of an immunoglobulin heavy chain. Thus, for example, the CH2 region of a human IgG1 antibody corresponds to amino acids 231-340 according to the EU numbering as set forth in Kabat (*ibid*). However, the CH2 region may also be any of the other subtypes as described herein.

25 The term "CH3 region" or "CH3 domain" as used herein refers to the CH3 region of an immunoglobulin heavy chain. Thus, for example, the CH3 region of a human IgG1 antibody corresponds to amino acids 341-447 according to the EU numbering as set forth in Kabat (*ibid*). However, the CH3 region may also be any of the other subtypes as described herein.

30 The term "monovalent antibody" means in the context of the present disclosure that an antibody molecule is capable of binding a single molecule of the antigen, and thus is not capable of antigen cross-linking.

A "CD137 antibody" or "anti-CD137 antibody" is an antibody as described above, which binds specifically to the antigen CD137.

35

A "CD137xPD-L1 antibody" or "anti-CD137xPD-L1 antibody" is a bispecific antibody, which comprises two different antigen-binding regions, one of which binds specifically to the antigen CD137 and one of which binds specifically to the antigen PD-L1.

- 5 The term "biosimilar" (e.g., of an approved reference product/biological drug) as used herein refers to a biologic product that is similar to the reference product based on data from (a) analytical studies demonstrating that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; (b) animal studies (including the assessment of toxicity); and/or (c) a clinical study or studies (including the assessment of immunogenicity and
- 10 pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is approved and intended to be used and for which approval is sought (e.g., that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product). In some embodiments, the biosimilar biological product and reference product utilizes the
- 15 same mechanism or mechanisms of action for the condition or conditions of use prescribed, recommended, or suggested in the proposed labeling, but only to the extent the mechanism or mechanisms of action are known for the reference product. In some embodiments, the condition or conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product. In some embodiments, the route of
- 20 administration, the dosage form, and/or the strength of the biological product are the same as those of the reference product. A biosimilar can be, e.g., a presently known antibody having the same primary amino acid sequence as a marketed antibody, but may be made in different cell types or by different production, purification, or formulation methods.
- 25 As used herein, the terms "binding" or "capable of binding" in the context of the binding of an antibody to a predetermined antigen or epitope typically is a binding with an affinity corresponding to a K_D of about 10^{-7} M or less, such as about 10^{-8} M or less, such as about 10^{-9} M or less, about 10^{-10} M or less, or about 10^{-11} M or even less, when determined using Bio-Layer Interferometry (BLI) or, for instance, when determined using surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument
- 30 using the antigen as the ligand and the antibody as the analyte. The antibody binds to the predetermined antigen with an affinity corresponding to a K_D that is at least ten-fold lower, such as at least 100-fold lower, for instance at least 1,000-fold lower, such as at least 10,000-fold lower, for instance at least 100,000-fold lower than its K_D for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely related antigen. The amount with which the affinity is higher is
- 35 dependent on the K_D of the antibody, so that when the K_D of the antibody is very low (that is, the antibody is highly specific), then the degree to which the affinity for the antigen is lower than the affinity for a non-specific antigen may be at least 10,000-fold.

The term " k_d " (sec^{-1}), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. Said value is also referred to as the k_{off} value.

- 5 The term " K_D " (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction.

Two antibodies have the "same specificity" if they bind to the same antigen and to the same epitope. Whether an antibody to be tested recognizes the same epitope as a certain antigen-binding antibody, i.e.,
10 the antibodies bind to the same epitope, may be tested by different methods well known to a person skilled in the art.

The competition between the antibodies can be detected by a cross-blocking assay. For example, a competitive ELISA assay may be used as a cross-blocking assay. E.g., target antigen may be coated on
15 the wells of a microtiter plate and antigen-binding antibody and candidate competing test antibody may be added. The amount of the antigen-binding antibody bound to the antigen in the well indirectly correlates with the binding ability of the candidate competing test antibody that competes therewith for binding to the same epitope. Specifically, the larger the affinity of the candidate competing test antibody is for the same epitope, the smaller the amount of the antigen-binding antibody bound to the antigen-coated well. The amount of the antigen-binding antibody bound to the well can be measured by labeling
20 the antibody with detectable or measurable labeling substances.

An antibody competing for binding to an antigen with another antibody, e.g., an antibody comprising heavy and light chain variable regions as described herein, or an antibody having the specificity for an
25 antigen of another antibody, e.g., an antibody comprising heavy and light chain variable regions as described herein, may be an antibody comprising variants of said heavy and/or light chain variable regions as described herein, e.g. modifications in the CDRs and/or a certain degree of identity as described herein.

30 An "isolated multispecific antibody" as used herein is intended to refer to a multispecific antibody which is substantially free of other antibodies having different antigenic specificities (for instance an isolated bispecific antibody that specifically binds to CD137 and PD-L1 is substantially free of monospecific antibodies that specifically bind to CD137 or PD-L1).

35 The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.

When used herein the term "heterodimeric interaction between the first and second CH3 regions" refers to the interaction between the first CH3 region and the second CH3 region in a first-CH3/second-CH3 heterodimeric antibody.

5

When used herein the term "homodimeric interactions of the first and second CH3 regions" refers to the interaction between a first CH3 region and another first CH3 region in a first-CH3/first-CH3 homodimeric antibody and the interaction between a second CH3 region and another second CH3 region in a second-CH3/second-CH3 homodimeric antibody.

10

When used herein the term "homodimeric antibody" refers to an antibody comprising two first Fab-arms or half-molecules, wherein the amino acid sequence of said Fab-arms or half-molecules is the same.

15

When used herein the term "heterodimeric antibody" refers to an antibody comprising a first and a second Fab-arm or half-molecule, wherein the amino acid sequence of said first and second Fab-arms or half-molecules are different. In particular, the CH3 region, or the antigen-binding region, or the CH3 region and the antigen-binding region of said first and second Fab-arms/half-molecules are different.

20

The term "reducing conditions" or "reducing environment" refers to a condition or an environment in which a substrate, such as a cysteine residue in the hinge region of an antibody, is more likely to become reduced than oxidized.

25

The present disclosure also describes multispecific antibodies, such as bispecific antibodies, comprising functional variants of the VL regions, VH regions, or one or more CDRs of the bispecific antibodies of the examples. A functional variant of a VL, VH, or CDR used in the context of a bispecific antibody still allows each antigen-binding region of the bispecific antibody to retain at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the affinity and/or the specificity/selectivity of the parent bispecific antibody and in some cases such a bispecific antibody may be associated with greater affinity, selectivity and/or specificity than the parent bispecific antibody.

30

Such functional variants typically retain significant sequence identity to the parent bispecific antibody. The percent identity between two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % homology = # of identical positions/total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The percent identity between two nucleotide or amino acid sequences may e.g. be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci 4, 11-17 (1988) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue

35

table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences may be determined using the Needleman and Wunsch, J. Mol. Biol. 48, 444-453 (1970) algorithm.

In the context of the present disclosure, unless otherwise indicated, the following notations are used to describe a mutation: i) substitution of an amino acid in a given position is written as e.g. K409R which means a substitution of a lysine in position 409 of the protein with an arginine; and ii) for specific variants the specific three or one letter codes are used, including the codes Xaa and X to indicate any amino acid residue. Thus, the substitution of lysine with arginine in position 409 is designated as: K409R, and the substitution of lysine with any amino acid residue in position 409 is designated as K409X. In case of deletion of lysine in position 409 it is indicated by K409*.

Exemplary variants include those which differ from the VH and/or VL and/or CDRs of the parent sequences mainly by conservative substitutions; for example, 12, such as 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 of the substitutions in the variant are conservative amino acid residue replacements.

In the context of the present disclosure, conservative substitutions may be defined by substitutions within the classes of amino acids as defined in tables 2 and 3.

The term "CD137" as used herein, refers to CD137 (4-1BB), also referred to as tumor necrosis factor receptor superfamily member 9 (TNFRSF9), which is the receptor for the ligand TNFSF9/4-1BBL. CD137 (4-1BB) is believed to be involved in T-cell activation. Other synonyms for CD137 include, but are not limited to, 4-1BB ligand receptor, CDw137, T-cell antigen 4-1BB homolog and T-cell antigen ILA. In one embodiment, CD137 (4-1BB) is human CD137 (4-1BB), having UniProt accession number Q07011. The sequence of human CD137 is also shown in SEQ ID NO: 37. Amino acids 1-23 of SEQ ID NO: 37 correspond to the signal peptide of human CD137; while amino acids 24-186 of SEQ ID NO: 37 correspond to the extracellular domain of human CD137; and the remainder of the protein, i.e. from amino acids 187-213 and 214-255 of SEQ ID NO: 37 are transmembrane and cytoplasmic domain, respectively.

The "Programmed Death-1 (PD-1)" receptor refers to an immuno-inhibitory receptor belonging to the CD28 family. PD-1 (also known as CD279) is expressed predominantly on previously activated T cells in vivo, and binds to two ligands, PD-L1 (also known as B7-H1 or CD274) and PD-L2 (also known as B7-DC or CD273). The term "PD-1" as used herein includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs having at least one common epitope with hPD-1. The sequence of human PD-1 is also shown in SEQ ID NO: 39. "Programmed Death Ligand-1 (PD-L1)" is

one of two cell surface glycoprotein ligands for PD-1 (the other being PD-L2) that downregulates T cell activation and cytokine secretion upon binding to PD-1.

The term "PD-L1" as used herein includes human PD-L1 (hPD-L1), variants, isoforms, and species homologs of hPD-L1, such as macaque (cynomolgus monkey), African elephant, wild boar and mouse PD-L1 (cf., e.g., Genbank accession no. NP_054862.1, XP_005581836, XP_003413533, XP_005665023 and NP_068693, respectively), and analogs having at least one common epitope with hPD-L1. The sequence of human PD-L1 is also shown in SEQ ID NO: 40, wherein amino acids 1-18 are predicted to be a signal peptide.. The term "PD-L2" as used herein includes human PD-L2 (hPD-L2), variants, isoforms, and species homologs of hPD-L2, and analogs having at least one common epitope with hPD-L2. The ligands of PD-1 (PD-L1 and PD-L2) are expressed on the surface of antigen-presenting cells, such as dendritic cells or macrophages, and other immune cells. Binding of PD-1 to PD-L1 or PD-L2 results in downregulation of T cell activation. Cancer cells expressing PD-L1 and/or PD-L2 are able to switch off T cells expressing PD-1 what results in suppression of the anticancer immune response. The interaction between PD-1 and its ligands results in a decrease in tumor infiltrating lymphocytes, a decrease in T cell receptor mediated proliferation, and immune evasion by the cancerous cells. Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1, and the effect is additive when the interaction of PD-1 with PD-L2 is blocked as well.

The term "dysfunctional", as used herein, refers to an immune cell that is in a state of reduced immune responsiveness to antigen stimulation. Dysfunctional includes unresponsive to antigen recognition and impaired capacity to translate antigen recognition into downstream T cell effector functions, such as proliferation, cytokine production (e.g., IL-2) and/or target cell killing.

The term "anergy", as used herein, refers to the state of unresponsiveness to antigen stimulation resulting from incomplete or insufficient signals delivered through the T cell receptor (TCR). T cell anergy can also result upon stimulation with antigen in the absence of co-stimulation, resulting in the cell becoming refractory to subsequent activation by the antigen even in the context of co-stimulation. The unresponsive state can often be overridden by the presence of IL-2. Anergic T cells do not undergo clonal expansion and/or acquire effector functions.

The term "exhaustion", as used herein, refers to immune cell exhaustion, such as T cell exhaustion as a state of T cell dysfunction that arises from sustained TCR signaling that occurs during many chronic infections and cancer. It is distinguished from anergy in that it arises not through incomplete or deficient signaling, but from sustained signaling. Exhaustion is defined by poor effector function, sustained expression of inhibitory receptors and a transcriptional state distinct from that of functional effector or memory T cells. Exhaustion prevents optimal control of diseases (e.g., infection and tumors).

Exhaustion can result from both extrinsic negative regulatory pathways (e.g., immunoregulatory cytokines) as well as cell intrinsic negative regulatory pathways (inhibitory immune checkpoint pathways, such as described herein).

5 "Enhancing T cell function" means to induce, cause or stimulate a T cell to have a sustained or amplified biological function, or renew or reactivate exhausted or inactive T cells. Examples of enhancing T cell function include increased secretion of γ -interferon from CD8⁺ T cells, increased proliferation, increased antigen responsiveness (e.g., tumor clearance) relative to such levels before the intervention. In one embodiment, the level of enhancement is as least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%,
10 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 200%, or more. Manners of measuring this enhancement are known to one of ordinary skill in the art.

The term "inhibitory nucleic acid" or "inhibitory nucleic acid molecule" as used herein refers to a nucleic
15 acid molecule, e.g., DNA or RNA, that totally or partially reduces, inhibits, interferes with or negatively modulates one or more PD-1 proteins. Inhibitory nucleic acid molecules include, without limitation, oligonucleotides, siRNA, shRNA, antisense DNA or RNA molecules, and aptamers (e.g., DNA or RNA aptamers).

20 The term "oligonucleotide" as used herein refers to a nucleic acid molecule that is able to decrease protein expression, in particular expression of a PD-1 protein, such as the PD-1 proteins described herein. Oligonucleotides are short DNA or RNA molecules, typically comprising from 2 to 50 nucleotides. Oligonucleotides may be single-stranded or double-stranded. A PD-1 inhibitor oligonucleotide may be an antisense-oligonucleotide.

25 Antisense-oligonucleotides are single-stranded DNA or RNA molecules that are complementary to a given sequence, in particular to a sequence of the nucleic acid sequence (or a fragment thereof) of a PD-1 protein. Antisense RNA is typically used to prevent protein translation of mRNA, e.g., of mRNA encoding a PD-1 protein, by binding to said mRNA. Antisense DNA is typically used to target a specific,
30 complementary (coding or non-coding) RNA. If binding takes place, such a DNA/RNA hybrid can be degraded by the enzyme RNase H. Moreover, morpholino antisense oligonucleotides can be used for gene knockdowns in vertebrates. For example, Kryczek et al., 2006 (J Exp Med, 203:871-81) designed B7-H4-specific morpholinos that specifically blocked B7-H4 expression in macrophages, resulting in increased T cell proliferation and reduced tumor volumes in mice with tumor associated antigen (TAA)-
35 specific T cells.

The terms "siRNA" or "small interfering RNA" or "small inhibitory RNA" are used interchangeably herein and refer to a double-stranded RNA molecule with a typical length of 20-25 base pairs that interferes with expression of a specific gene, such as a gene coding for a PD-1 protein, with a complementary nucleotide sequence. In one embodiment, siRNA interferes with mRNA therefore blocking translation, e.g., translation of a PD-1 protein. Transfection of exogenous siRNA may be used for gene knockdown, however, the effect may be only transient, especially in rapidly dividing cells. Stable transfection may be achieved, e.g., by RNA modification or by using an expression vector. Useful modifications and vectors for stable transfection of cells with siRNA are known in the art. siRNA sequences may also be modified to introduce a short loop between the two strands resulting in a "small hairpin RNA" or "shRNA". shRNA can be processed into a functional siRNA by Dicer. shRNA has a relatively low rate of degradation and turnover. Accordingly, the PD-1 inhibitor may be a shRNA.

The term "aptamer" as used herein refers to a single-stranded nucleic acid molecule, such as DNA or RNA, typically in a length of 25-70 nucleotides that is capable of binding to a target molecule, such as a polypeptide. In one embodiment, the aptamer binds to a PD-1 protein such as the PD-1 proteins described herein. For example, an aptamer according to the disclosure can specifically bind to a PD-1 protein or polypeptide, or to a molecule in a signaling pathway that modulates the expression of a PD-1 protein or polypeptide. The generation and therapeutic use of aptamers is well known in the art (see, e.g., US 5,475,096).

The terms "small molecule inhibitor" or "small molecule" are used interchangeably herein and refer to a low molecular weight organic compound, usually up to 1000 daltons, that totally or partially reduces, inhibits, interferes with, or negatively modulates one or more PD-1 proteins as described above. Such small molecular inhibitors are usually synthesized by organic chemistry, but may also be isolated from natural sources, such as plants, fungi, and microbes. The small molecular weight allows a small molecule inhibitor to rapidly diffuse across cell membranes. For example, various A2AR antagonists known in the art are organic compounds having a molecular weight below 500 daltons.

The term "cell based therapy" refers to the transplantation of cells (e.g., T lymphocytes, dendritic cells, or stem cells) expressing a PD-1 inhibitor into a subject for the purpose of treating a disease or disorder (e.g., a cancer disease).

The term "oncolytic virus" as used herein, refers to a virus capable of selectively replicating in and slowing the growth or inducing the death of a cancerous or hyperproliferative cell, either *in vitro* or *in vivo*, while having no or minimal effect on normal cells. An oncolytic virus for the delivery of a PD-1 inhibitor comprises an expression cassette that may encode a PD-1 inhibitor that is an inhibitory nucleic acid molecule, such as a siRNA, shRNA, an oligonucleotide, antisense DNA or RNA, an aptamer, an

antibody or a fragment thereof or a soluble PD-1 protein or fusion. The oncolytic virus preferably is replication competent and the expression cassette is under the control of a viral promoter, e.g., synthetic early/late poxvirus promoter. Exemplary oncolytic viruses include vesicular stomatitis virus (VSV), rhabdoviruses (e.g., picornaviruses such as Seneca Valley virus; SVV-001), coxsackievirus, parvovirus, Newcastle disease virus (NDV), herpes simplex virus (HSV; OncoVEX GMCSF), retroviruses (e.g., influenza viruses), measles virus, reovirus, Sinbis virus, vaccinia virus, as exemplarily described in WO 2017/209053 (including Copenhagen, Western Reserve, Wyeth strains), and adenovirus (e.g., Delta-24, Delta-24-RGD, ICOVIR-5, ICOVIR-7, Onyx-015, ColoAd1, H101, AD5/3-D24-GMCSF). Generation of recombinant oncolytic viruses comprising a soluble form of a PD-1 inhibitor and methods for their use are disclosed in WO 2018/022831, herein incorporated by reference in its entirety. Oncolytic viruses can be used as attenuated viruses.

"Treatment cycle" is herein defined as the time period, within the effects of separate dosages of the binding agent add on due to the pharmacodynamics of the binding agent, or in other words the time period after the subject's body is essentially cleared from the administered binding agent. Multiple small doses in a small time window, e.g. within 2-24 few hours, such as 2-12 hours or on the same day, might be equal to a larger single dose.

In the present context, the term "treatment", "treating" or "therapeutic intervention" relates to the management and care of a subject for the purpose of combating a condition such as a disease or disorder. The term is intended to include the full spectrum of treatments for a given condition from which the subject is suffering, such as administration of the therapeutically effective compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relieve the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of an individual for the purpose of combating the disease, condition or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. In one embodiment, "treatment" refers to the administration of an effective amount of a therapeutically active binding agent, such as of a therapeutically active antibody, of the present disclosure with the purpose of easing, ameliorating, arresting or eradicating (curing) symptoms or disease states.

The response to treatment as well as the resistance to, failure to respond to and/or relapse from treatment with a binding agent of the present disclosure may be determined according to the Response Evaluation Criteria in Solid Tumors; version 1.1 (RECIST Criteria v1.1). The RECIST Criteria are set forth in the table below (LD: longest dimension).

Table 4: Definition of Response (RECIST Criteria v1.1)

	Category	Criteria
Based on target lesions	Complete Response (CR)	Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to < 10 mm.
	Partial Response (PR)	≥ 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.
	Stable Disease (SD)	Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of LDs since the treatment started.
	Progressive Disease (PD)	≥ 20% increase in the sum of the LDs of target lesions, taking as reference the smallest sum of the LDs recorded since the treatment started or the appearance of one or more new lesions.
Based on non-target lesions	CR	Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).
	SD	Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
	PD	Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

The "best overall response" is the best response recorded from the start of the treatment until disease progression/recurrence (the smallest measurements recorded since the treatment started will be used as the reference for PD). Subjects with CR or PR are considered to be objective response. Subjects with CR, PR or SD are considered to be in disease control. Subjects with NE are counted as non-responders. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (the smallest measurements recorded since the treatment started will be used as the reference for PD). Subjects with CR, PR or SD are considered to be in disease control. Subjects with NE are counted as non-responders.

"Duration of response (DOR)" only applies to subjects whose confirmed best overall response is CR or PR and is defined as the time from the first documentation of objective tumor response (CR or PR) to the date of first PD or death due to underlying cancer.

"Progression-free survival (PFS)" is defined as the number of days from Day 1 in Cycle 1 to the first documented progression or death due to any cause.

"Overall survival (OS)" is defined as the number of days from Day 1 in Cycle 1 to death due to any cause. If a subject is not known to have died, then OS will be censored at the latest date the subject was known to be alive (on or before the cut-off date).

In the context of the present disclosure, the term "treatment regimen" refers to a structured treatment plan designed to improve and maintain health.

The term "effective amount" or "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount of a binding agent, such as an antibody, like a multispecific antibody or monoclonal antibody, may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the binding agent to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the binding agent or a fragment thereof, are outweighed by the therapeutically beneficial effects. In the case that a reaction in a patient is insufficient with an initial dose, higher doses (or effectively higher doses achieved by a different, more localized route of administration) may be used. In case that unwanted side effects occur in a patient with a dose, lower doses (or effectively lower doses achieved by a different, more localized route of administration) may be used.

As used herein, the term "cancer" includes a disease characterized by aberrantly regulated cellular growth, proliferation, differentiation, adhesion, and/or migration. By "cancer cell" is meant an abnormal cell that grows by a rapid, uncontrolled cellular proliferation and continues to grow after the stimuli that initiated the new growth cease.

The term "cancer" according to the present disclosure also comprises cancer metastases. By "metastasis" is meant the spread of cancer cells from its original site to another part of the body. The formation of metastasis is a very complex process and depends on detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membranes to enter the body cavity and vessels, and then, after being transported by the blood, infiltration of target organs. Finally, the growth of a new tumor, i.e. a secondary tumor or metastatic tumor, at the target site depends on angiogenesis. Tumor metastasis often occurs even after the removal of the primary tumor because tumor cells or components may remain and develop metastatic potential. In one embodiment, the term "metastasis" according to the present disclosure relates to "distant metastasis" which relates to a metastasis which is remote from the primary tumor and the regional lymph node system.

Terms such as "reduce", "inhibit", "interfere", and "negatively modulate" as used herein means the ability to cause an overall decrease, for example, of about 5% or greater, about 10% or greater, about 15% or greater, about 20% or greater, about 25% or greater, about 30% or greater, about 40% or greater, about 50% or greater, or about 75% or greater, in the level. The term "inhibit" or similar phrases includes a complete or essentially complete inhibition, i.e. a reduction to zero or essentially to zero.

Terms such as "increase" or "enhance" in one embodiment relate to an increase or enhancement by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 80%, or at least about 100%.

"Physiological pH" as used herein refers to a pH of 7.5 or about 7.5.

As used in the present disclosure, "% by weight" refers to weight percent, which is a unit of concentration measuring the amount of a substance in grams (g) expressed as a percent of the total weight of the total composition in grams (g).

The term "TPS" or "tumor proportion score," refers to the percentage of tumor cells expressing PD-L1 on the cell membrane. TPS typically includes the percentage of neoplastic cells expressing PD-L1 at any intensity (weak, moderate, or strong), which can be determined using an immunohistochemical assay using a diagnostic anti-human PD-L1 mAb, e.g. antibody 20C3 and antibody 22C3, described in WO 2014/100079. Cells are considered to express PD-L1 if membrane staining is present, including cells with partial membrane staining.

The term "freezing" relates to the solidification of a liquid, usually with the removal of heat.

The term "lyophilizing" or "lyophilization" refers to the freeze-drying of a substance by freezing it and then reducing the surrounding pressure (*e.g.*, below 15 Pa, such as below 10 Pa, below 5 Pa, or 1 Pa or less) to allow the frozen medium in the substance to sublime directly from the solid phase to the gas phase. Thus, the terms "lyophilizing" and "freeze-drying" are used herein interchangeably.

The term "recombinant" in the context of the present disclosure means "made through genetic engineering". In one embodiment, a "recombinant object" in the context of the present disclosure is not occurring naturally.

The term "naturally occurring" as used herein refers to the fact that an object can be found in nature. For example, a peptide or nucleic acid that is present in an organism (including viruses) and can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally occurring. The term "found in nature" means "present in nature" and includes known objects as well as objects that have not yet been discovered and/or isolated from nature, but that may be discovered and/or isolated in the future from a natural source.

According to the present disclosure, the term "peptide" comprises oligo- and polypeptides and refers to substances which comprise about two or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, about 16 or more, about 20 or more, and up to about 50, about 100 or about 150, consecutive amino acids linked to one another via peptide bonds. The term

"protein" refers to large peptides, in particular peptides having at least about 151 amino acids, but the terms "peptide" and "protein" are used herein usually as synonyms.

A "therapeutic protein" has a positive or advantageous effect on a condition or disease state of a subject when provided to the subject in a therapeutically effective amount. In one embodiment, a therapeutic protein has curative or palliative properties and may be administered to ameliorate, relieve, alleviate, reverse, delay onset of or lessen the severity of one or more symptoms of a disease or disorder. A therapeutic protein may have prophylactic properties and may be used to delay the onset of a disease or to lessen the severity of such disease or pathological condition. The term "therapeutic protein" includes entire proteins or peptides and can also refer to therapeutically active fragments thereof. It can also include therapeutically active variants of a protein. Examples of therapeutically active proteins include, but are not limited to, antigens for vaccination and immunostimulants such as cytokines.

The term "portion" refers to a fraction. With respect to a particular structure such as an amino acid sequence or protein the term "portion" thereof may designate a continuous or a discontinuous fraction of said structure.

The terms "part" and "fragment" are used interchangeably herein and refer to a continuous element. For example, a part of a structure such as an amino acid sequence or protein refers to a continuous element of said structure. When used in context of a composition, the term "part" means a portion of the composition. For example, a part of a composition may any portion from 0.1% to 99.9% (such as 0.1%, 0.5%, 1%, 5%, 10%, 50%, 90%, or 99%) of said composition.

"Fragment", with reference to an amino acid sequence (peptide or protein), relates to a part of an amino acid sequence, *i.e.* a sequence which represents the amino acid sequence shortened at the N-terminus and/or C-terminus. A fragment shortened at the C-terminus (N-terminal fragment) is obtainable, *e.g.*, by translation of a truncated open reading frame that lacks the 3'-end of the open reading frame. A fragment shortened at the N-terminus (C-terminal fragment) is obtainable, *e.g.*, by translation of a truncated open reading frame that lacks the 5'-end of the open reading frame, as long as the truncated open reading frame comprises a start codon that serves to initiate translation. A fragment of an amino acid sequence comprises, *e.g.*, at least 50 %, at least 60 %, at least 70 %, at least 80%, at least 90% of the amino acid residues from an amino acid sequence. A fragment of an amino acid sequence preferably comprises at least 6, in particular at least 8, at least 12, at least 15, at least 20, at least 30, at least 50, or at least 100 consecutive amino acids from an amino acid sequence.

According to the present disclosure, a part or fragment of a peptide or protein preferably has at least one functional property of the peptide or protein from which it has been derived. Such functional properties

comprise a pharmacological activity, the interaction with other peptides or proteins, an enzymatic activity, the interaction with antibodies, and the selective binding of nucleic acids. *E.g.*, a pharmacological active fragment of a peptide or protein has at least one of the pharmacological activities of the peptide or protein from which the fragment has been derived. A part or fragment of a peptide or protein preferably comprises a sequence of at least 6, in particular at least 8, at least 10, at least 12, at least 15, at least 20, at least 30 or at least 50, consecutive amino acids of the peptide or protein. A part or fragment of a peptide or protein preferably comprises a sequence of up to 8, in particular up to 10, up to 12, up to 15, up to 20, up to 30 or up to 55, consecutive amino acids of the peptide or protein.

By "variant" herein is meant an amino acid sequence that differs from a parent amino acid sequence by virtue of at least one amino acid modification. The parent amino acid sequence may be a naturally occurring or wild type (WT) amino acid sequence, or may be a modified version of a wild type amino acid sequence. Preferably, the variant amino acid sequence has at least one amino acid modification compared to the parent amino acid sequence, *e.g.*, from 1 to about 20 amino acid modifications, and preferably from 1 to about 10 or from 1 to about 5 amino acid modifications compared to the parent.

By "wild type" or "WT" or "native" herein is meant an amino acid sequence that is found in nature, including allelic variations. A wild type amino acid sequence, peptide or protein has an amino acid sequence that has not been intentionally modified.

Preferably the degree of similarity, preferably identity between a given amino acid sequence and an amino acid sequence which is a variant of said given amino acid sequence will be at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The degree of similarity or identity is given preferably for an amino acid region which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the entire length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is given preferably for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids, in some embodiments continuous amino acids. In some embodiments, the degree of similarity or identity is given for the entire length of the reference amino acid sequence. The alignment for determining sequence similarity, preferably sequence identity can be done with art known tools, preferably using the best sequence alignment, for example, using Align, using standard settings, preferably EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.

"Sequence similarity" indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences indicates the percentage of amino acids that are identical between the sequences. "Sequence identity" between two nucleic acid sequences indicates the percentage of nucleotides that are identical between the sequences.

The terms "% identical" and "% identity" or similar terms are intended to refer, in particular, to the percentage of nucleotides or amino acids which are identical in an optimal alignment between the sequences to be compared. Said percentage is purely statistical, and the differences between the two sequences may be but are not necessarily randomly distributed over the entire length of the sequences to be compared. Comparisons of two sequences are usually carried out by comparing the sequences, after optimal alignment, with respect to a segment or "window of comparison", in order to identify local regions of corresponding sequences. The optimal alignment for a comparison may be carried out manually or with the aid of the local homology algorithm by Smith and Waterman, 1981, *Adv. App. Math.* 2, 482, with the aid of the local homology algorithm by Needleman and Wunsch, 1970, *J. Mol. Biol.* 48, 443, with the aid of the similarity search algorithm by Pearson and Lipman, 1988, *Proc. Natl Acad. Sci. USA* 88, 2444, or with the aid of computer programs using said algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In some embodiments, percent identity of two sequences is determined using the BLASTN or BLASTP algorithm, as available on the United States National Center for Biotechnology Information (NCBI) website (*e.g.*, at blast.ncbi.nlm.nih.gov/Blast.cgi). In some embodiments, the algorithm parameters used for BLASTN algorithm on the NCBI website include: (i) Expect Threshold set to 10; (ii) Word Size set to 28; (iii) Max matches in a query range set to 0; (iv) Match/Mismatch Scores set to 1, -2; (v) Gap Costs set to Linear; and (vi) the filter for low complexity regions being used. In some embodiments, the algorithm parameters used for BLASTP algorithm on the NCBI website include: (i) Expect Threshold set to 10; (ii) Word Size set to 3; (iii) Max matches in a query range set to 0; (iv) Matrix set to BLOSUM62; (v) Gap Costs set to Existence: 11 Extension: 1; and (vi) conditional compositional score matrix adjustment.

Percentage identity is obtained by determining the number of identical positions at which the sequences to be compared correspond, dividing this number by the number of positions compared (*e.g.*, the number of positions in the reference sequence) and multiplying this result by 100.

In some embodiments, the degree of similarity or identity is given for a region which is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the entire length of the reference sequence. For example, if the reference amino acid sequence consists of 200 amino acid residues, the degree of identity is given for at least about 100, at least about 120, at

least about 140, at least about 160, at least about 180, or about 200 amino acid residues, in some embodiments continuous amino acid residues. In some embodiments, the degree of similarity or identity is given for the entire length of the reference sequence.

- 5 Homologous amino acid sequences exhibit according to the present disclosure at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and preferably at least 95%, at least 98 or at least 99% identity of the amino acid residues.

10 The amino acid sequence variants described herein may readily be prepared by the skilled person, for example, by recombinant DNA manipulation. The manipulation of DNA sequences for preparing peptides or proteins having substitutions, additions, insertions or deletions, is described in detail in Sambrook et al. (1989), for example. Furthermore, the peptides and amino acid variants described herein may be readily prepared with the aid of known peptide synthesis techniques such as, for example, by solid phase synthesis and similar methods.

15

In one embodiment, a fragment or variant of an amino acid sequence (peptide or protein) is preferably a "functional fragment" or "functional variant". The term "functional fragment" or "functional variant" of an amino acid sequence relates to any fragment or variant exhibiting one or more functional properties identical or similar to those of the amino acid sequence from which it is derived, *i.e.*, it is functionally equivalent. With respect to antigens or antigenic sequences, one particular function is one or more immunogenic activities displayed by the amino acid sequence from which the fragment or variant is derived. The term "functional fragment" or "functional variant", as used herein, in particular refers to a variant molecule or sequence that comprises an amino acid sequence that is altered by one or more amino acids compared to the amino acid sequence of the parent molecule or sequence and that is still capable of fulfilling one or more of the functions of the parent molecule or sequence, *e.g.*, inducing an immune response. In one embodiment, the modifications in the amino acid sequence of the parent molecule or sequence do not significantly affect or alter the characteristics of the molecule or sequence. In different embodiments, the function of the functional fragment or functional variant may be reduced but still significantly present, *e.g.*, immunogenicity of the functional variant may be at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the parent molecule or sequence. However, in other embodiments, immunogenicity of the functional fragment or functional variant may be enhanced compared to the parent molecule or sequence.

35 An amino acid sequence (peptide, protein or polypeptide) "derived from" a designated amino acid sequence (peptide, protein or polypeptide) refers to the origin of the first amino acid sequence. Preferably, the amino acid sequence which is derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical or homologous to that particular sequence or

a fragment thereof. Amino acid sequences derived from a particular amino acid sequence may be variants of that particular sequence or a fragment thereof. For example, it will be understood by one of ordinary skill in the art that the antigens suitable for use herein may be altered such that they vary in sequence from the naturally occurring or native sequences from which they were derived, while retaining the desirable activity of the native sequences.

"Isolated" means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not "isolated", but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated". An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell. In a preferred embodiment, the binding agent used in the present disclosure is in substantially purified form.

The term "genetic modification" or simply "modification" includes the transfection of cells with nucleic acid. The term "transfection" relates to the introduction of nucleic acids, in particular RNA, into a cell. For purposes of the present disclosure, the term "transfection" also includes the introduction of a nucleic acid into a cell or the uptake of a nucleic acid by such cell, wherein the cell may be present in a subject, *e.g.*, a patient. Thus, according to the present disclosure, a cell for transfection of a nucleic acid described herein can be present *in vitro* or *in vivo*, *e.g.* the cell can form part of an organ, a tissue and/or an organism of a patient. According to the present disclosure, transfection can be transient or stable. For some applications of transfection, it is sufficient if the transfected genetic material is only transiently expressed. RNA can be transfected into cells to transiently express its coded protein. Since the nucleic acid introduced in the transfection process is usually not integrated into the nuclear genome, the foreign nucleic acid will be diluted through mitosis or degraded. Cells allowing episomal amplification of nucleic acids greatly reduce the rate of dilution. If it is desired that the transfected nucleic acid actually remains in the genome of the cell and its daughter cells, a stable transfection must occur. Such stable transfection can be achieved by using virus-based systems or transposon-based systems for transfection. Generally, nucleic acid encoding antigen is transiently transfected into cells. RNA can be transfected into cells to transiently express its coded protein.

According to the present disclosure, an analog of a peptide or protein is a modified form of said peptide or protein from which it has been derived and has at least one functional property of said peptide or protein. *E.g.*, a pharmacological active analog of a peptide or protein has at least one of the pharmacological activities of the peptide or protein from which the analog has been derived. Such modifications include any chemical modification and comprise single or multiple substitutions, deletions and/or additions of any molecules associated with the protein or peptide, such as carbohydrates, lipids and/or proteins or peptides. In one embodiment, "analogs" of proteins or peptides

include those modified forms resulting from glycosylation, acetylation, phosphorylation, amidation, palmitoylation, myristoylation, isoprenylation, lipidation, alkylation, derivatization, introduction of protective/blocking groups, proteolytic cleavage or binding to an antibody or to another cellular ligand. The term "analog" also extends to all functional chemical equivalents of said proteins and peptides.

5

"Activation" or "stimulation", as used herein, refers to the state of an immune effector cell such as T cell that has been sufficiently stimulated to induce detectable cellular proliferation. Activation can also be associated with initiation of signaling pathways, induced cytokine production, and detectable effector functions. The term "activated immune effector cells" refers to, among other things, immune effector cells that are undergoing cell division.

10

The term "priming" refers to a process wherein an immune effector cell such as a T cell has its first contact with its specific antigen and causes differentiation into effector cells such as effector T cells.

15

The term "clonal expansion" or "expansion" refers to a process wherein a specific entity is multiplied. In the context of the present disclosure, the term is preferably used in the context of an immunological response in which immune effector cells are stimulated by an antigen, proliferate, and the specific immune effector cell recognizing said antigen is amplified. Preferably, clonal expansion leads to differentiation of the immune effector cells.

20

An "antigen" according to the present disclosure covers any substance that will elicit an immune response and/or any substance against which an immune response or an immune mechanism such as a cellular response is directed. This also includes situations wherein the antigen is processed into antigen peptides and an immune response or an immune mechanism is directed against one or more antigen peptides, in particular if presented in the context of MHC molecules. In particular, an "antigen" relates to any substance, preferably a peptide or protein, that reacts specifically with antibodies or T-lymphocytes (T-cells). According to the present disclosure, the term "antigen" comprises any molecule which comprises at least one epitope, such as a T cell epitope. Preferably, an antigen in the context of the present disclosure is a molecule which, optionally after processing, induces an immune reaction, which is preferably specific for the antigen (including cells expressing the antigen). In one embodiment, an antigen is a disease-associated antigen, such as a tumor antigen, a viral antigen, or a bacterial antigen, or an epitope derived from such antigen.

25

30

The term "epitope" refers to an antigenic determinant in a molecule such as an antigen, *i.e.*, to a part in or fragment of the molecule that is recognized by the immune system, for example, that is recognized by antibodies T cells or B cells, in particular when presented in the context of MHC molecules. In one embodiment, "epitope" means a protein determinant capable of specific binding to an antibody. Epitopes

35

usually consist of surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. The epitope may comprise amino acid residues directly involved in the binding and other amino acid residues, which are not directly involved in the binding, such as amino acid residues which are effectively blocked or covered by the specifically antigen-binding peptide (in other words, the amino acid residue is within the footprint of the specifically antigen-binding peptide).

An epitope of a protein preferably comprises a continuous or discontinuous portion of said protein and is preferably between about 5 and about 100, preferably between about 5 and about 50, more preferably between about 8 and about 40, most preferably between about 10 and about 25 amino acids in length, for example, the epitope may be preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length. It is particularly preferred that the epitope in the context of the present disclosure is a T cell epitope.

The term "optional" or "optionally" as used herein means that the subsequently described event, circumstance or condition may or may not occur, and that the description includes instances where said event, circumstance, or condition occurs and instances in which it does not occur.

As used herein, the terms "linked", "fused", or "fusion" are used interchangeably. These terms refer to the joining together of two or more elements or components or domains.

The term "disease" (also referred to as "disorder" herein) refers to an abnormal condition that affects the body of an individual. A disease is often construed as a medical condition associated with specific symptoms and signs. A disease may be caused by factors originally from an external source, such as infectious disease, or it may be caused by internal dysfunctions, such as autoimmune diseases. In humans, "disease" is often used more broadly to refer to any condition that causes pain, dysfunction, distress, social problems, or death to the individual afflicted, or similar problems for those in contact with the individual. In this broader sense, it sometimes includes injuries, disabilities, disorders, syndromes, infections, isolated symptoms, deviant behaviors, and atypical variations of structure and function, while in other contexts and for other purposes these may be considered distinguishable categories. Diseases usually affect individuals not only physically, but also emotionally, as contracting and living with many diseases can alter one's perspective on life, and one's personality.

The term "therapeutic treatment" relates to any treatment which improves the health status and/or prolongs (increases) the lifespan of an individual. Said treatment may eliminate the disease in an

individual, arrest or slow the development of a disease in an individual, inhibit or slow the development of a disease in an individual, decrease the frequency or severity of symptoms in an individual, and/or decrease the recurrence in an individual who currently has or who previously has had a disease.

The terms "prophylactic treatment" or "preventive treatment" relate to any treatment that is intended to prevent a disease from occurring in an individual. The terms "prophylactic treatment" or "preventive treatment" are used herein interchangeably. Similarly, the term "method for preventing" in the context of progression of a disease, such as progression of a tumor or cancer, relates to any method that is intended to prevent the disease from progressing in an individual.

The terms "individual" and "subject" are used herein interchangeably. They refer to a human or another mammal (*e.g.*, mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate), or any other non-mammal-animal, including birds (chicken), fish or any other animal species that can be afflicted with or is susceptible to a disease or disorder (*e.g.*, cancer). Unless otherwise stated, the terms "individual" and "subject" do not denote a particular age, and thus encompass adults, elderlies, children, and newborns. In embodiments of the present disclosure, the "individual" or "subject" is a "patient".

The term "patient" means an individual or subject for treatment, in particular a diseased individual or subject.

Aspects and embodiments of the present disclosure

In a first aspect, the present disclosure provides a binding agent for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject the binding agent prior to, simultaneously with, or after administration of an antibody binding to Programmed Death-1 (PD-1), or an antigen-binding fragment thereof, wherein the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1,

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively;

and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively,

and

the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

Binding agent binding to CD137 and PD-L1

In one embodiment, CD137 is human CD137, in particular human CD137 comprising the sequence set forth in SEQ ID NO: 38. In one embodiment, PD-L1 is human PD-L1, in particular human PD-L1 comprising the sequence set forth in SEQ ID NO: 40. In one embodiment, CD137 is human CD137 and PD-L1 is human PD-L1. In one embodiment, CD137 is human CD137 comprising the sequence set forth in SEQ ID NO: 38, and PD-L1 is human PD-L1 comprising the sequence set forth in SEQ ID NO: 40.

In one embodiment of the binding agent according to the first aspect, the first binding region binding to human CD137 comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 or 9 and a light chain variable region (VL) region and comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 5 or 10.

In further embodiment of the binding agent according to the first aspect, the second binding region binding to human PD-L1 comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 11 and a light chain variable region (VL) region comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 15.

In one embodiment of the binding agent according to the first aspect,

- a) the first binding region binding to human CD137 comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 or 9 and a light chain variable region (VL) region and comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 5 or 10; and
- b) the second binding region binding to human PD-L1 comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 11 and a light chain variable region (VL) region

comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 15.

5 In one embodiment of the binding agent according to the first aspect, the first binding region binding to human CD137 comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 1 or 9 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 5 or 10.

10 In a further embodiment of the binding agent according to the first aspect, the second binding region binding to human PD-L1 comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 11 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 15.

In one embodiment of the binding agent according to the first aspect,
15 a) the first binding region binding to human CD137 comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 1 or 9 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 5 or 10;
and
b) the second binding region binding to human PD-L1 comprises a heavy chain variable region
20 (VH) comprising the amino acid sequence set forth in SEQ ID NO: 11 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 15.

In one embodiment of the binding agent according to the first aspect,
a) the first binding region binding to human CD137 comprises a heavy chain variable region (VH)
25 comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 5;
and
b) the second binding region binding to human PD-L1 comprises a heavy chain variable region
(VH) comprising the amino acid sequence set forth in SEQ ID NO: 11 and a light chain variable region
30 (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 15.

The binding agent may in particular be an antibody, such as a multispecific antibody, e.g., a bispecific antibody. Also, the binding agent may be in the format of a full-length antibody or an antibody fragment.

35 It is further preferred that the binding agent is a human antibody or a humanized antibody.

Each variable region may comprise three complementarity determining regions (CDR1, CDR2, and CDR3) and four framework regions (FR1, FR2, FR3, and FR4).

5 The complementarity determining regions (CDRs) and the framework regions (FRs) may be arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

In one embodiment of the first aspect, the binding agent comprises

- 10 i) a polypeptide comprising said first heavy chain variable region (VH) and a first heavy chain constant region (CH), and
- ii) a polypeptide comprising said second heavy chain variable region (VH) and a second heavy chain constant region (CH).

In one embodiment of the first aspect, the binding agent comprises

- 15 i) a polypeptide comprising said first light chain variable region (VL) and further comprising a first light chain constant region (CL), and
- ii) a polypeptide comprising said second light chain variable region (VL) and further comprising a second light chain constant region (CL).

20 In one embodiment of the first aspect, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises

- i) a polypeptide comprising said first heavy chain variable region (VH) and said first heavy chain constant region (CH), and
- 25 ii) a polypeptide comprising said first light chain variable region (VL) and said first light chain constant region (CL);

and the second binding arm comprises

- iii) a polypeptide comprising said second heavy chain variable region (VH) and said second heavy chain constant region (CH), and
- 30 iv) a polypeptide comprising said second light chain variable region (VL) and said second light chain constant region (CL).

In one embodiment of the first aspect, the binding agent comprises i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, the first heavy chain comprising a first heavy chain constant region and the first light chain comprising a first light chain constant region; 35 and ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1, the second heavy chain comprising a second heavy chain constant region and the second light chain comprising a second light chain constant region.

Each of the first and second heavy chain constant regions (CH) may comprise one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region and a CH3 region.

5

Each of the first and second heavy chain constant regions (CHs) may comprise a CH3 region, wherein the two CH3 regions comprise asymmetrical mutations. Asymmetrical mutations mean that the sequences of said first and second CH3 regions contain amino acid substitutions at non-identical positions. For example, one of said first and second CH3 regions contains a mutation at the position corresponding to position 405 in a human IgG1 heavy chain according to EU numbering, and the other of said first and second CH3 regions contains a mutation at the position corresponding to position 409 in a human IgG1 heavy chain according to EU numbering.

10

In said first heavy chain constant region (CH) at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering may have been substituted, and in said second heavy chain constant region (CH) at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering may have been substituted. In particular embodiments, the first and the second heavy chains are not substituted in the same positions (i.e., the first and the second heavy chains contain asymmetrical mutations).

15

20

In one embodiment of the binding agent according to the first aspect, (i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first heavy chain constant region (CH), and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second heavy chain constant region (CH), or (ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first heavy chain, and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second heavy chain.

25

30

In one embodiment of the first aspect, the binding agent induces Fc-mediated effector function to a lesser extent compared to another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CHs) comprising human IgG1 hinge, CH2 and CH3 regions.

In one particular embodiment of the binding agent according to the first aspect, said first and second heavy chain constant regions (CHs) are modified so that the antibody induces Fc-mediated effector function to a lesser extent compared to an antibody which is identical except for comprising non-

35

modified first and second heavy chain constant regions (CHs). In particular, each or both of said non-modified first and second heavy chain constant regions (CHs) may comprise, consists of or consist essentially of the amino acid sequence set forth in SEQ ID NO: 19 or 25.

- 5 The Fc-mediated effector function may be determined by measuring binding of the binding agent to Fc γ receptors, binding to C1q, or induction of Fc-mediated cross-linking of Fc γ receptors. In particular, the Fc-mediated effector function may be determined by measuring binding of the binding agent to C1q.

- 10 The first and second heavy chain constant regions of the binding agent may have been modified so that binding of C1q to said antibody is reduced compared to a wild-type antibody, preferably reduced by at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100%, wherein C1q binding is preferably determined by ELISA.

- 15 In one embodiment of the binding agent according to the first aspect, in at least one of said first and second heavy chain constant regions (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

- 20 In one embodiment of the binding agent according to the first aspect, the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering may be F and E, respectively, in said first and second heavy chains.

- 25 In particular, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering may be F, E, and A, respectively, in said first and second heavy chain constant regions (HCs).

- 30 In one embodiment of the binding agent according to the first aspect, the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F and E, respectively, wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is R, or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.
- 35

In one embodiment of the binding agent according to the first aspect, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F, E, and A, respectively, wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain constant region is R, or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.

In one embodiment of the binding agent according to the first aspect, the constant region of said first and/or second heavy chain comprises an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 19 or SEQ ID NO: 25 [IgG1-FC];
- b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at the most 10 substitutions, such as at the most 9 substitutions, at the most 8, at the most 7, at the most 6, at the most 5, at the most 4, at the most 3, at the most 2 or at the most 1 substitution compared to the amino acid sequence defined in a) or b).

In one embodiment of the binding agent according to the first aspect, the constant region of said first or second heavy chain, such as the second heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 20 or SEQ ID NO: 26 [IgG1-F405L];
- b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at the most 9 substitutions, such as at the most 8, at the most 7, at the most 6, at the most 5, at the most 4, at the most 3, at the most 2 or at the most 1 substitution compared to the amino acid sequence defined in a) or b).

In one embodiment of the binding agent according to the first aspect, the constant region of said first or second heavy chain, such as the first heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 21 or 27 [IgG1-F409R];

- b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at the most 10 substitutions, such as at the most 9 substitutions, at the most 8, at the most 7, at the most 6, at the most 5, at the most 4 substitutions, at the most 3, at the most 2 or at the most 1 substitution compared to the amino acid sequence defined in a) or b).

In one embodiment of the binding agent according to the first aspect, the constant region of said first and/or second heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 22 or SEQ ID NO: 28 [IgG1-Fc_FEA];
- b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at the most 7 substitutions, such as at the most 6 substitutions, at the most 5, at the most 4, at the most 3, at the most 2 or at the most 1 substitution compared to the amino acid sequence defined in a) or b).

In one embodiment of the binding agent according to the first aspect, the constant region of said first and/or second heavy chain, such as the second heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 24 or SEQ ID NO: 30 [IgG1-Fc_FEAL];
- b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at the most 6 substitutions, such as at the most 5 substitutions, at the most 4 substitutions, at the most 3, at the most 2 or at the most 1 substitution compared to the amino acid sequence defined in a) or b).

In one embodiment of the binding agent according to the first aspect, the constant region of said first and/or second heavy chain, such as the first heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 23 or SEQ ID NO: 29 [IgG1-Fc_FEAR];
- b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and

- c) a sequence having at the most 6 substitutions, such as at the most 5 substitutions, at the most 4, at the most 3, at the most 2 or at the most 1 substitution compared to the amino acid sequence defined in a) or b).

5 In one embodiment of the first aspect, the binding agent comprises a kappa (κ) light chain constant region.

In one embodiment of the first aspect, the binding agent comprises a lambda (λ) light chain constant region.

10

In one embodiment of the binding agent according to the first aspect, the first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

15 In one embodiment of the binding agent according to the first aspect, the second light chain constant region is a lambda (λ) light chain constant region or a kappa (κ) light chain constant region.

In one embodiment of the binding agent according to the first aspect, the first light chain constant region is a kappa (κ) light chain constant region and the second light chain constant region is a lambda (λ) light chain constant region or the first light chain constant region is a lambda (λ) light chain constant region and the second light chain constant region is a kappa (κ) light chain constant region.

20

In one embodiment of the binding agent according to the first aspect, the kappa (κ) light chain comprises an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 35;
- 25 b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at the most 10 substitutions, such as at the most 9 substitutions, at the most 8, at the most 7, at the most 6, at the most 5, at the most 4 substitutions, at the most 3, at the
- 30 most 2 or at the most 1 substitution, compared to the amino acid sequence defined in a) or b).

In one embodiment of the binding agent according to the first aspect, the lambda (λ) light chain comprises an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 36;
- 35 b) a subsequence of the sequence in a), such as a subsequence wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and

c) a sequence having at the most 10 substitutions, such as at the most 9 substitutions, at the most 8, at the most 7, at the most 6, at the most 5, at the most 4 substitutions, at the most 3, at the most 2 or at the most 1 substitution, compared to the amino acid sequence defined in a) or b).

5 The binding agent (in particular, antibody) according to the first aspect is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4. In particular, the binding agent may be a full-length IgG1 antibody. In preferred embodiments of the first aspect, the binding agent (in particular, antibody) is of the IgG1m(f) allotype.

10 In a preferred embodiment of the binding agent according to the first aspect, the binding agent comprises

i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, wherein the first heavy chain comprising the sequence set forth in SEQ ID NO: 31, and the first light chain comprising the sequence set forth in SEQ ID NO: 32;

15 ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1, wherein the second heavy chain comprising the sequence set forth in SEQ ID NO: 33, and the second light chain comprising the sequence set forth in SEQ ID NO: 34.

20 The binding agent for use according to the first aspect may in particular be acasunlimab or a biosimilar thereof.

In currently preferred embodiments, the amount of binding agent administered in each dose and/or in each treatment cycle is

25 a) about 0.3-5 mg/kg body weight or about 25-400 mg in total; and/or

b) about $2.1 \times 10^{-9} - 3.4 \times 10^{-8}$ mol/kg body weight or about $1.7 \times 10^{-7} - 2.7 \times 10^{-6}$ mol in total.

According to these embodiments, the dose defined in mg/kg may be converted to flat dose, and *vice versa*, based on the median body weight of the subjects to whom the binding agent is administered being 80 kg

30 The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.3-4.0 mg/kg body weight or about 25-320 mg in total; and/or

about $2.1 \times 10^{-9} - 2.7 \times 10^{-8}$ mol/kg body weight or about $1.7 \times 10^{-7} - 2.2 \times 10^{-6}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.38-4.0 mg/kg body weight or about 30-320 mg in total; and/or

35 about $2.6 \times 10^{-9} - 2.7 \times 10^{-8}$ mol/kg body weight or about $2.4 \times 10^{-7} - 2.2 \times 10^{-6}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.5-3.3 mg/kg body weight or about 40-260 mg in total; and/or

about $3.4 \times 10^{-9} - 2.2 \times 10^{-8}$ mol/kg body weight or about $2.7 \times 10^{-7} - 1.8 \times 10^{-6}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.6-2.5 mg/kg body weight or about 50-200 mg in total; and/or

about $4.3 \times 10^{-9} - 1.7 \times 10^{-8}$ mol/kg body weight or about $3.4 \times 10^{-7} - 1.4 \times 10^{-6}$ mol in total.

- 5 The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.8-1.8 mg/kg body weight or about 60-140 mg in total; and/or
about $5.1 \times 10^{-9} - 1.2 \times 10^{-8}$ mol/kg body weight or about $4.1 \times 10^{-7} - 9.5 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.9-1.8 mg/kg body weight or about 70-140 mg in total; and/or

- 10 about $6.0 \times 10^{-9} - 1.2 \times 10^{-8}$ mol/kg body weight or about $4.8 \times 10^{-7} - 9.5 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 1-1.5 mg/kg body weight or about 80-120 mg in total; and/or

about $6.8 \times 10^{-9} - 1.0 \times 10^{-8}$ mol/kg body weight or about $5.5 \times 10^{-7} - 8.2 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 1.1-1.4 mg/kg body weight or about 90-110 mg in total; and/or

- 15 about $7.7 \times 10^{-9} - 9.4 \times 10^{-9}$ mol/kg body weight or about $6.1 \times 10^{-7} - 7.5 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 1.2-1.3 mg/kg body weight or about 95-105 mg in total; and/or

about $6.8 \times 10^{-9} - 8.9 \times 10^{-9}$ mol/kg body weight or about $6.5 \times 10^{-7} - 7.2 \times 10^{-7}$ mol in total.

- 20 The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.8-1.5 mg/kg body weight or about 65-120 mg in total; and/or
about $5.5 \times 10^{-9} - 1.0 \times 10^{-8}$ mol/kg body weight or about $4.4 \times 10^{-7} - 8.2 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be about 0.9-1.3 mg/kg body weight or about 70-100 mg in total; and/or

- 25 about $6.0 \times 10^{-9} - 8.5 \times 10^{-9}$ mol/kg body weight or about $4.8 \times 10^{-7} - 6.8 \times 10^{-7}$ mol in total.

about 0.9-1.1 mg/kg body weight or about 75-90 mg in total; and/or

about $6.4 \times 10^{-9} - 7.7 \times 10^{-9}$ mol/kg body weight or about $5.1 \times 10^{-7} - 6.1 \times 10^{-7}$ mol in total.

Further, the amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.3-4.0 mg/kg body weight or 25-320 mg in total; and/or

- 30 $2.1 \times 10^{-9} - 2.7 \times 10^{-8}$ mol/kg body weight or $1.7 \times 10^{-7} - 2.2 \times 10^{-6}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.38-4.0 mg/kg body weight or 30-320 mg in total; and/or

$2.6 \times 10^{-9} - 2.7 \times 10^{-8}$ mol/kg body weight or $2.4 \times 10^{-7} - 2.2 \times 10^{-6}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.5-3.3 mg/kg body weight or 40-260 mg in total; and/or

- 35 $3.4 \times 10^{-9} - 2.2 \times 10^{-8}$ mol/kg body weight or $2.7 \times 10^{-7} - 1.8 \times 10^{-6}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.6-2.5 mg/kg body weight or 50-200 mg in total; and/or

$4.3 \times 10^{-9} - 1.7 \times 10^{-8}$ mol/kg body weight or $3.4 \times 10^{-7} - 1.4 \times 10^{-6}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.8-1.8 mg/kg body weight or 60-140 mg in total; and/or

$5.1 \times 10^{-9} - 1.2 \times 10^{-8}$ mol/kg body weight or $4.1 \times 10^{-7} - 9.5 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.9-1.8 mg/kg body weight or 70-140 mg in total; and/or

$6.0 \times 10^{-9} - 1.2 \times 10^{-8}$ mol/kg body weight or $4.8 \times 10^{-7} - 9.5 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 1-1.5 mg/kg body weight or 80-120 mg in total; and/or

$6.8 \times 10^{-9} - 1.0 \times 10^{-8}$ mol/kg body weight or $5.5 \times 10^{-7} - 8.2 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 1.1-1.4 mg/kg body weight or 90-110 mg in total; and/or

$7.7 \times 10^{-9} - 9.4 \times 10^{-9}$ mol/kg body weight or $6.1 \times 10^{-7} - 7.5 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 1.2-1.3 mg/kg body weight or 95-105 mg in total; and/or

$6.8 \times 10^{-9} - 8.9 \times 10^{-9}$ mol/kg body weight or $6.5 \times 10^{-7} - 7.2 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.8-1.5 mg/kg body weight or 65-120 mg in total; and/or

$5.5 \times 10^{-9} - 1.0 \times 10^{-8}$ mol/kg body weight or $4.4 \times 10^{-7} - 8.2 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.9-1.3 mg/kg body weight or 70-100 mg in total; and/or

$6.0 \times 10^{-9} - 8.5 \times 10^{-9}$ mol/kg body weight or $4.8 \times 10^{-7} - 6.8 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may in particular be 0.9-1.1 mg/kg body weight or 75-90 mg in total; and/or

$6.4 \times 10^{-9} - 7.7 \times 10^{-9}$ mol/kg body weight or $5.1 \times 10^{-7} - 6.1 \times 10^{-7}$ mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may be

a) about 1.1 mg/kg body weight or about 80 mg in total; and/or

b) about 6.8×10^{-9} mol/kg body weight or about 5.5×10^{-7} mol in total.

The amount of binding agent administered in each dose and/or in each treatment cycle may be

a) 1.1 mg/kg body weight or 80 mg in total; and/or

b) 6.8×10^{-9} mol/kg body weight or 5.5×10^{-7} mol in total.

It is currently preferred that the amount of binding agent administered in each dose and/or in each treatment cycle is

a) about 1.25 mg/kg body weight or about 100 mg in total; and/or

- b) about 8.5×10^{-9} mol/kg body weight or about 6.8×10^{-7} mol in total.

It is equally preferred that the amount of binding agent administered in each dose and/or in each treatment cycle is

- a) 1.25 mg/kg body weight or 100 mg in total; and/or
 5 b) 8.5×10^{-9} mol/kg body weight or 6.8×10^{-7} mol in total.

The binding agent may be administered in any manner and by any route known in the art. In a preferred embodiment, the binding agent is administered systemically, such as parenterally, in particular intravenously.

10

The binding agent may be administered in the form of any suitable pharmaceutical composition as described herein. In a preferred embodiment, the binding agent is administered in the form of an infusion.

- 15 The binding agent for use according to the invention may be administered by using intravenous (IV) infusion, such as by intravenous infusion over a minimum of 30 minutes, such as over a minimum of 60 minutes e.g., by using intravenous infusion over 30 to 120 minutes. Preferably, the binding agent for use according to the invention is administered by using intravenous (IV) infusion over 30 minutes.

- 20 The binding agent can be administered prior to, simultaneously with, or after administration of the PD-1 inhibitor.

In one embodiment, the binding agent is administered prior to the administration of the PD-1 inhibitor. For example, the gap between the end of the administration of the binding agent and the beginning of the administration of the PD-1 inhibitor can be at least about 10 min, such as at least about 15 min, at least about 20 min, at least about 25 min, at least about 30 min, at least about 35 min, at least about 40 min, at least about 45 min, at least about 50 min, at least about 55 min, at least about 60 min, at least about 90 min, or at least about 120 min, and up to about 14 days (up to about 2 weeks), such as up to about 13 days, up to about 12 days, up to about 11 days, up to about 10 days, up to about 9 days, up to about 8 days, up to about 7 days (up to about 1 week), up to about 6 days, up to about 5 days, up to about 4 days, up to about 3 days, up to about 2 days, up to about 1 day (up to about 24 h), up to about 18 h, up to about 12 h, up to about 6 h, up to about 5 h, up to about 4 h, up to about 3 h, up to about 2.5 h, or up to about 2 h.

- 35 In one embodiment, the binding agent is administered after the administration of the PD-1 inhibitor. For example, the gap between the end of the administration of the PD-1 inhibitor and the beginning of the administration of the binding agent can be at least about 10 min, such as at least about 15 min, at least

about 20 min, at least about 25 min, at least about 30 min, at least about 35 min, at least about 40 min, at least about 45 min, at least about 50 min, at least about 55 min, at least about 60 min, at least about 90 min, or at least about 120 min, and up to about 14 days (up to about 2 weeks), such as up to about 13 days, up to about 12 days, up to about 11 days, up to about 10 days, up to about 9 days, up to about 8 days, up to about 7 days (up to about 1 week), up to about 6 days, up to about 5 days, up to about 4 days, up to about 3 days, up to about 2 days, up to about 1 day (up to about 24 h), up to about 18 h, up to about 12 h, up to about 6 h, up to about 5 h, up to about 4 h, up to about 3 h, up to about 2.5 h, or up to about 2 h.

10 In one embodiment, the binding agent is administered simultaneously with the PD-1 inhibitor. For example, the binding agent and the PD-1 inhibitor may be administered using a composition comprising both drugs. Alternatively, the binding agent may be administered into one extremity of the subject, and the PD-1 inhibitor may be administered into another extremity of the subject.

15 Antibody binding to PD-1

The antibody binding to PD-1 or the antigen-binding fragment thereof preferably comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity, such as at least 90% sequence identity, 95% sequence identity, 98% sequence identity or 99 % sequence identity, to the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity, such as at least 90% sequence identity, 95% sequence identity, 98% sequence identity or 99 % sequence identity, to the amino acid sequence of SEQ ID NO: 50.

25 In currently most preferred embodiments, the antibody binding to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable region comprising, consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising, consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 50.

30 The antibody binding to PD-1 or the antigen-binding fragment thereof may comprise a heavy chain comprising, consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 51 and a light chain comprising, consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 52.

35 The antibody binding to PD-1 used according to the present invention preferably prevents inhibitory signals associated with PD-1. The antibody binding to PD-1 preferably disrupts or inhibits inhibitory signaling associated with PD-1.

Inhibiting or blocking of PD-1 signaling, as described herein, results in preventing or reversing immune-suppression and establishment or enhancement of T cell immunity against cancer cells. In one embodiment, inhibition of PD-1 signaling, as described herein, reduces or inhibits dysfunction of the immune system. In one embodiment, inhibition of PD-1 signaling, as described herein, renders dysfunctional immune cells less dysfunctional. In one embodiment, inhibition of PD-1 signaling, as described herein, renders a dysfunctional T cell less dysfunctional.

In one embodiment, the PD-1 inhibitor prevents the interaction between PD-1 and PD-L1. In another embodiment, the PD-1 inhibitor prevents the interaction between PD-1 and PD-L2.

In particular, the antibody binding to PD-1 or the antigen-binding fragment thereof is a chimerized, humanized or human antibody.

In a preferred embodiment, the antibody binding to PD-1 is an isolated antibody.

. Without being bound by theory the combination of a binding agent comprising a first binding region binding to CD137 and a second binding region binding to PD-L1 as defined above with an antibody binding to PD-1 as defined above is believed to increase the response rate and lead to improved duration of response in subjects receiving the combination therapy because the combination therapy leads to complete blockade of the PD-1 pathway with concurrent conditional activation of 4-1BB. A PD-1 blocking antibody blocks interaction with both PD-L1 and PD-L2. It is further believed that the combination therapy with an antibody binding to PD-1 makes increased amounts of PD-L1 available to be bound by the binding agent.

The PD-1 inhibitor may in particular be pembrolizumab or a biosimilar thereof.

In a further embodiment the PD-1 inhibitor is an antibody comprising a heavy chain variable region (VH) comprising or consisting of or consisting essentially of the sequence set forth in SEQ ID NO: 49, and a light chain variable region (VL) comprising, consisting of or consisting essentially of the sequence set forth in SEQ ID NO: 50. The PD-1 inhibitor may in particular be an antibody comprising a heavy chain comprising, consisting of or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 51, and a light chain comprising, consisting of or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 52.

Anti-PD-1 antibodies of the disclosure are preferably monoclonal, and may be multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments

produced by a Fab expression library, and PD-1 binding fragments of any of the above. In some embodiments, an anti-PD-1 antibody described herein binds specifically to PD-1 (*e.g.*, human PD-1). The immunoglobulin molecules of the disclosure can be of any isotype (*e.g.*, IgG, IgE, IgM, IgD, IgA and IgY), class (*e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

5

antigen-binding fragments (*e.g.*, human antigen-binding fragments) as described herein and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V_L or V_H domain. Antigen-binding fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, CH3 and CL domains. Also included in the present disclosure are antigen-binding fragments comprising any combination of variable region(s) with a hinge region, CH1, CH2, CH3 and CL domains. In some embodiments, the anti-PD-1 antibodies or antigen-binding fragments thereof are human, murine (*e.g.*, mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camelid, horse, or chicken.

15

In some embodiments, numbering of amino acid residues in CDR sequences of anti-PD-1 antibodies or antigen-binding fragments thereof provided herein are according to the IMGT numbering scheme as described in Lefranc, M. P. *et al.*, Dev. Comp. Immunol., 2003, 27, 55-77.

20

The antibody binding to PD-1 or the antigen-binding fragment thereof also include derivatives and constructs that are modified, *i.e.*, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding to PD-1. For example, but not by way of limitation, the anti-PD-1 antibody derivatives include antibodies that have been modified, *e.g.*, by glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative or construct may contain one or more non-classical amino acids.

25

30

Preferably, the antibody binding to PD-1 or the antigen-binding fragment thereof is administered in a suitable amount. The amount of antibody binding to PD-1 or antigen-binding fragment thereof administered in each dose and/or treatment cycle may in particular be in a range, wherein more than 5%, preferably more than 10%, more preferably more than 15%, even more preferably more than 20%, even more preferably more than 25%, even more preferably more than 30%, even more preferably more than 35%, even more preferably more than 40%, even more preferably more than 45%, most preferably more than 50% of said PD-1 inhibitors bind to PD-1.

35

In certain embodiments, the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof and the amount of PD-1 inhibitor administered, e.g., in each dose and/or in each treatment cycle, is about 10 – about 1000 mg in total such as about 100 – about 600 mg in total, e.g., about 150 – about 600 mg in total, about 150 – about 500 mg in total, about 175 – about 500 mg in total, about 175 – about 450 mg in total, about 200 – about 450 mg in total or such as about 200 – about 400 mg in total.

In certain embodiments, the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof and the amount of PD-1 inhibitor administered, e.g., in each dose and/or in each treatment cycle, is 10 – 1000 mg in total such as 100 – 600 mg in total, e.g., 150 – 600 mg in total, 150 – 500 mg in total, 175 – 500 mg in total, 175 – 450 mg in total, 200 – 450 mg in total or such as 200 – 400 mg in total.

In certain embodiments, the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof and the amount of antibody binding to PD-1 administered, e.g., in each dose and/or in each treatment cycle, is about 100 - 600 mg in total; and/or about 6.84×10^{-7} – 4.11×10^{-7} mol in total.

In certain embodiments, the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof and the amount of antibody binding to PD-1 administered, e.g., in each dose and/or in each treatment cycle, is about 100 - 400 mg in total; and/or about 6.84×10^{-7} – 2.73×10^{-6} mol in total, such as 100 - 400 mg in total; and/or 6.84×10^{-7} – 2.73×10^{-6} mol in total.

In certain embodiments, the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof and the amount of antibody binding to PD-1 administered, e.g., in each dose and/or in each treatment cycle, is about 200 - 400 mg in total; and/or about 6.84×10^{-7} – 2.73×10^{-6} mol in total, such as 200 - 400 mg in total; and/or 6.84×10^{-7} – 2.73×10^{-6} mol in total.

In certain embodiments, the amount of antibody binding to PD-1 or antigen-binding fragment thereof administered, e.g., in each dose and/or in each treatment cycle, is about 200 mg or about 1.37×10^{-6} mol in total, such as 200 mg or 1.37×10^{-6} mol in total.

In certain embodiments, the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof and the amount of antibody binding to PD-1 or antigen-binding fragment thereof administered, e.g., in each dose and/or in each treatment cycle, is about 200 mg or about 1.37×10^{-6} mol in total, such as 200 mg or 1.37×10^{-6} mol in total.

In certain embodiments, the amount of antibody binding to PD-1 or antigen-binding fragment thereof administered, e.g., in each dose and/or in each treatment cycle, is about 400 mg in total or about 2.73×10^{-6} in total, such as 400 mg in total or 2.73×10^{-6} in total.

5 In certain embodiments, the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof and the amount of antibody binding to PD-1 or antigen-binding fragment thereof administered, e.g., in each dose and/or in each treatment cycle, is about 400 mg in total or about 2.73×10^{-6} in total, such as 400 mg in total or 2.73×10^{-6} in total.

10 The antibody binding to PD-1 or antigen-binding fragment thereof may be administered in any manner and by any route known in the art. The mode and route of administration will depend on the type of antibody to be used. In a preferred embodiment, the antibody binding to PD-1 or antigen-binding fragment thereof is administered systemically, such as parenterally, in particular intravenously.

15 The antibody binding to PD-1 or antigen-binding fragment thereof may be administered in the form of any suitable pharmaceutical composition as described herein. In a preferred embodiment, the antibody binding to PD-1 or antigen-binding fragment thereof is administered in the form of an infusion, such as an intravenous infusion.

20

Subject and tumor or cancer to be treated

The subject to be treated according to the present disclosure is preferably a human subject.

25 In one preferred embodiment, the tumor or cancer to be treated is a solid tumor or cancer. The tumor or cancer may be a metastatic tumor or cancer.

Preferably, the tumor or cancer may be selected from the group consisting of melanoma, ovarian cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC)), colorectal cancer, head and neck cancer, gastric cancer, breast cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, pancreatic cancer, hepatic cancer, thymoma and thymic carcinoma, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancers, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes, endometrial cancer, prostate cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma and mesothelioma. More preferably, the tumor or cancer is selected from the group consisting of melanoma, lung cancer, colorectal cancer, pancreatic cancer, and head and neck cancer.

30

35

In particular embodiments, the tumor or cancer is selected from the group consisting of lung cancer (e.g. non-small cell lung cancer (NSCLC), urothelial cancer (cancer of the bladder, ureter, urethra, or renal pelvis), endometrial cancer (EC), breast cancer (e.g. triple negative breast cancer (TNBC)), squamous cell carcinoma of the head and neck (SCCHN) (e.g. cancer of the oral cavity, pharynx or larynx) and cervical cancer.

Preferably, the tumor is a PD-L1 positive tumor. In certain embodiments, it is preferred that PD-L1 is expressed in $\geq 1\%$ of the cancer cells or tumor cells. The expression of PD-L1 may be determined using techniques known to the person skilled in the art and may e.g. be assessed by immunohistochemistry (IHC).

The tumor or cancer may in particular be a lung cancer. The lung cancer may be a non-small cell lung cancer (NSCLC), such as a squamous or a non-squamous NSCLC. Lung cancer is the second most common malignancy with an estimated age-standardized incidence rate of 22.4 per 100,000 and a leading cause of cancer death for both men and women (Kantar, 2021). Worldwide, approximately 2,206,771 new cases of lung cancer and 1,796,144 deaths are estimated in 2020 (GLOBOCAN, 2020). Non-small-cell lung cancer (NSCLC) accounts for 85% to 90% of all cases, with a 5-year survival rate of approximately 18% across all stages of the disease, and only 3.5% for metastatic disease (Jemal et al., 2011) (Kantar, 2021; SEER, 2018). In the 1L setting, treatment typically consists of platinum-based chemotherapy in combination with immunotherapy, or a targeted therapy, depending on molecular and biomarker analysis and the histology of the tumor (NCCN, 2021d). More recently, the advent of PD-1 and programmed death ligand 1 (PD-L1) inhibitors have improved outcomes for patients without driver mutations (approximately 62% of the non-squamous population and 77% of the squamous population (Kantar, 2021)). More treatment alternatives are needed for patients whose tumors do not harbor certain oncogenic mutations or do not express the biomarker for checkpoint inhibitor (CPI) options. Novel combinations with complementary approaches to enhance response may further address the unmet need in this population. For patients in the 2L setting, SOC is limited to platinum-based chemotherapy, a CPI monotherapy or docetaxel with or without ramucirumab depending on the previous therapy received. For patients in the third-line (3L) setting, chemotherapy monotherapy is the standard. Novel therapies are needed to limit toxicity and potentially enhance efficacy in this population (NCCN, 2021d).

In one embodiment, wherein the tumor or cancer is lung cancer, this tumor or cancer is a non-small cell lung cancer (NSCLC), such as a squamous or non-squamous NSCLC. The tumor or cancer may in particular be a metastatic cancer, such as metastatic NSCLC.

In one embodiment, wherein the tumor or cancer is lung cancer, in particular NSCLC, the tumor or cancer does not have an epidermal growth factor (EGFR)-sensitizing mutation and/or anaplastic

lymphoma (ALK) translocation / ROS1 rearrangement. EGFR-sensitizing mutations are those mutations that are amenable to treatment with an approved tyrosine kinase inhibitor (TKI).

In one embodiment, wherein the tumor or cancer is lung cancer, in particular NSCLC, the tumor or cancer comprises cancer cells and PD-L1 is expressed in $\geq 1\%$ of the cancer cells. Such expression may be determined by any means and method known to the skilled person, such as by immunohistochemistry (IHC), such as determined by a local SOC testing (preferably an FDA-approved test) or at a central laboratory.

In one embodiment, wherein the tumor or cancer is lung cancer, in particular NSCLC, the tumor or cancer comprises cancer cells and PD-L1 is expressed in 1% to 49% of the cancer cells. Such expression may be determined by any means and method known to the skilled person, such as by immunohistochemistry (IHC), such as determined by a local SOC testing (preferably an FDA-approved test) or at a central laboratory.

In one embodiment, wherein the tumor or cancer is lung cancer, in particular NSCLC, the tumor or cancer comprises cancer cells and PD-L1 is expressed in $\geq 50\%$ of the cancer cells. Such expression may be determined by any means and method known to the skilled person, such as by immunohistochemistry (IHC), such as determined by a local SOC testing (preferably an FDA-approved test) or at a central laboratory.

In one embodiment, the subject has not received prior systemic treatment of metastatic disease i.e., the subject has not received any systemic treatment of metastatic disease prior to receiving treatment according to the invention. According to this embodiment, the tumor or cancer is preferably a lung cancer, such as NSCLC.

In one embodiment, the subject has not received prior treatment with a checkpoint inhibitor/an immune checkpoint (ICP) inhibitor, i.e., before the treatment according to the first aspect, the subject has not received treatment with ICP inhibitor. In further embodiments, the subject has not received prior treatment with a PD-1 inhibitor or a PD-L1 inhibitor, such as anti- PD-1 antibody or an anti-PD-L1 antibody. In these embodiments the tumor or cancer is preferably a lung cancer, such as NSCLC.

In a further embodiment, the subject has not received prior treatment with a 4-1BB (CD137) targeted agent, with an antitumor vaccine, or with autologous cell immunotherapy. In one embodiment, the subject has not received prior treatment with an anti-4-1BB (CD137) antibody. In these embodiments the tumor or cancer is preferably a lung cancer, such as NSCLC.

In other embodiments the tumor or cancer has relapsed and/or is refractory after treatment, such as systemic treatment with a checkpoint inhibitor.

The subject may have received at least one prior line of systemic therapy, such as systemic therapy comprising a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody. The cancer or tumor may in particular have relapsed and/or is refractory, or the subject has progressed after treatment with a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy.

In particular embodiments the treatment according to the invention is provided to a subject having received prior treatment; e.g. as defined above, wherein the last prior treatment was with a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy. The last prior treatment may be with a PD1 inhibitor or PD-L1 inhibitor defined above.

Preferably, the therapy according to the invention is provided to a subject when the time from progression of that subject on last treatment with a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody is 8 months or less, such as 7 months or less, 6 months or less, 5 months or less, 4 months or less, 3 months or less, 2 months or less, 1 month or less, 3 weeks or less or such as 2 weeks or less.

By analogy, it may be preferred to offer therapy according to the present invention to a subjects when the time from last dosing of a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody as part of last prior treatment is 8 months or less, such as 7 months or less, 6 months or less, 5 months or less, 4 months or less, 3 months or less, 2 months or less, 1 month or less, 3 weeks or less or such as 2 weeks or less.

In further embodiments the cancer or tumor has relapsed and/or is refractory, or the subject has progressed during or after

- i) platinum doublet chemotherapy following treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody, or
- ii) treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody following platinum doublet chemotherapy.

Also, in these embodiments the tumor or cancer is preferably a lung cancer, such as NSCLC.

The subject receiving treatment according to the invention may in particular be a subject who has not received prior treatment with a taxane chemotherapeutic; e.g., docetaxel or paclitaxel, such as prior treatment of NSCLC with a taxane chemotherapeutic e.g., docetaxel.

5

Treatment regimen

The binding agent and the PD-1 inhibitor can be administered by any suitable way, such as intravenously, intraarterially, subcutaneously, intradermally, intramuscularly, intranodally, or intratumorally.

10

In one embodiment of the first aspect, the binding agent defined above is administered to the subject by systemic administration. Preferably, the binding agent is administered to the subject by intravenous injection or infusion. In one embodiment, the binding agent is administered in at least one treatment cycle.

15

In one embodiment, the antibody binding to PD-1 or antigen-binding fragment thereof is in particular administered to the subject by systemic administration. Preferably, the antibody binding to PD-1 or antigen-binding fragment thereof is administered to the subject by intravenous injection or infusion. In one embodiment, the antibody binding to PD-1 or antigen-binding fragment thereof is administered in at least one treatment cycle.

20

In one embodiment, the binding agent defined above and the antibody binding to PD-1 or antigen-binding fragment thereof are in particular administered to the subject by systemic administration. Preferably, the binding agent and the antibody binding to PD-1 or antigen-binding fragment thereof are administered to the subject by intravenous injection or infusion. In one embodiment, the binding agent and the antibody binding to PD-1 or antigen-binding fragment thereof are administered in at least one treatment cycle.

25

In one embodiment, each treatment cycle is about two weeks (14 days), three weeks (21 days) or four weeks (28 days), five weeks (35 days) or 6 weeks (48 days). In preferred embodiments each treatment cycle is three weeks (21 days). In other preferred embodiments, each treatment cycle is 6 weeks (48 days).

30

In particular embodiments, one dose of the binding agent defined above and one dose of the antibody binding to PD-1 or antigen-binding fragment thereof are administered or infused every second week (1Q2W), every third week (1Q3W) or every fourth week (1Q4W), every fifth week (1Q5W), preferably every third week (1Q3W). In other embodiments, one dose of the binding agent defined above and one

35

dose of the antibody binding to PD-1 or antigen-binding fragment thereof are administered every six weeks (1Q6W). The amount of binding agent and the amount of antibody binding to PD-1 or antigen-binding fragment thereof are preferably as defined above.

- 5 In some embodiments, one dose or each dose is administered or infused on day 1 of each treatment cycle. For example, one dose of the binding agent defined above and one dose of the antibody binding to PD-1 or antigen-binding fragment thereof may be administered on day 1 of each treatment cycle.

10 In some embodiments a 100 mg dose of the binding agent defined above and a 200 mg dose of the antibody binding to PD-1 or antigen-binding fragment thereof are administered every three weeks (1Q3W).

15 In other embodiments a 100 mg dose of the binding agent defined above and a 400 mg dose of the antibody binding to PD-1 or antigen-binding fragment thereof are administered every six weeks (1Q6W).

20 In particular embodiments, 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 200 mg dose of the antibody binding to PD-1 or antigen-binding fragment thereof, which is pembrolizumab or a biosimilar thereof, are administered every three weeks (1Q3W), such as on day one of each three-week treatment cycle.

25 In particular embodiments, the tumor or cancer is NSCLC; and a 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 200 mg dose of the antibody binding to PD-1 or antigen-binding fragment thereof, which is pembrolizumab or a biosimilar thereof, are administered every three weeks (1Q3W), such as on day one of each three-week treatment cycle.

30 In other embodiments a 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 400 mg dose of the antibody binding to PD-1 or antigen-binding fragment thereof, which is pembrolizumab or a biosimilar thereof, are administered every six weeks (1Q6W), such as on day one of every six-week treatment cycle.

35 In still other embodiments, the tumor or cancer is NSCLC; and wherein a 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 400 mg dose of the antibody binding to PD-1 or antigen-binding fragment thereof, which is pembrolizumab, are administered every six weeks (1Q6W), such as on day one of every six-week treatment cycle.

The antibody binding to PD-1 or antigen-binding fragment thereof may be administered first, followed by the binding agent. Alternatively, the binding agent is administered first, followed by the antibody binding to PD-1 or antigen-binding fragment thereof .

- 5 Each dose may be administered or infused over a minimum of 30 minutes, such as over a minimum of 60 minutes, a minimum of 90 minutes, a minimum of 120 minutes or a minimum of 240 minutes.

The binding agent may in particular be administered by using intravenous (IV) infusion over 30 minutes, such as over a minimum of 40 minutes, a minimum of 50 minutes or such as over a minimum of 60
10 minutes.

The antibody binding to PD-1 or antigen-binding fragment thereof may in particular be administered as an intravenous infusion over 30 minutes, such as over a minimum of 40 minutes, a minimum of 50 minutes or such as over a minimum of 60 minutes.

15

The binding agent defined above and the antibody binding to PD-1 or antigen-binding fragment thereof may be administered simultaneously. In an alternative preferred embodiment, the binding agent and the PD-1 inhibitor are administered separately.

- 20 The binding agent defined above and the antibody binding to PD-1 or antigen-binding fragment thereof may be administered in any suitable form (e.g., naked as such). However, it is preferred that the binding agent and the PD-1 inhibitor, are administered in the form of any suitable pharmaceutical composition as described herein. In one embodiment, at least the binding agent and the antibody binding to PD-1 or antigen-binding fragment thereof are administered in the form of separate pharmaceutical compositions
25 (i.e., one pharmaceutical composition for the binding agent and one pharmaceutical composition for the antibody binding to PD-1 or antigen-binding fragment thereof), preferably the binding agent and the antibody binding to PD-1 or antigen-binding fragment thereof are administered in the form of separate pharmaceutical compositions (i.e., one pharmaceutical composition for the binding agent and one pharmaceutical composition for the antibody binding to PD-1 or antigen-binding fragment thereof).

30

- A composition or pharmaceutical composition may be formulated with a carrier, excipient and/or diluent as well as any other components suitable for pharmaceutical compositions, including known adjuvants, in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. The
35 pharmaceutically acceptable carriers or diluents as well as any known adjuvants and excipients should be suitable for the binding agent and/or the antibody binding to PD-1 or antigen-binding fragment and the chosen mode of administration. Suitability for carriers and other components of pharmaceutical

compositions is determined based on the lack of significant negative impact on the desired biological properties of the chosen compound or pharmaceutical composition (e.g., less than a substantial impact [10% or less relative inhibition, 5% or less relative inhibition, etc.] upon antigen binding).

5 A composition, in particular the pharmaceutical composition of the binding agent defined above, the pharmaceutical composition of the antibody binding to PD-1 or antigen-binding fragment thereof, may include diluents, fillers, salts, buffers, detergents (e.g., a nonionic detergent, such as Tween-20 or Tween-80), stabilizers (e.g., sugars or protein-free amino acids), preservatives, solubilizers, and/or other materials suitable for inclusion in a pharmaceutical composition.

10 Pharmaceutically acceptable carriers, excipients or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).

15 Pharmaceutical carriers, excipients or diluents can be selected with regards to the intended route of administration and standard pharmaceutical practice.

Pharmaceutically acceptable carriers include any and all suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, antioxidants and absorption-delaying agents, and
20 the like that are physiologically compatible with the active compound, in particular a binding agent defined above and the antibody binding to PD-1 or antigen-binding fragment thereof.

Examples of suitable aqueous and non-aqueous carriers which may be employed in the (pharmaceutical) compositions include water, saline, phosphate buffered saline, ethanol, dextrose, polyols (such as
25 glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, corn oil, peanut oil, cottonseed oil, and sesame oil, carboxymethyl cellulose colloidal solutions, tragacanth gum and injectable organic esters, such as ethyl oleate, and/or various buffers. Other carriers are well known in the pharmaceutical arts.

30 Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the (pharmaceutical) compositions is contemplated.

35 The term "excipient" as used herein refers to a substance which may be present in a (pharmaceutical) composition of the present disclosure but is not an active ingredient. Examples of excipients, include

without limitation, carriers, binders, diluents, lubricants, thickeners, surface active agents, preservatives, stabilizers, emulsifiers, buffers, flavoring agents, or colorants.

The term "diluent" relates a diluting and/or thinning agent. Moreover, the term "diluent" includes any one or more of fluid, liquid or solid suspension and/or mixing media. Examples of suitable diluents include ethanol, glycerol and water

A (pharmaceutical) composition may also comprise pharmaceutically acceptable antioxidants for instance (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

A (pharmaceutical) composition may also comprise isotonicity agents, such as sugars, polyalcohols, such as mannitol, sorbitol, glycerol or sodium chloride in the composition.

A (pharmaceutical) composition may also contain one or more adjuvants appropriate for the chosen route of administration such as preservatives, wetting agents, emulsifying agents, dispersing agents, preservatives or buffers, which may enhance the shelf life or effectiveness of the composition. The composition as used herein may be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and micro-encapsulated delivery systems. Such carriers may include gelatin, glyceryl monostearate, glyceryl distearate, biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, poly-ortho esters, and polylactic acid alone or with a wax, or other materials well known in the art. Methods for the preparation of such formulations are generally known to those skilled in the art, see e.g. Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

"Pharmaceutically acceptable salts" comprise, for example, acid addition salts which may, for example, be formed by using a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, suitable pharmaceutically acceptable salts may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); ammonium (NH_4^+); and salts formed with suitable organic ligands (e.g., quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate). Illustrative examples of pharmaceutically acceptable salts

include, but are not limited to, acetate, adipate, alginate, arginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, galactate, galacturonate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, hydroxynaphthoate, iodide, isobutyrate, isothionate, lactate, lactobionate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate/diphosphate, phthalate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, sulfate, suberate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, undecanoate, valerate, and the like (see, for example, S. M. Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., 66, pp. 1-19 (1977)).

Salts which are not pharmaceutically acceptable may be used for preparing pharmaceutically acceptable salts and are included in the present disclosure.

In one embodiment, the binding agent, and the PD-1 inhibitor, used herein may be formulated to ensure proper distribution *in vivo*. Pharmaceutically acceptable carriers for parenteral administration include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except in so far as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Other active or therapeutic compounds may also be incorporated into the compositions.

Pharmaceutical compositions for injection must typically be sterile and stable under the conditions of manufacture and storage. The composition may be formulated as a solution, micro-emulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier may be an aqueous or a non-aqueous solvent or dispersion medium containing for instance water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as glycerol, mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin. Sterile injectable solutions may be prepared by incorporating the active compound in the

required amount in an appropriate solvent with one or a combination of ingredients e.g. as enumerated above, as required, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients e.g. from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, examples of methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Sterile injectable solutions may be prepared by incorporating the active compounds in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, examples of methods of preparation are vacuum-drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

In certain embodiments the binding agent for use according to the invention is formulated in a composition or formulation comprising histidine, sucrose and Polysorbate-80, and having a pH from about 5 to about 6, such as from 5 to 6. In particular, the binding agent for use according to the invention may be in a composition or formulation comprising about 20 mM histidine, about 250 mM Sucrose, about 0.02% Polysorbate-80, and having a pH of about 5.5, such as a composition or formulation comprising 20 mM histidine, 250 mM Sucrose, 0.02% Polysorbate-80, and having a pH of 5.5. The formulation may in particular embodiments comprise about 10 to about 30 mg binding agent/mL, such as 10-30 mg binding agent/mL, in particular about 20 mg binding agent/mL, such as 20 mg binding agent/mL.

The binding agent for use according to the invention may be provided in a composition as defined above and may then be diluted in 0.9% NaCl (saline) prior to administration.

In a second aspect, the present disclosure provides a kit comprising

(i) a binding agent comprising a first binding region binding to CD137 and a second binding region binding to PD-L1

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively,

and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively, and

(ii) an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the antibody inhibits PD-1 activity, and comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

The embodiments disclosed herein with respect to the first aspect (in particular regarding the binding agent, and the antibody binding to PD-1, or an antigen-binding fragment thereof also apply to the kit of the second aspect. In one embodiment, the kit comprises at least two containers, wherein one thereof contains the binding agent (as such or in the form of a (pharmaceutical) composition) and the second container contains the antibody binding to PD-1, or an antigen-binding fragment thereof (as such or in the form of a (pharmaceutical) composition).

In a third aspect, the present disclosure provides a kit of the second aspect for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject. The embodiments disclosed herein with respect to the first aspect (in particular regarding the binding agent, the PD-1 inhibitor, the treatment regimen, the specific tumor/cancer, and the subject) and/or the second aspect also apply to the kit for use of the third aspect.

In a fourth aspect, the present disclosure provides a method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject a binding agent prior to, simultaneously with, or after administration of an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1;

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively,

and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively,

5 and wherein the antibody inhibits PD-1 activity, and comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively,
10 and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

The embodiments disclosed herein with respect to the first aspect (in particular regarding the binding agent, the PD-1 inhibitor, the treatment regimen, the specific tumor/cancer, and the subject) also apply
15 to the method of the fourth aspect.

In a further aspect, the present disclosure provides an antibody binding to PD-1, or an antigen-binding fragment thereof for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject the PD-1 inhibitor prior to,
20 simultaneously with, or after administration of an antibody binding to PD-1, or an antigen-binding fragment thereof,

wherein the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48,
25 respectively, or the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively, and

wherein the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1
30

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively,

35 and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a

light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively.

The embodiments disclosed herein with respect to the first aspect (in particular regarding the binding agent, the PD-1 inhibitor, the optional one or more additional therapeutic agents, the treatment regimen, the specific tumor/cancer, and the subject) also apply to the PD-1 inhibitor for use of this further aspect.

Citation of documents and studies referenced herein is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the contents of these documents are based on the information available to the applicants and do not constitute any admission as to the correctness of the contents of these documents.

The description (including the following examples) is presented to enable a person of ordinary skill in the art to make and use the various embodiments. Descriptions of specific devices, techniques, and applications are provided only as examples. Various modifications to the examples described herein will be readily apparent to those of ordinary skill in the art, and the general principles defined herein may be applied to other examples and applications without departing from the spirit and scope of the various embodiments. Thus, the various embodiments are not intended to be limited to the examples described herein and shown, but are to be accorded the scope consistent with the claims.

Items of the present disclosure

1. A binding agent for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject the binding agent prior to, simultaneously with, or after administration of an antibody binding to Programmed Death-1 (PD-1), or an antigen-binding fragment thereof,

wherein

the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1;

a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively;

and

b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively

and

the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively; or the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

2. The binding agent for use according to item 1, wherein the antibody binding to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 50.
3. The binding agent for use of anyone of the preceding items, wherein the antibody binding to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 50.
4. The binding agent for use of any one of the preceding items, wherein the antibody binding to PD-1 or the antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 51 and a light chain comprising the amino acid sequence of SEQ ID NO: 52.
5. The binding agent for use of any one of the preceding items, wherein the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof.
6. The binding agent for use of any one of the preceding items, wherein PD-L1 is human PD-L1, in particular human PD-L1 comprising the sequence set forth in SEQ ID NO: 40, and/or CD137 is human CD137, in particular human CD137 comprising the sequence set forth in SEQ ID NO: 38.
7. The binding agent for use of any one of the preceding items, wherein the first binding region of the binding agent comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 or 9 and a light chain variable region (VL) region

and comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 5 or 10.

8. The binding agent for use of any one of the preceding items, wherein
the second binding region of the binding agent comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 11 and a light chain variable region (VL) region comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 15.

9. The binding agent for use of any one of the preceding items, wherein the first binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 1 or 9 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 5 or 10.

10. The binding agent for use of any one of the preceding items, wherein the second binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 11 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 15.

11. The binding agent for use of any one of the preceding items, wherein
- a) the first binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 5;
 - and
 - b) the second binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 11 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 15.

12. The binding agent for use of any one of the preceding items, wherein the binding agent is a multispecific antibody, such as a bispecific antibody.

13. The binding agent for use of any one of the preceding items, wherein the binding agent is in the format of a full-length antibody or an antibody fragment.

14. The binding agent for use of any one of the preceding items, wherein each variable region comprises three complementarity determining regions (CDR1, CDR2, and CDR3) and four framework regions (FR1, FR2, FR3, and FR4).
- 5 15. The binding agent for use of item 13, wherein said complementarity determining regions and said framework regions are arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- 10 16. The binding agent for use of any one of the preceding items, wherein the binding agent comprises
- i) a polypeptide comprising, consisting of or consisting essentially of, said first heavy chain variable region (VH) and a first heavy chain constant region (CH), and
 - ii) a polypeptide comprising, consisting of or consisting essentially of, said second heavy chain variable region (VH) and a second heavy chain constant region (CH).
- 15 17. The binding agent for use of any one of the preceding items, wherein the binding agent comprises
- i) a polypeptide comprising said first light chain variable region (VL) and further comprising a first light chain constant region (CL), and
 - 20 ii) a polypeptide comprising said second light chain variable region (VL) and further comprising a second light chain constant region (CL).
- 25 18. The binding agent for use of any one of the preceding items, wherein the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises
- i) a polypeptide comprising said first heavy chain variable region (VH) and a first heavy chain constant region (CH), and
 - ii) a polypeptide comprising said first light chain variable region (VL) and a first light chain constant region (CL);
- 30 and the second binding arm comprises
- iii) a polypeptide comprising said second heavy chain variable region (VH) and a second heavy chain constant region (CH), and
 - iv) a polypeptide comprising said second light chain variable region (VL) and a second light chain constant region (CL).
- 35 19. The binding agent for use of any one of the preceding items, wherein the binding agent comprises

- i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, and
- ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1.

5

20. The binding agent for use of any one of the preceding items, wherein said binding agent comprises

- i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, the first heavy chain comprising a first heavy chain constant region and the first light chain comprising a first light chain constant region; and
- ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1, the second heavy chain comprising a second heavy chain constant region and the second light chain comprising a second light chain constant region.

10

15 21. The binding agent for use of any one of items 16-20, wherein each of the first and second heavy chain constant regions (CH) comprises one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region and a CH3 region.

20 22. The binding agent for use of any one of items 16-21, wherein each of the first and second heavy chain constant regions (CHs) comprises a CH3 region and wherein the two CH3 regions comprise asymmetrical mutations.

23. The binding agent for use of any one of items 16-21, wherein in said first heavy chain constant region (CH) at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and in said second heavy chain constant region (CH) at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein said first and said second heavy chains are not substituted in the same positions.

25

30

24. The binding agent for use of item 23, wherein (i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first heavy chain constant region (CH), and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second heavy chain constant region (CH), or (ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain

35

according to EU numbering is R in said first heavy chain, and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second heavy chain.

- 5 25. The binding agent for use of any of the preceding items, wherein said binding agent induces Fc-mediated effector function to a lesser extent compared to another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CHs) comprising human IgG1 hinge, CH2 and CH3 regions.
- 10 26. The binding agent for use of item 25, wherein said first and second heavy chain constant regions (CHs) are modified so that the antibody induces Fc-mediated effector function to a lesser extent compared to an antibody which is identical except for comprising non-modified first and second heavy chain constant regions (CHs).
- 15 27. The binding agent for use of item 26, wherein each of said non-modified first and second heavy chain constant regions (CHs) comprises the amino acid sequence set forth in SEQ ID NO: 19 or 25.
- 20 28. The binding agent for use of item 26 or 27, wherein said Fc-mediated effector function is measured by binding to Fc γ receptors, binding to C1q, or induction of Fc-mediated crosslinking of Fc γ receptors.
- 25 29. The binding agent for use of item 28, wherein said Fc-mediated effector function is measured by binding to C1q.
- 30 30. The binding agent for use of any one of items 25-29, wherein said first and second heavy chain constant regions have been modified so that binding of C1q to said antibody is reduced compared to a wild-type antibody, preferably reduced by at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100%, wherein C1q binding is preferably determined by ELISA.
- 35 31. The binding agent for use of any one of the preceding items, wherein in at least one of said first and second heavy chain constant regions (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

32. The binding agent for use of item 31, wherein the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively, in said first and second heavy chains.
- 5 33. The binding agent for use of item 31 or 32, wherein the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first and second heavy chain constant regions (HCs).
- 10 34. The binding agent for use of any one of items 31-33, wherein the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F and E, respectively, and wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is R, or (ii) the position
15 corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.
- 20 35. The binding agent for use of any one of items 31-34, wherein the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F, E, and A, respectively, and wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain constant region is R,
25 or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.
- 30 36. The binding agent for use of any one of items 16-35, wherein the constant region of said first and/or second heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
35 a) the sequence set forth in SEQ ID NO: 19 or 25 [IgG1-FC];
b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and

- c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

5 37. The binding agent for use of any one of items 16-36, wherein the constant region of said first or second heavy chain, such as the second heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 20 or 26 [IgG1-F405L];
- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7,
10 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 9 substitutions, such as at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

15 38. The binding agent for use of any one of items 16-36, wherein the constant region of said first or second heavy chain, such as the first heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 21 or 27 [IgG1-K409R];
- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7,
20 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions
25 or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

39. The binding agent for use of any one of items 16-15, wherein the constant region of said first and/or second heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 22 or 28 [IgG1-Fc_FEA];
- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7,
30 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 7 substitutions, such as at most 6 substitutions, at most 5, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the
35 amino acid sequence defined in a) or b).

40. The binding agent for use of any one of items 16-39, wherein the constant region of said first and/or second heavy chain, such as the second heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
- a) the sequence set forth in SEQ ID NO: 24 or 30[IgG1-Fc_FEAL];
 - 5 b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
 - c) a sequence having at most 6 substitutions, such as at most 5 substitutions, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to
 - 10 the amino acid sequence defined in a) or b).
41. The binding agent for use of any one of items 16-40, wherein the constant region of said first and/or second heavy chain, such as the first heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
- 15 a) the sequence set forth in SEQ ID NO: 23 or 29 [IgG1-Fc_FEAR];
 - b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
 - c) a sequence having at most 6 substitutions, such as at most 5 substitutions, at most 4, at
 - 20 most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).
42. The binding agent for use of any one of the preceding items, wherein said binding agent comprises a kappa (κ) light chain constant region.
- 25
43. The binding agent for use of any one of the preceding items, wherein said binding agent comprises a lambda (λ) light chain constant region.
44. The binding agent for use of any one of the preceding items, wherein said first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.
- 30
45. The binding agent for use of any one of the preceding items, wherein said second light chain constant region is a lambda (λ) light chain constant region or a kappa (κ) light chain constant region.
- 35

46. The binding agent for use of any one of the preceding items, wherein said first light chain constant region is a kappa (κ) light chain constant region and said second light chain constant region is a lambda (λ) light chain constant region or said first light chain constant region is a lambda (λ) light chain constant region and said second light chain constant region is a kappa (κ) light chain constant region.
47. The binding agent for use of any one of items 42-46, wherein the kappa (κ) light chain comprises an amino acid sequence selected from the group consisting of
- a) the sequence set forth in SEQ ID NO:35,
 - b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
 - c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).
48. The binding agent for use of any one of items 43-47, wherein the lambda (λ) light chain comprises an amino acid sequence selected from the group consisting of
- a) the sequence set forth in SEQ ID NO: 36,
 - b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
 - c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).
49. The binding agent for use of any one of the preceding items, wherein the binding agent is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
50. The binding agent for use of any one of the preceding items, wherein the binding agent is a full-length IgG1 antibody.
51. The binding agent for use of any one of the preceding items, wherein the binding agent is an antibody of the IgG1m(f) allotype.
52. The binding agent for use of any one of the preceding items, wherein the binding agent comprises

- i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, wherein the first heavy chain comprising the sequence set forth in SEQ ID NO: 31, and the first light chain comprising the sequence set forth in SEQ ID NO: 32;
- 5 ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1, wherein the second heavy chain comprising the sequence set forth in SEQ ID NO: 33, and the second light chain comprising the sequence set forth in SEQ ID NO: 34.
- 10 53. The binding agent for use according to any one of the preceding items, wherein the binding agent is acasunlimab or a biosimilar thereof.
54. The binding agent for use according to any one of the preceding items, wherein the binding agent is in a composition or formulation comprising histidine, sucrose and Polysorbate-80, and
15 has a pH from 5 to 6.
55. The binding agent for use according to any one of the preceding items, wherein the binding agent is in a composition or formulation comprising about 20 mM histidine, about 250 mM Sucrose, about 0.02% Polysorbate-80, and having a pH of about 5.5.
20
56. The binding agent for use according to any one of the preceding items, wherein the binding agent is in a composition or formulation comprising 10-30 mg binding agent/mL, such as 20 mg binding agent/mL.
- 25 57. The binding agent for use according to any one of the preceding items, wherein the binding agent is in a composition as defined in any one of items 54 to 56 and is diluted in 0.9% NaCl (saline) prior to administration.
58. The binding agent for use of any one of the preceding items, wherein the subject is a human
30 subject.
59. The binding agent for use of any one of the preceding items, wherein the tumor or cancer is a solid tumor or cancer.
- 35 60. The binding agent for use according to any one of the preceding items, wherein said tumor is a PD-L1 positive tumor.

61. The binding agent for use of any one of the preceding items, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (*e.g.*, non-small cell lung cancer (NSCLC)), colorectal cancer, head and neck cancer, gastric cancer, breast cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, pancreatic cancer, hepatic cancer, thymoma and thymic carcinoma, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancers, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes, endometrial cancer, prostate cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma and mesothelioma.
62. The binding agent for use according to any one of the preceding items, wherein the tumor or cancer is selected from the group consisting of lung cancer (*e.g.* non-small cell lung cancer (NSCLC), urothelial cancer (cancer of the bladder, ureter, urethra, or renal pelvis), endometrial cancer (EC), breast cancer (*e.g.* triple negative breast cancer (TNBC)) and squamous cell carcinoma of the head and neck (SCCHN) (*e.g.* cancer of the oral cavity, pharynx or larynx)..
63. The binding agent for use of item 61 or 62, wherein the tumor or cancer is lung cancer, in particular a non-small cell lung cancer (NSCLC), such as a squamous or non-squamous NSCLC.
64. The binding agent for use of any one of items 61 to 63, wherein the tumor or cancer is metastatic, such as metastatic NSCLC.
65. The binding agent for use of item 61 to 64, wherein the lung cancer, in particular NSCLC, does not have an epidermal growth factor (EGFR)-sensitizing mutation and/or anaplastic lymphoma (ALK) translocation / ROS1 rearrangement.
66. The binding agent for use of any one of items 61 to 65, wherein the lung cancer, in particular NSCLC, comprises cancer cells and PD-L1 is expressed in $\geq 1\%$ of the cancer cells or tumor cells *e.g.* as assessed by immunohistochemistry (IHC).
67. The binding agent for use of item 66, wherein the lung cancer, in particular NSCLC, comprises cancer cells and PD-L1 is expressed in 1% to 49% of the cancer cells or tumor cells *e.g.* as assessed by immunohistochemistry (IHC).
68. The binding agent for use of item 66, wherein the lung cancer, in particular NSCLC, comprises cancer cells and PD-L1 is expressed in $\geq 50\%$ of the cancer cells or tumor cells *e.g.* as assessed by immunohistochemistry (IHC).

69. The binding agent for use of the preceding items, wherein the subject has not received prior systemic treatment of metastatic disease.
- 5 70. The binding agent for use of any one of the preceding items, wherein the subject has not received prior treatment with a checkpoint inhibitor; e.g., a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti- PD-1 antibody or an anti-PD-L1 antibody.
- 10 71. The binding agent for use of any one of the preceding items, wherein the subject has not received prior treatment with a 4-1BB (CD137) targeted agent, such as an anti-4-1BB (CD137) antibody, with an antitumor vaccine, or with autologous cell immunotherapy.
- 15 72. The binding agent for use of any one of items 1 to 68, wherein the tumor or cancer has relapsed and/or is refractory after treatment, such as systemic treatment with a checkpoint inhibitor.
73. The binding agent for use of any one of items 1 to 68 and 72, wherein the subject has received at least 1 prior line of systemic therapy, such as systemic therapy comprising a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody.
- 20 74. The binding agent for use of any one of items 1 to 68, 72 and 73, wherein the cancer or tumor has relapsed and/or is refractory, or the subject has progressed after treatment with a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy.
- 25 75. The binding agent for use of any one of items 1 to 68 and 72 to 74, wherein last prior treatment was with a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy.
- 30 76. The binding agent for use of any one of items 1 to 68 and 72 to 74, wherein the time from progression on last treatment with a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody is 8 months or less, such as 7 months or less, 6 months or less, 5 months or less, 4 months or less, 3 months or less, 2 months or less, 1 month or less, 3 weeks or less or such as 2 weeks or less.
- 35

77. The binding agent for use of any one of items 1 to 68 and 72 to 74, wherein the time from last dosing of a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody as part of last prior treatment is 8 months or less, such as 7 months or less, 6 months or less, 5 months or less, 4 months or less, 3 months or less, 2 months or less, 1 month or less, 3 weeks or less or such as 2 weeks or less.
78. The binding agent for use of any one of items 1 to 68 and 72 to 74, wherein the cancer or tumor has relapsed and/or is refractory, or the subject has progressed during or after
- i) platinum doublet chemotherapy following treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody, or
 - ii) treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody following platinum doublet chemotherapy.
79. The binding agent for use of any one of the preceding items, wherein the subject has not received prior treatment with a taxane chemotherapeutic agent e.g., docetaxel, such as prior treatment of NSCLC with a taxane chemotherapeutic agent e.g., docetaxel.
80. The binding agent for use of any one of the preceding items, wherein the binding agent and the antibody binding to PD-1, or the antigen-binding fragment thereof are administered in at least one treatment cycle, each treatment cycle being three weeks (21 days) or six weeks (42 days).
81. The binding agent for use of any one of the preceding items, wherein one dose of the binding agent and one dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every third week (1Q3W).
82. The binding agent for use of any one of the preceding items, wherein one dose of the binding agent and one dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every six weeks (1Q6W).
83. The binding agent for use of any one of the preceding items, wherein one dose of the binding agent and one dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered on day 1 of each treatment cycle.
84. The binding agent for use of any one of the preceding items, wherein the amount of said binding agent administered in each dose and/or in each treatment cycle is 100 mg.

85. The binding agent for use of any one of the preceding items, wherein the amount of said antibody binding to PD-1, or the antigen-binding fragment thereof administered in each dose and/or in each treatment cycle is 200 mg.
- 5 86. The binding agent for use of any one of the preceding items, wherein the amount of said antibody binding to PD-1, or the antigen-binding fragment thereof administered in each dose and/or in each treatment cycle is 400 mg.
- 10 87. The binding agent for use of any one of the preceding items, wherein a 100 mg dose of the binding agent and a 200 mg dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every three weeks (1Q3W).
- 15 88. The binding agent for use of any one of the preceding items, wherein a 100 mg dose of the binding agent and a 400 mg dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every six weeks (1Q6W).
- 20 89. The binding agent for use of any one of the preceding items, wherein the tumor or cancer is NSCLC; and wherein a 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 200 mg dose of the antibody binding to PD-1, which is pembolizumab, are administered every three weeks (1Q3W), such as on day one of each three-week treatment cycle.
- 25 90. The binding agent for use of any one of items 1-88, wherein the tumor or cancer is NSCLC; and wherein a 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 400 mg dose of the antibody binding to PD-1, which is pembolizumab, are administered every six weeks (1Q6W), such as on day one of every six-week treatment cycle.
- 30 91. The binding agent for use of any one of the preceding items, wherein the antibody binding to PD-1, or the antigen-binding fragment thereof is administered first, followed by the binding agent.
- 35 92. The binding agent for use of any one of the preceding items, wherein the binding agent is administered by using intravenous (IV) infusion over a minimum of 30 minutes, such as over a minimum of 60 minutes.
93. The binding agent for use of any one of the preceding items, wherein the binding agent is administered by using intravenous (IV) infusion over 30 minutes.

94. The binding agent for use of any one of the preceding items, wherein the PD-1 inhibitor is administered as an intravenous infusion over 30 minutes.
95. A kit comprising
- 5 (i) a binding agent comprising a first binding region binding to CD137 and a second binding region binding to PD-L1
- a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively,
- 10 b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively,
- 15 and
- (ii) an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.
- 20
- 25 96. The kit according to item 95, wherein the binding agent and/or the antibody binding to PD-1, or the antigen-binding fragment thereof is as defined in any one of items 1 to 94.
97. The kit according to item 95 or 96, wherein the binding agent, and the antibody binding to PD-1, or the antigen-binding fragment thereof are for systemic administration, in particular for injection or infusion, such as intravenous injection or infusion.
- 30
98. The kit according to any one of items 95-97 for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject.
99. The kit for use according to item 98, wherein the tumor or cancer and/or the subject and/or the method is/are as defined in any one of items 1-94.
- 35

100. A method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject a binding agent prior to, simultaneously with, or after administration of an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1
- 5 a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively;
- 10 and
- b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively
- 15 and
- wherein the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody binding to PD-1 comprises a
- 20 heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.
101. The method of item 100, wherein the tumor or cancer and/or the subject and/or the method and/or the binding agent and/or the PD-1 inhibitor is/are as defined in any one of items 1-94.
- 25

Further aspects of the present disclosure are disclosed herein.

Examples

Example 1: Cytokine secretion in co-cultures of purified CD8⁺ T cells and allogeneic mature dendritic cells (mDCs)

5

Methods

Monocyte and T cells from healthy donors

CD14⁺ monocytes and purified CD8⁺ T cells were obtained from Precision Medicine or BioIVT. Allogeneic donor pairs were used for the allogenic mixed lymphocyte reaction (MLR assay).

10

Differentiation of monocytes to immature dendritic cells

Human CD14⁺ monocytes were obtained from healthy donors (see above). For differentiation into immature dendritic cells (iDCs), $1 - 1.5 \times 10^6$ monocytes/mL were cultured for six days in Roswell Park Memorial Institute (RPMI) 1640 complete medium (ATCC modification formula; ThermoFisher, cat. no. A1049101) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS; Gibco, cat. no. 16140071), 100 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF; BioLegend, cat. no. 766106) and 300 ng/mL interleukin-4 (IL-4; BioLegend, cat. no. 766206) in T25 culture flasks (Falcon, cat. no. 353108) at 37°C. Once during these six days, the medium was replaced with fresh medium with supplements.

20

Maturation of iDCs

To mature the iDCs, the cells were harvested by collecting non-adherent cells, counted, incubated at $1 - 1.5 \times 10^6$ cells/mL in RPMI 1640 complete medium supplemented with 10% FBS, 100 ng/mL GM-CSF, 300 ng/mL IL-4 and $1 \times$ with lipopolysaccharide (LPS; ThermoFisher, cat. no. 00-4976-93) for 24 h prior to start of the MLR assay at 37°C.

25

Mixed lymphocyte reaction (MLR)

One day prior to the start of an MLR assay, purified CD8⁺ T cells, obtained from allogeneic healthy donors, were thawed. Cells were resuspended at 1×10^6 cells/mL in RPMI 1640 complete medium supplemented with 10% FBS and 10 ng/mL IL-2 (BioLegend, cat. no. 589106) and incubated O/N at 37°C.

30

The next day, the LPS-matured dendritic cells (mDCs, see Maturation of iDCs) and allogeneic purified CD8⁺ T cells were harvested and resuspended in AIM-V medium (ThermoFisher, cat. no. 12055091) at 4×10^5 cells/mL and 4×10^6 cells/mL, respectively.

35

In co-cultures, 20,000 mDCs were incubated with 200,000 allogeneic purified CD8⁺ T cells (DC:T cell ratio of 1:10) in the presence of GEN1046 (0.001 - 30 µg/mL) either alone or in combination with research-grade pembrolizumab (0.1 - 30 µg/mL or 0.1 - 100 µg/mL), research-grade pembrolizumab

(0.1 - 30 µg/mL or 0.1 – 100 µg/mL), bsIgG1-PD-L1×ctrl (30 µg/mL), bsIgG1-ctrl×4-1BB (30 µg/mL), isotype control antibodies IgG4 (100 µg/mL), or IgG1-ctrl-FEAL (30 µg/mL; Table 5) in AIM-V medium in a 96-well round-bottom plate (Falcon, cat. no. 353227) at 37°C. After 5 days, the plates were centrifuged at 500 ×g for 5 min and the supernatant was carefully transferred from each well to a new 96-well round bottom plate.

The collected supernatants from the MLR assay were analyzed for interferon (IFN)γ levels by enzyme-linked immunosorbent assay (ELISA) using an Alpha Lisa IFNγ kit (Perkin Elmer, cat. no. AL217) on an Envision instrument, according to the manufacturer's instructions. TNFα and IL-2 were measured as part of the Milliplex MAP- Human cytokine/TH17 panel (Millipore Sigma, cat. no. SPR1526) on a Luminex FLEXMAP 3D instrument.

Table 5:

Test compound	Supplier, cat. no.	Comprising SEQ ID NOs
GEN1046	N/A	CD137 binding arm: SEQ ID NOs: 1, 5, 35, 29 PD-L1 binding arm: SEQ ID NOs: 11, 15, 36, 30
bslgG1-PD-L1xctrl ¹	N/A	SEQ ID NO: 11, 15, 53, 54, 35, 36, 29, 30
bslgG1-ctrlx4-1BB ¹	N/A	SEQ ID NO: 35, 36, 1, 5, 35, 36, 29, 30
IgG1-ctrl-FEAL ²	N/A	SEQ ID NO: 53, 54, 30
Pembrolizumab	Selleckchem, cat. no. A2005 (non-clinical/research-grade version of the clinical product pembrolizumab; Lot no. A200504)	N/A
IgG4	Biolegend, cat. no. 403702 (isotype control antibody for pembrolizumab)	N/A

¹Control binding moiety based on anti-HIV gp120 antibody IgG1-b12 (Barbas et al., J Mol Biol 230: 812-823)

Results

GEN1046 induced IL-2 secretion in co-cultures of purified CD8+ T cells and allogeneic mDCs compared to IgG1-ctrl-FEAL in three donor pairs (see Figure 2). By contrast, pembrolizumab only induced limited increase in IL-2 (<50 pg/mL) compared to the isotype control IgG4 antibody. Concurrent exposure to GEN1046 and pembrolizumab induced a potent increase in IL-2 compared to either GEN1046 or pembrolizumab alone, increasing the maximum concentration of IL-2 about 2-3 fold compared to GEN1046 alone.

In addition, GEN1046 induced IFN γ secretion in co-cultures of purified CD8⁺ T cells and allogeneic mDCs compared to IgG1-ctrl-FEAL in three donor pairs (see Figure 3). Similarly, pembrolizumab enhanced IFN γ secretion in all three donor pairs, although to a more limited extent compared to
 5 GEN1046. Concurrent exposure to GEN1046 and pembrolizumab induced a further increase in IFN γ compared to either GEN1046 or pembrolizumab alone, especially at lower doses of GEN1046 (<1 μ g/mL).

Furthermore, GEN1046 induced TNF α secretion in co-cultures of purified CD8⁺ T cells and allogeneic
 10 mDCs compared to IgG1-ctrl-FEAL in three donor pairs (see Figure 4). By contrast, pembrolizumab only induced limited amounts of TNF α compared to GEN1046. Concurrent exposure to GEN1046 and pembrolizumab induced a slight increase in TNF α compared to GEN1046 alone, especially at 0.1 μ g/mL GEN1046 with all concentrations of pembrolizumab tested, indicating a left shift in potency.

15 Together, these results indicate that combining GEN1046 with pembrolizumab potentiates IFN γ , IL-2 and TNF α secretion relative to each antibody alone in an mDC/CD8⁺ T cell MLR assay. While potentiation of IFN γ was observed mainly at low concentrations of GEN1046, combination of GEN1046 with pembrolizumab showed potentiation of IL-2 at multiple concentrations.

20 **Example 2: MC38 mouse colon cancer tumor outgrowth**

Methods

MC38 mouse colon cancer cells were cultured in Dulbecco's Modified Eagle Medium supplemented
 25 with 10% heat-inactivated fetal bovine serum at 37°C, 5% CO₂. MC38 cells were harvested from a cell culture growing in log-phase and quantified.

MC38 cells (1×10^6 tumor cells in 100 μ L PBS) were injected subcutaneously in the right lower flank of female C57BL/6 mice (obtained from Vital River Laboratories Research Models and Services; age 6-8 weeks at start of experiment).

30 Tumor growth was evaluated three times per week using a caliper. Tumor volumes (mm³) were calculated from caliper measurements as $([\text{length}] \times [\text{width}]^2) / 2$, where the length is the longest tumor dimension and the width is the longest tumor dimension perpendicular to the length.

Treatment was initiated when tumors had reached a median volume of 64 mm³. Mice were randomized into groups (n = 10/group) with equal average tumor volume prior to treatment (64 mm³). On treatment
 35 days, the mice were injected intraperitoneally with mbsIgG2a-PD-L1x4-1BB (5 mg/kg; injection volume of 10 μ L/g body weight; two doses weekly for three weeks [2QW $\times$ 3]), an anti-mouse PD-1 antibody (anti-mPD-1; 10 mg/kg; injection volume of 10 μ L/g body weight; 2QW $\times$ 3; clone RMP1-14;

Leinco Technologies, cat. no. P372), a combination of mbsIgG2a-PD-L1x4-1BB (5 mg/kg) with anti-mPD-1 (10 mg/kg; in two separate injections [mbsIgG2a-PD-L1x4-1BB followed by anti-mPD-1 after 20 min] with an injection volume of 10 μ L/g body weight; 2QW $\times$ 3), or PBS with an injection volume of 10 μ L/g body weight (Table 6).

- 5 The mice were monitored daily for clinical signs of illness. Body weight measurements were performed three times a week after randomization. The experiment ended for the individual mice when the tumor volume exceeded 1500 mm³ or when the animals reached humane endpoints (e.g. when mice showed body weight loss > 20%, when tumors showed ulceration [> 75%], when serious clinical signs were observed and/or when the tumor growth blocked the physical activity of the mouse).

10

Table 6. Treatment groups and dosing regimen

Treatment group	N per group	Treatment	Dose ^a	Dosing route	Dosing regimen	Seq IDs/ Supplier, cat. no.
1	10	PBS	N/A	IP	2QW $\times$ 3 _a	N/A
2	10	Anti-mPD-1	10 mg/kg	IP	2QW $\times$ 3 _a	Leinco Technologies, cat. no. P372
3	10	mbsIgG2a-PD-L1x4-1BB	5 mg/kg	IP	2QW $\times$ 3 _a	Seq IDs: 60, 61, 55, 56, 57, 58, 59
4	10	mbsIgG2a-PD-L1x4-1BB + Anti-mPD-1	5 mg/kg + 10 mg/kg	IP	2QW $\times$ 3 _a	Seq IDs: 60, 61, 55, 56, 57, 58, 59 Leinco Technologies, cat. no. P372

^a 2QW $\times$ 3: two doses weekly for three weeks

Results

- 15 Rapid tumor outgrowth was observed in MC38-bearing mice treated with PBS (Figure 5A). In mice treated with anti-mPD-1 (10 mg/kg) or mbsIgG2a-PD-L1x4-1BB (5 mg/kg) delayed tumor outgrowth was observed, with a more pronounced delay in tumor outgrowth induced by mbsIgG2a-PD-L1x4-1BB (Figure 5A). In mice treated with mbsIgG2a-PD-L1x4-1BB (5 mg/kg) combined with anti-mPD-1 (10 mg/kg; both 2QW $\times$ 3) complete tumor regressions were observed in 6/10 mice at day 21 post-treatment
- 20 initiation compared to no complete tumor regressions observed for either agent alone in this model (Figure 5A). Kaplan-Meier analysis showed that treatment with the combination of mbsIgG2a-PD-L1x4-1BB and anti-mPD-1 induced a significant increase in progression-free survival, defined as the percentage of mice with tumor volume smaller than 500 mm³, when compared to the PBS-treated group ($p < 0.001$) and compared to either antibody alone ($p \leq 0.001$; Mantel-Cox; Figure 5B, Table 7). Hence,
- 25 therapeutic synergy was observed with this combination, defined as superior ($p < 0.05$) antitumor efficacy relative to the activity shown by each agent as monotherapy.

These results provide rationale for evaluating the combination of GEN1046 with an anti-PD-1 antibody to further amplify the anti-tumor immune response in cancer patients to produce durable and deep clinical responses and enhance survival.

30

Table 7. Mantel-Cox analysis of the progression-free survival induced by mbsIgG2a-PD-L1x4-1BB, anti-mPD-1 (either alone or in combination) in the MC38 model in C57BL/6 mice

Treatment groups compared			Progression-free survival ¹
			Mantel-Cox P value
PBS	vs	Anti-mPD-1	0.012
PBS	vs	mbsIgG2a-PD-L1x4-1BB	<0.001
PBS	vs	mbsIgG2a-PD-L1x4-1BB + anti-mPD-1	<0.001
Anti-mPD-1	vs	mbsIgG2a-PD-L1x4-1BB	0.515
Anti-mPD-1	vs	mbsIgG2a-PD-L1x4-1BB + anti-mPD-1	0.001
mbsIgG2a-PD-L1x4-1BB (5 mg/kg)	vs	mbsIgG2a-PD-L1x4-1BB + anti-mPD-1	<0.001

¹Tumor volume < 500mm³ was used as the cut-off for progression-free survival. Mantel-Cox analysis was performed at Day 45.

5

Example 3: Antigen-specific CD8+ T cell proliferation assay to determine the proliferation dose-response of GEN1046 and anti-PD-1 antibody Pembrolizumab in an antigen-specific T cell assay with active PD1/PD-L1 axis.

To measure induction of T cell proliferation by DuoBody-PD-L1x4-1BB or Pembrolizumab, an antigen-specific T cell proliferation assay with active PD1/PD-L1 axis was performed.

10

HLA-A2+ peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors (Transfusionszentrale, University Hospital, Mainz, Germany). Monocytes were isolated from PBMCs by magnetic-activated cell sorting (MACS) technology using anti-CD14 MicroBeads (Miltenyi; cat. no. 130-050-201), according to the manufacturer's instructions. The peripheral blood lymphocytes (PBLs, CD14-negative fraction) were frozen for future T-cell isolation. For differentiation into immature DCs (iDCs), 1x10⁶ monocytes/mL were cultured for five days in RPMI GlutaMAX (Life technologies GmbH, cat. no. 61870-044) containing 5% human AB serum (Sigma-Aldrich Chemie GmbH, cat. no. H4522-100ML), sodium pyruvate (Life technologies GmbH, cat. no. 11360-039), non-essential amino acids (Life technologies GmbH, cat. no. 11140-035), 100 IU/mL penicillin-streptomycin (Life technologies GmbH, cat. no. 15140-122), 1000 IU/mL granulocyte-macrophage colony-stimulating factor (GM-CSF; Miltenyi, cat. no. 130-093-868) and 1000 IU/mL interleukin-4 (IL-4; Miltenyi, cat. no. 130-093-924). Once during these five days, half of the medium was replaced with fresh medium. iDCs were harvested by collecting non-adherent cells and adherent cells were detached by incubation with PBS containing 2mM EDTA for 10 min at 37°. After washing iDCs were frozen in RPMI GlutaMAX containing 10 % v/v DMSO (AppliChem GmbH, cat. no. A3672,0050) + 50% v/v human AB serum for future antigen-specific T cell assays.

15

20

25

One day prior to the start of an antigen-specific CD8+ T cell proliferation assay, frozen PBLs and iDCs, from the same donor, were thawed. CD8+ T cells were isolated from PBLs by MACS technology using anti-CD8 MicroBeads (Miltenyi, cat. no. 130-045-201), according to the manufacturer's instructions.

About $10\text{--}15 \times 10^6$ CD8⁺ T cells were electroporated with 10 µg of in vitro translated (IVT)-RNA encoding the alpha-chain plus 10 µg of IVT-RNA encoding the beta-chain of a claudin-6-specific murine TCR (HLA-A2-restricted; described in WO 2015150327 A1) plus 10 µg IVT-RNA encoding PD-1 in 250 µL X-Vivo15 (Biozym Scientific GmbH, cat. no.881026) in a 4-mm electroporation cuvette (VWR International GmbH, cat. no. 732-0023) using the BTX ECM® 830 Electroporation System device (BTX; 500 V, 1 x 3 ms pulse). Immediately after electroporation, cells were transferred into fresh IMDM medium (Life Technologies GmbH, cat. no. 12440-061) supplemented with 5% human AB serum and rested at 37°C, 5% CO₂ for at least 1 hour. T cells were labeled using 1.6 µM carboxyfluorescein succinimidyl ester (CFSE; Invitrogen, cat. no. C34564) in PBS according to the manufacturer's instructions, and incubated in IMDM medium supplemented with 5% human AB serum, O/N.

Up to 5×10^6 thawed iDCs were electroporated with either 1 µg (GEN1046 dose-response) or 3 µg (Pembrolizumab dose-response) IVT-RNA encoding full length claudin-6, in 250 µL X-Vivo15 medium, using the electroporation system as described above (300 V, 1x12 ms pulse) and incubated in IMDM medium supplemented with 5% human AB serum, O/N.

The next day, cells were harvested. Cell surface expression of claudin-6 and PD-L1 on DCs and TCR and PD-1 on T cells was checked by flow cytometry. DCs were stained with an Alexa647-conjugated CLDN6-specific antibody (non-commercially available; in-house production) and with anti-human CD274 antibody (PD-L1, eBiosciences, cat. no.12-5983) and T cells were stained with an anti-Mouse TCR β Chain antibody (Becton Dickinson GmbH, cat. no. 553174) and with anti-human CD279 antibody (PD-1, eBioscience, cat. no. 17-2799). Electroporated DCs were incubated with electroporated, CFSE-labeled T cells in a ratio of 1:10 in the presence of GEN1046 (at 3-fold serial dilutions from 1 to 0.00015 µg/mL) or clinical-grade Pembrolizumab (at 4-fold serial dilutions from 0.8 to 0.00005 µg/mL; Keytruda, Phoenix Apotheke, PZN 10749897) in IMDM GlutaMAX supplemented with 5% human AB serum in a 96-well round-bottom plate. Flow cytometric analysis of T cell proliferation based on CFSE-dilution was performed after 5 days on a BD FACSCanto™ II or BD FACSCelesta™ flow cytometer (Becton Dickinson GmbH). Acquired data was analyzed using FlowJo software version 10.7.1. The expansion index values (determines the fold-expansion of the overall culture) per treatment condition were calculated and plotted as a function of the GEN1046 or Pembrolizumab concentration. Dose-response curves were generated and EC₂₀, EC₅₀, EC₉₀ and Hill-Slope values were calculated in GraphPad Prism version 9 (GraphPad Software, Inc.) using a 4-parameter logarithmic fit.

The GEN1046 dose response was analyzed at 3-fold serial dilutions from 1 to 0.00015 µg/mL (Figure 6A) with EC₂₀, EC₅₀, EC₉₀ and Hill-Slope values given in Table 8. A strong proliferation induction effect was seen with a mean EC₅₀ of 0.0064 µg/mL across four donors tested.

The Pembrolizumab dose response was analyzed at 4-fold serial dilutions from 0.8 to 0.00005 $\mu\text{g/mL}$ (Figure 6B) with EC_{50} , EC_{90} and Hill-Slope values given in Table 9. A strong proliferation induction effect was seen with a mean EC_{50} of 0.0149 $\mu\text{g/mL}$ across four donors tested.

- 5 **Table 8.** Determination of EC_{20} , EC_{50} and EC_{90} -values of GEN1046 based on CD8^+ T-cell expansion data as measured by an antigen-specific T-cell proliferation assay. Data shown are the values calculated based on the four parameter logarithmic fits.

Donor	EC_{50} value [$\mu\text{g/mL}$]	Hill-Slope	Calc. EC_{20} [$\mu\text{g/mL}$]	Calc. EC_{90} [$\mu\text{g/mL}$]
28	0.00754	1.485	0.00296	0.03311
89	0.00776	1.469	0.00302	0.03464
02	0.00523	1.910	0.00253	0.01651
72	0.00506	1.334	0.00179	0.02626
Mean	0.0064	1.549	0.0026	0.0276

- 10 **Table 9.** Determination of EC_{50} and EC_{90} -values of approved anti-PD-1 antibody Pembrolizumab based on CD8^+ T-cell expansion data as measured by an antigen-specific T-cell proliferation assay. Data shown are the values calculated based on the four parameter logarithmic fits. Mean is the arithmetic mean.

Donor	EC_{50} value [$\mu\text{g/mL}$]	Hill-Slope	Calc. EC_{90} [$\mu\text{g/mL}$]
26268_B	0.0218	1.122	0.1545
26685_A	0.0115	0.974	0.1098
26395_B	0.0113	0.9689	0.1091
Mean	0.0149	1.021	0.1245

15

Example 4: Release of the PD-1/PD-L1-mediated T cell inhibition and additional co-stimulation of CD8^+ T cell proliferation by GEN1046 in the presence or absence of anti-PD-1 antibody Pembrolizumab.

- To measure induction of T cell proliferation by GEN1046 in combination with anti-PD-1 antibody Pembrolizumab or IgG1-ctrl antibody, an antigen-specific T cell proliferation assay with active PD1/PD-L1 axis was performed (general assay set-up analogous to example 1). In short, claudin-6-IVT-RNA electroporated DCs were incubated with claudin-6-specific TCR- and PD1-IVT-RNA electroporated, CFSE-labeled T cells (ratio of 1:10) in the presence of GEN1046 in combination with a fixed concentration of Pembrolizumab or isotype control antibody IgG1-ctrl in IMDM GlutaMAX
- 20

supplemented with 5% human AB serum in a 96-well round-bottom plate. Three different concentrations of GEN1046 were tested, representing optimal, half-maximal and sub-optimal effective concentrations determined in previous experiments (0.2 µg/mL >EC90; 0.0067 µg/mL ≈EC50; 0.0022 µg/mL ≈EC20, see Example 1, Table 1). Pembrolizumab and the IgG1-ctrl antibody were tested at a concentration of 0.8 µg/mL, a concentration well above the EC90 value for Pembrolizumab (see Example 1, Table 2). Medium and 0.8 µg/mL IgG1-ctrl only were used to determine baseline proliferation. Pembrolizumab (0.8 µg/mL) was used as additional checkpoint inhibition control. Flow cytometric analysis of T cell proliferation based on CFSE-dilution was performed after 5 days on a BD FACSCanto™ II or BD FACSCelesta™ flow cytometer (Becton Dickinson GmbH). Acquired data was analyzed using FlowJo software version 10.7.1. The expansion index values per treatment condition were calculated and plotted using GraphPad Prism version 9 (GraphPad Software, Inc.).

Incubation of PD-1 and claudin-6-specific TCR expressing CD8+ T cells with DCs expressing PD-L1 and cognate antigen resulted in a minimal proliferation induction with expansion index values slightly above 1 in the medium only and IgG1-ctrl treated cultures for all three donors tested (see Figure 7). Releasing the PD-1:PD-L1 mediated inhibition by adding Pembrolizumab to the co-culture setting resulted in a modest increase of the expansion index, indicated by the dashed line in the graph. A more pronounced as well as dose-dependent increase in T cell proliferation was observed after addition of GEN1046, with the highest concentration tested resulting in the highest proliferation induction compared to the medium and low concentration single compound treatment conditions. Of note, the lowest concentration of 0.0022 µg/mL GEN1046 (w/o Pembrolizumab combination) resulted in expansion index values which were on par or even below those values recorded for the Pembrolizumab only control, being indicative of a sub-optimal PD-1:PD-L1 checkpoint blockade. In striking contrast, independent of the GEN1046 concentration tested, T cell proliferation induction for the GEN1046 with Pembrolizumab combination was always superior to the DuoBody-PD-L1x4-1BB without Pembrolizumab condition. The difference in expansion indices in between the w/ and w/o Pembrolizumab condition was particularly strong for the medium and low GEN1046 concentrations. Especially, in case of the sub-optimal GEN1046 condition (0.0022 µg/mL ≈EC20), addition of Pembrolizumab induced CD8+ T cell proliferation with considerably higher expansion indices compared to those observed for the Pembrolizumab only control.

Example 6: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

The study is an open-label, multi-center, phase 1/2a safety trial of GEN1046 (DuoBody® PD L1×4 1BB). The trial consists of 2 parts; a first-in-human (FIH) dose escalation (phase 1) and an expansion (phase 2a). The dose escalation evaluated GEN1046 in subjects with solid malignant tumors to

determine the maximum tolerated dose (MTD) or maximum administered dose and/or the recommended phase 2 dose (RP2D).

The expansion further evaluates the safety, tolerability, PK, and anti-tumor activity of the selected dose(s) in select solid tumors expansion cohorts for non-small cell lung cancer (NSCLC) (PD-1/L1 pre-treated and PD-1/L1 naïve), urothelial cancer (UC), endometrial cancer (EC), triple negative breast cancer (TNBC) (in subjects who have received prior treatment with a PD-1/L1 inhibitor and in subjects who have not received such treatment): and squamous cell carcinoma of the head and neck (SCCHN).

Table 10: Expansion cohorts

Cohort No.	n	Cancer Type	Sub-cohort	Prior Treatment	Trial Treatment
EC1	140	NSCLC		Prior CPI treatment	GEN1046 100 mg 1Q3W
EC2	40	NSCLC		PD-1/L1 naïve	GEN1046 100 mg 1Q3W
EC3	40	UC		Prior CPI treatment	GEN1046 100 mg 1Q3W
EC4	40	Endometrial cancer		PD-1/L1 naïve	GEN1046 100 mg 1Q3W
EC5	40	TNBC	5a	Prior CPI treatment	GEN1046 100 mg 1Q3W
			5b	PD-1/L1 naïve	GEN1046 100 mg 1Q3W
EC6	40	SCCHN	6a	Prior CPI treatment	GEN1046 100 mg 1Q3W
			6b	PD-1/L1 naïve	GEN1046 100 mg 1Q3W

A diagram of the trial design is provided in Figure 8. Further disclosure of the dose escalation and the expansion cohorts, as well as preliminary results from dose escalation are provided in International Patent Application WO 2021/156326.

Expansion Cohorts (EC) A and B: NSCLC Treatment-Naïve for Metastatic Disease: GEN1046 in Combination with Pembrolizumab)

Expansion Cohorts ECA and ECB evaluates 100 mg GEN1046 in combination with pembrolizumab at 2 different dosing schedules:

ECA tests a GEN1046 regimen of 100 mg 1Q3W with a pembrolizumab regimen of 200 mg 1Q3W.

Based on PK/pharmacodynamic modeling, this regimen of GEN1046 is expected to result in peak trimer formation and sustained 4-1BB activation, which in combination with pembrolizumab may allow for optimum engagement of both targets/pathways and improved anti-tumor efficacy.

ECB evaluates a GEN1046 regimen of 100 mg 1Q6W with a pembrolizumab regimen of 400 mg 1Q6W.

Based on PK/pharmacodynamic modeling, this regimen of GEN1046 is expected to provide intermittent/transient activation of 4-1BB in a 6-week dosing cycle compared to sustained 4-1BB

activation in a 3-week dosing cycle. Transient activation of 4-1BB is expected to allow for resetting of the T-cell response and reduce chronic interferon signaling (Weber, E. W., et al. (2021), Science 372 (6537)), which may prevent exhaustion of tumor infiltrating CD8+ T cells due to continuous 4-1BB activation and, in combination with pembrolizumab, may provide improved depth and duration of response (DoR).

Pembrolizumab regimens of 200 mg Q3W and 400 mg Q6W have been approved as first- and second-line SOC treatment for NSCLC, respectively.

Treatment Discontinuation

Treatment continues until the subject fulfills one of the treatment discontinuation criteria (please see below).

Inclusion criteria

Expansion cohorts A and B

- a. Subjects with metastatic NSCLC who have received no prior systemic treatment regimens for metastatic disease. Subjects must not have received prior treatment with a PD-1/L1 inhibitor. Subjects must have radiographic disease progression on or after last prior treatment. This is not required for subjects who have newly diagnosed disease.
- b. Subjects with NSCLC of any histology are enrolled. Subjects with a histological or cytological diagnosis of non-squamous NSCLC must not have an EGFR-sensitizing mutation and/or ALK translocation/ROS1 rearrangement. EGFR-sensitizing mutations are those mutations that are amenable to treatment with an approved TKI.
- c. Subjects must have a PD-L1 expression result from the central laboratory available prior to Cycle 1 Day 1 (C1D1) from a fresh tumor sample obtained by core-needle or excisional biopsy OR from resected tumor tissue at the time that metastatic disease was diagnosed.
- d. Tumor demonstrates PD-L1 expression in $\geq 1\%$ of tumor cells (TPS $\geq 1\%$) as assessed by immunohistochemistry (IHC) determined by central laboratory testing.

For Both Dose Escalation and Expansion

3. Subject must be a man or woman ≥ 18 years of age.
4. Subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the trial and is willing to participate in the trial prior to any trial related assessments or procedures.
5. Subject must have measurable disease according to RECIST 1.1.
6. Subject must have Eastern Cooperative Oncology Group (ECOG) 0-1.
7. Subject must have organ and bone marrow function as follows:

a. Bone marrow/hematological function:

absolute neutrophil count (ANC) $\geq 1.5 \times 10^9/\text{L}$; hemoglobin $\geq 9.0 \text{ g/dL}$; platelet count $\geq 100 \times 10^9/\text{L}$

b. Liver function:

5 - Total bilirubin $\leq$ upper limit of normal (ULN)

- ALT $\leq 1.5 \times \text{ULN}$

- AST $\leq 1.5 \times \text{ULN}$

- Albumin $\geq 30 \text{ g/L}$

c. Coagulation status:

10 - Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.5

- Activated partial thromboplastin time (aPTT) $\leq 1.5 \times \text{ULN}$ (without anticoagulation therapy)

- Subjects receiving anticoagulant therapies should have the PT and aPTT within the therapeutic range of intended use of anticoagulants

15 d. Renal function:

Glomerular filtration rate (GFR) $\geq 45 \text{ mL/min/1.73 m}^2$ – e.g. according to the abbreviated Modification of Diet in Renal Disease equation:

$$\text{GFR} = 186 \times (\text{SCr}^{-1.154}) \times (\text{age}^{-0.203})$$

20 (where SCr, the serum creatinine level, is expressed in mg/dL; multiply it by 0.742 if the subject is female; multiply it by 1.212, if the subject is African-American (Levey et al., 1999).

12. A) In the dose escalation part, all subjects must provide a tumor tissue sample (Formalin Fixed Paraffin Embedded blocks/slides) from archival tissue or fresh biopsy collected before Cycle 1 Day 1, preferably derived from advanced disease stage.

25 B) In the expansion part, all subjects must provide a mandatory fresh biopsy (formalin fixed paraffin embedded [FFPE] blocks/slides) (bronchoscopy-guided biopsies, fine needle aspirates, cell blocks, cell pellets, clots, bone marrow, and cytological specimens are not acceptable) which contains tumor tissue and is taken after failure/stop of last prior treatment.

Exclusion Criteria

30 Any potential subject who meets any of the following criteria will be excluded from participating in the trial.

1. Subject has uncontrolled intercurrent illness, including but not limited to:

- a. Ongoing or active infection requiring IV treatment with anti-infective therapy that has been administered less than 2 weeks prior to first dose.
- b. Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris or cardiac arrhythmia.
- 5 c. Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management.
- d. Ongoing or recent (within 1 year) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse event (irAEs).
- 10 e. Subjects with a history of grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment should be excluded. Subjects with irAEs below grade 3 that led to discontinuation should be discussed with the sponsor.
- f. Subjects with a prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade are excluded.
- 15 g. History of chronic liver disease or evidence of hepatic cirrhosis.
- h. History of non-infectious pneumonitis that has required steroids or currently has pneumonitis.
- i. History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of GEN1046.
- 20 j. Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
- 2. All subjects should undergo a computed tomography (CT) scan or magnetic resonance imaging (MRI) of the brain to document new or existing CNS lesions. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, spinal cord compression (from disease), carcinomatous meningitis, or stroke will be excluded.
- 25 a. Transient ischemic attack >1 month prior to screening is allowed.
- b. Subjects with newly identified or known unstable or symptomatic CNS metastases will be excluded. Subjects with previously treated brain metastases may participate provided they are radiologically stable (i.e. without evidence of progression) for at least 28 days by repeat imaging (note that the repeat imaging should be performed during trial screening). Subjects
- 30 should be clinically stable and should not be undergoing acute corticosteroid therapy or steroid taper or have received stereotactic radiation or whole-brain radiation within 14 days prior to C1D1. Chronic steroid therapy is acceptable provided that the dose is stable for the last 14 days prior to C1D1 (≤ 10 mg prednisone daily or equivalent).

3. Prior therapy:

a. Radiotherapy: Radiotherapy within 14 days prior to first GEN1046 administration. Palliative radiotherapy will be allowed.

b. Unless otherwise noted below, treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1046 administration. Accepted exceptions are bisphosphonates (e.g. pamidronate, zoledronic acid, etc) and denosumab.

c. Subject has received any investigational agent (including investigational vaccines) or used an invasive investigational medical device within 28 days before the planned first dose of GEN1046 or is currently enrolled in an interventional trial.

Note: Subjects who are in the follow-up phase of an interventional trial may participate if the subject has not received the investigational agent within 28 days of the first dose of GEN1046.

d. Prior treatment with live, attenuated vaccines within 3 weeks prior to initiation of GEN1046 treatment.

e. Chronic systemic immunosuppressive corticosteroid doses, i.e. prednisone >10 mg daily or a cumulative dose >150 mg prednisone within 14 days before the first GEN1046 administration. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.

f. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor (GM-CSF) support 4 weeks prior to first GEN1046 administration or being chronically transfusion dependent.

g. History of $\geq$ grade 3 allergic reactions to monoclonal antibody (mAb) therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.

h. Subjects who discontinued treatment due to disease progression within the first 6 weeks of a CPI containing treatment.

i. Prior treatment with a 4-1BB (CD137) targeted agent.

j. Prior treatment with a T-cell agonist or anti-cytotoxic T lymphocyte-associated protein 4 targeted agent within 12 weeks prior to the initiation of treatment.

4. Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to grade 1 or less with the exception of alopecia, anorexia, vitiligo, fatigue, hyperthyroidism, hypothyroidism, and peripheral neuropathy. Anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy must have recovered to $\leq$ grade 2.

5. Known past or current malignancy other than inclusion diagnosis, except for:
 - a. Cervical carcinoma of Stage 1B or less.
 - b. Non-invasive basal cell or squamous cell skin carcinoma.
 - c. Non-invasive, superficial bladder cancer.
 - 5 d. Prostate cancer with currently undetectable PSA.
 - e. Breast cancer in BRCA1 or BRCA2 positive ovarian cancer subject (not applicable for breast cancer expansion cohort).
 - f. Any curable cancer with a CR of >2 years duration.
6. Subject has known allergies, hypersensitivity, or intolerance to GEN1046 or its excipients.
- 10 7. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g. compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
8. Subject has had major surgery, (e.g. requiring general anesthesia) within 4 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time

15 the subject is expected to participate in the trial.

Note: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.
9. Known history of seropositivity for human immunodeficiency virus (HIV).
10. Known history/positive serology for hepatitis B (unless immune due to vaccination or resolved

20 natural infection or unless passive immunization due to immunoglobulin therapy):
 - a. Positive test for antibodies to hepatitis B core antigens

and

b. Negative test for antibodies to hepatitis B surface antigens.
11. Known medical history or ongoing hepatitis C infection that has not been cured.
- 25 12. Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the trial or evaluation of the trial result.
13. Subject has been dosed in this trial before.
14. Subject is a woman who is pregnant or breast-feeding.
15. Subject has contraindications to the use of pembrolizumab per local prescribing information.

30 Administration of GEN1046

GEN1046 is administered using intravenous (IV) infusion over a minimum of 60 minutes on Day 1 of each treatment cycle of either 21 days or 42 days after all procedures and assessments have been completed.

In ECA and -B, subjects receive GEN1046 100 mg 1Q3W in combination with pembrolizumab 200 mg 1Q3W (ECA) or GEN1046 100 mg 1Q6W in combination with pembrolizumab 400 mg 1Q6W (ECB).

Administration of pembrolizumab

ECA and ECB: Pembrolizumab 200 mg or 400 mg is administered on Day 1 of each 3-week OR 6-week treatment cycle, respectively, after all pre-treatment procedures and assessments have been completed.

Pembrolizumab is administered first, followed by GEN1046. Pembrolizumab is administered as an intravenous infusion over 30 minutes. Pembrolizumab must be promptly followed by a saline flush to clear the line before starting the infusion of GEN1046. The time in between infusions is approximately 30 minutes or longer depending on the situation. Dose reductions for pembrolizumab are not recommended.

Trial drug information

GEN1046 – 20 mg/mL formulated in 20 mM histidine, 250 mM Sucrose, 0.02% Polysorbate-80, pH 5.5 – is a clear to opalescent, colorless to slightly yellow solution supplied as a concentrate for solution for infusion to be diluted (at site) in 0.9% NaCl (saline).

Pembrolizumab (Keytruda®) infusion is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for IV infusion.

20 Infusion-Related Reactions (IRR) to GEN1046

For subjects who experience an IRR associated with administration of GEN1046:

- Grade 1: If an IRR grade 1 occurs, the infusion does not need to be interrupted and can be continued at the investigator's discretion at half the infusion rate under close medical supervision.
- Grade 2-3: If an IRR grade 2 or 3 occurs, the infusion should be interrupted, and appropriate medical management instituted. The infusion may be re-started at the investigator's discretion at half the infusion rate under close medical supervision if symptoms have resolved to $\leq$ grade 1 within an hour.
 - o Subjects who have experienced prior infusion related grade 2 or 3 reactions in the trial should be pre-medicated. Pre-medication to prevent IRR in subsequent infusions may be administered at the investigator's discretion according to local guidelines but preferably includes an antihistamine (e.g. diphenhydramine 50 mg or equivalent antihistamine), acetaminophen/paracetamol (e.g. acetaminophen 500-1000 mg or equivalent), and if considered necessary, subjects should receive corticosteroids at a suggested maximum dose of 100 mg prednisone or equivalent.

- o If the subject has a second grade 3 IRR despite pre-medication, the infusion should be stopped and the subject should be withdrawn from treatment.
- Grade 4: If anaphylaxis or grade 4 IRR occurs, administration of GEN1046 should be discontinued immediately and permanently and appropriate medical therapy should be administered.

Infusion-Related Reactions to Pembrolizumab

Pembrolizumab may cause severe or life-threatening IRRs including severe hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after drug infusion and generally resolve completely within 24 hours of completion of infusion.

Table 11: Side Effects Associated with Pembrolizumab

Most Common Side Effects (≥20% of patients)	Less Common Side Effects (may be severe or life threatening)
• <i>Fatigue</i> • <i>Cough</i> • <i>Nausea</i> • <i>Pruritus</i> • <i>Rash</i> • <i>Decreased appetite</i> • <i>Constipation</i> • <i>Arthralgia</i> • <i>Diarrhea</i>	• <i>Immune-related AEs</i> • <i>Infusion-related reactions</i> • <i>Please refer to the local label of pembrolizumab</i>

Discontinuation of Treatment

Subjects receive GEN1046 treatment on Day 1 of each 3-week or 6-week treatment cycle until one of the predefined discontinuation of treatment criteria (below) has been met.

Subjects in cohorts ECA and ECB receive pembrolizumab treatment in combination with GEN1046 on Day 1 of each 3-week treatment cycle or on Day 1 of each 6-week treatment cycle, respectively, until progressive disease, or until 1 of the predefined discontinuation of treatment criteria has been met. Both GEN1046 and pembrolizumab should be discontinued. Subjects may only continue on GEN1046 or pembrolizumab monotherapy if approved by sponsor's medical monitor. Subjects move into the safety follow-up period once both drugs have been discontinued.

- Radiographic disease progression or confirmed radiographic disease progression by iRECIST
- Clinical progression
- Lost to follow-up
- Subject requests to discontinue treatment
- Death
- Unacceptable AEs requiring trial treatment discontinuation
- Investigator believes that it is in the best interest of the subject to stop trial treatment

- Withdrawal of consent
- Pregnancy

Efficacy Assessment

- 5 All subjects have imaging of the brain, thorax, abdomen, and pelvis performed during screening. Head and neck imaging is always required for subjects with SCCHN.

Tumor imaging is preferably acquired by computed tomography (CT). Up to 5 target lesions (maximum 2 per organ) are defined at screening and are followed throughout the trial. Non-target lesions are also assessed throughout the trial. Initial tumor imaging at screening is performed within 21 days prior to the
10 date of first dose. The site reviews screening images to confirm the subject has measurable disease per RECIST 1.1.

- On-trial imaging is performed every 6 weeks (± 7 days) for 50 weeks, and every 12 weeks (± 7 days) thereafter from the date of first dose until disease progression is assessed by the investigator (unless the investigator elects to continue treatment and follow iRECIST), the start of new anti-cancer therapy,
15 withdrawal of consent, or death, whichever occurs first.

RECIST 1.1 criteria are used for secondary endpoint response evaluation (Eisenhauer et al., 2009, Eur J Cancer 45, 228-247.); iRECIST are used for exploratory endpoint response evaluation (Seymour et al., 2017, Lancet Oncol 18, e143-e152). If the investigator elects to apply iRECIST, treatment should continue until PD has been verified.

- 20 Additional CT scans or MRI scans may be performed at the investigators discretion to confirm response or new symptoms. Tumor imaging to confirm PR or CR should be performed at least 4 weeks after the first indication of a response is observed.

iRECIST Assessment of Disease

- 25 iRECIST is based on RECIST 1.1 but has been modified to account for the unique response patterns observed with immunotherapy. In this trial, iRECIST is evaluated as an exploratory endpoint (Seymour et al., 2017, Lancet Oncol 18, e143-e152).

- iRECIST disease progression should be confirmed at least 4 to 7 weeks after the first radiologic evidence of PD in clinically stable participants. Subjects who have unconfirmed disease progression may continue
30 on GEN1046 treatment until progression is confirmed as long as the subject is clinically stable. Subjects who are clinically stable must meet the following criteria:

- Subject must have clinical benefit from continuation of GEN1046 treatment (as assessed by the investigator) and must not have rapid disease progression
 - Subject is tolerating GEN1046 treatment
 - Subject must have a stable ECOG status
- 35

- Treatment beyond progression will not delay an imminent intervention to prevent serious complications for disease progression (e.g. central nervous system metastases requiring immediate treatment).

Any clinically unstable subjects are discontinued from GEN1046 treatment at the first occurrence of radiographic disease progression. If repeat imaging shows iRECIST confirmed disease progression (iCPD), subjects will discontinue GEN1046 treatment.

ECOG Performance Status

The ECOG performance status will be assessed by the investigator at screening, on Day 1 of each cycle, and at the treatment discontinuation visit. Performance status will be scored using the ECOG performance status scale index (Table 12).

Table 12:

Score	Definition
0	Fully active, able to carry out all normal activity without restriction.
1	Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g, light housework, office work.
2	Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
4	Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair.
5	Dead.

ECOG=Eastern Cooperative Oncology Group.

Preliminary results and conclusions

- Doses of 25 to 1200 mg Q3W that were evaluated in the escalation phase of the FIH trial were safe and generally well tolerated. The MTD was not reached.
- Preliminary evaluation of safety data showed no dose dependency, indicating there is no dose response with respect to frequency of AEs.
- Responses according to RECIST v1.1 were observed at GEN1046 doses of 80 to 200 mg Q3W in the dose-escalation phase of the FIH trial. Additionally, responses were also observed in expansion with a dose of 100 mg Q3W.
- Consistent modulation of pharmacodynamic markers (proliferating [Ki67+] effector memory CD8+ T cells and total CD8+ T cells and increased levels of IFN γ and IP-10) was observed in peripheral blood at dose levels ≤ 200 mg. Reduced modulation of these endpoints was observed at higher dose levels (≥ 400 mg).
- The semi-mechanistic PK/pharmacodynamic model (see example 13 in WO 2021/156326) predicted a bell-shaped response for trimer formation, which peaked around 100 mg Q3W. To

balance the trimer levels and target engagement with respect to PD-L1 RO, a dose of 100 mg Q3W was chosen that may provide optimum initial response to GEN1046.

- For GEN1046 monotherapy, progression-free survival (PFS) was longer in subjects having received prior treatment with checkpoint inhibitor (Figure 9).
- Clinica response to GEN1046 monotherapy in checkpoint inhibitor pre-treated NSCLC subjects associates with time from last prior anti-PD-1 therapy (Figure 12)
 - NSCLC subjects with benefit on GEN1046 monotherapy showed a trend for more recent treatment with last anti-PD-1 agent

Shorter time since anti-PD-1 agent containing therapy may suggest residual anti-PD-1 activity is facilitating response to GEN1046. Supportive of this, patients treated with anti-PD-1 agents in the clinic exhibit long-term PD-1 receptor occupancy by the therapeutic antibody which can last for more than 200 days (Brahmer et al., JCO 2010; 28(19): 3167–3175). Having therapeutic a-PD-1 agent still bound to the PD-1 receptors may in turn lead to a larger number of free PD-L1 molecules being available for binding to GEN1046.

Presence of residual a-PD-1 activity may also allow for more complete blockade of the PD-1 pathway (blocking interaction of PD-1 with both PD-L1 and PD-L2), which may be important for the biological activity of GEN1046 in the post-CPI setting.

More recent anti-PD-1 treatment may have direct impact on the tumor microenvironment, for example by initiating an anti-tumor immune response which can be enhanced by GEN1046 if it is given immediately or soon after progression on the anti-PD-1 containing therapy.

- Responders presented with “low” PD-1+ CD8 T cell frequency, which may reflect receptor occupancy (RO) by prior a-PD-1 treatment
- Conversely, non-responders presented with generally high PD-1+ CD8 T cell frequency which may indicate a more exhausted phenotype

Example 8: Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor

Trial design

The trial is a phase 2, multicenter, randomized, open-label trial evaluating the safety and efficacy of GEN1046 as monotherapy and in combination therapy with pembrolizumab in adult subjects with locally advanced or metastatic NSCLC after treatment with CPI-containing therapy.

Approximately 126 subjects will be enrolled in the trial, and 120 eligible subjects (40 in each arm) will be randomized to one of the treatment arms described below. Subjects must provide fresh and/or archival tumor tissue for prospective central confirmation of PD-L1 expression in the tumors. The percentage of subjects with non-squamous histology will be capped at approximately 70%. Randomization will be stratified by PD-L1 expression (TPS $\geq$ 50% vs 1% to 49%) and histology (squamous vs non-squamous).

- A. GEN1046 100 mg Q3W for the first 2 cycles followed by GEN1046 500 mg Q6W for the subsequent cycles
- B. GEN1046 100 mg Q3W in combination with pembrolizumab 200 mg Q3W
- C. GEN1046 100 mg Q6W in combination with pembrolizumab 400 mg Q6W

During a preliminary safety run-in, 6 subjects will be enrolled to Arms B and C (3 subjects per arm). These subjects will be closely monitored and followed for a minimum of 3 weeks. After completion of the safety run-in for these cohorts, the collected data (including, but not limited to, all relevant safety and clinical data) will be evaluated. After this review, if the combination regimen is considered well tolerated, randomization for Arms A, B, and C will begin.

Treatment for a subject should continue until the subject fulfils one of the treatment discontinuation criteria defined below.

Computed tomography (CT) with contrast or magnetic resonance imaging (MRI) is obtained at baseline before the first dose and 6, 12, 18, and 24 weeks ($\pm$ 7 days) after the first dose of the trial medication, and thereafter, every 9 weeks ($\pm$ 7 days). CT or MRI will continue to be obtained until disease progression (as assessed by the investigator), start of subsequent anticancer therapy, withdrawal of consent, or death, whichever occurs first. Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined disease progression must be confirmed by an additional confirmatory scan following the initial documented progressive disease (PD). Any clinically unstable subject is discontinued from trial treatment at the first occurrence of radiographic disease progression and is not required to have repeated imaging to confirm PD. Should delayed response to treatment be suspected, the investigator may continue treatment beyond the time of RECIST v1.1-defined progression, if the subject is experiencing clinical benefit. Once a subject experiences PD, survival status is collected every 12 weeks until death, withdrawal of consent, loss to follow up, or the end of the trial, whichever occurs first. Subsequent anti-cancer treatments and the subject's response to them are also collected. During treatment beyond RECIST v1.1-defined progression, iRECIST is used to assess subsequent progression.

Trial design rationale

The trial is a randomized, open-label trial evaluating the safety and efficacy of GEN1046 as monotherapy or in combination with pembrolizumab in adult subjects with relapsed/refractory metastatic NSCLC after treatment with CPI-containing therapy. Randomization is used to eliminate potential allocation bias while an open-label design will allow efficient AE/SAE management. PD L1

expression level is associated with efficacy for pembrolizumab and histology is an important baseline disease characteristic. Randomization will be stratified to ensure balance across arms for these 2 factors.

The primary objective is to evaluate the anti-tumor activity objective response rate (ORR) of GEN1046 as monotherapy and in combination with pembrolizumab. ORR is a well-established efficacy parameter for assessing anti-tumor activity in a proof-of-concept trial in NSCLC.

Dose and schedule rationale

The selection of the 100 mg Q3W dose for GEN1046 was based on clinical data from the FIH trial, GCT1046-01, where doses ranging from 25 to 1200 mg Q3W were evaluated in 61 subjects in the dose-escalation phase. In addition, a PK/pharmacodynamic model was developed to predict 4-1BB, GEN1046, PD-L1 trimolecular complex (trimer) formation, and RO for PD-L1 in tumors to understand the PK/pharmacodynamic/efficacy relationship (see Example 9).

In summary, the GEN1046 doses of 100 mg Q3W was selected based on the dose escalation study in Example 7.

Arm A will test a regimen of an activation dose of GEN1046 (100 mg Q3W for 2 cycles) followed by a higher maintenance dose of GEN1046 (500 mg administered Q6W for the subsequent cycles), based on the following:

- The semi-mechanistic PK/pharmacodynamic model shows that trimer formation in the tumor peaks at a GEN1046 regimen of 100 mg Q3W, which is expected to provide continuous 4-1BB activation and is selected as the activation dose for the first 2 cycles. In the GCT1046-01 trial, clinical data from the expansion cohort showed that the dose of 100 mg Q3W resulted in responses within the first 2 cycles.
- A maintenance regimen of GEN1046 500 mg Q6W will be used after the first 2 cycles and is predicted to provide higher PD-L1 RO over the dosing cycle and intermittent 4-1BB activation via engaging trimers to a lesser extent in comparison to 100 mg Q3W. This dose is expected to provide improved duration of response (DOR).

Arms B and C will evaluate GEN1046 in combination with pembrolizumab at 2 different dosing schedules:

- Arm B will test a GEN1046 regimen of 100 mg Q3W with a pembrolizumab regimen of 200 mg Q3W. At this regimen, GEN1046 is expected to result in peak trimer formation and sustained 4-1BB activation, which in combination with pembrolizumab may allow for optimum engagement of both targets/pathways and improved anti-tumor efficacy.
- Arm C will evaluate a GEN1046 regimen of 100 mg Q6W with a pembrolizumab regimen of 400 mg Q6W. Based on the PK/pharmacodynamic model, GEN1046 is expected to provide intermittent/transient activation of 4-1BB in a 6-week dosing cycle compared to sustained 4

1BB activation in a 3-week dosing cycle. Transient activation of 4-1BB is expected to allow for resetting of the T-cell response and reduce chronic interferon signaling (Weber, E. W., et al. (2021), Science 372 (6537)), which may prevent exhaustion of tumor infiltrating CD8+ T cells due to continuous 4-1BB activation and, in combination with pembrolizumab, may provide improved depth and DOR.

Pembrolizumab regimens of 200 mg Q3W and 400 mg Q6W have been approved as first- and second-line SOC treatment for NSCLC, respectively. Pembrolizumab 200 mg Q3W and 400 mg Q6W are expected to provide comparable efficacy and safety profiles (Lala et al., 2020, Eur J Cancer 131, 68-75).

Inclusion criteria

1. Subject must be at least 18 years of age.
2. Subject must have histologically or cytologically confirmed diagnosis of stage 4 NSCLC with at least 1 prior line of systemic therapy containing an anti-PD-1/PD-L1 mAb for metastatic disease.

Note: Subject must have received at least 2 doses of an approved anti-PD-1/PD-L1 mAb approved in NSCLC.

- a. Subject has progressed during or after treatment with 1 anti-PD-1/PD-L1 mAb administered either as monotherapy, or as SOC combination.
- b. Subject has progressed during or after platinum doublet chemotherapy following an anti-PD-1/PD-L1 mAb.
- c. Subject has progressed during or after an anti-PD-1/PD-L1 mAb following platinum doublet chemotherapy.

3. Subject must have PD-L1 tumor expression score of TPS $\geq 1\%$ assessed by a central laboratory during screening.

4. Subject must have measurable disease per RECIST v1.1.
5. Subject must have Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1 .
6. Subject must have life expectancy of at least 3 months.
7. Subject must have organ and bone marrow function as follows:

- a. Absolute neutrophil count (ANC) $\geq 1500/L$.
- b. Platelets $\geq 100,000/L$.
- c. Hemoglobin ≥ 9.0 g/dL (in the absence of transfusion within 4 weeks before randomization).
- d. Total bilirubin $\leq 1.5 \times$ institutional upper limit of normal (ULN) (except Gilbert syndrome, then direct bilirubin $\leq 2 \times$ institutional ULN and total bilirubin < 3 mg/dL).
- e. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) $\leq 3 \times$ ULN. In case of concomitant alkaline phosphatase increase of $> 2.5 \times$ ULN, ALT and AST levels must be $\leq 1.5 \times$ ULN.

- f. Glomerular filtration rate ≥ 45 mL/min/1.73 m² according to the abbreviated Modification of Diet in Renal Disease equation.
- g. Prothrombin time (PT)/international normalized ration (INR) $\leq 1.5 \times$ ULN (unless subject is on anticoagulation therapy, in which case PT should be within the therapeutic range of intended use of the anticoagulants).
- h. Activated partial thromboplastin time (aPTT) $\leq 1.5 \times$ ULN (unless subject is on anticoagulation therapy, in which case aPTT should be within the therapeutic range of intended use of the anticoagulants).

10 Exclusion criteria

Any potential subject who meets any of the following criteria will be excluded from participating in the trial.

1. Documentation of known EGFR, ROS1, or ALK mutations or gene rearrangements. If documentation of mutational status is not available, for subjects with non-squamous histology or a mixed histology of non-squamous and squamous, formalin-fixed, paraffin-embedded (FFPE) tumor tissue of any age should be submitted to a central laboratory designated by the sponsor for biomarker panel testing (which may include, but not limited to BRAF, METex 14 skipping, KRAS mutations, RET rearrangement, high-level MET amplification, or NTRK gene fusions). Subjects must not be randomized until biomarker status is available in source documentation at the site.
2. Subject has been exposed to any of the following prior therapies:
 - a. Prior treatment with docetaxel for NSCLC.
 - b. Prior treatment with a 4-1BB (CD137) targeted agent, any type of antitumor vaccine, or autologous cell immunotherapy.
 - c. Treatment with an anti-cancer agent within 28 days prior to GEN1046 administration.
 - d. Any investigational agent for the treatment of stage 4 NSCLC.
 - e. Prior treatment with live, attenuated vaccines within 30 days prior to initiation of GEN1046. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed. Experimental and/or non-authorized SARS-CoV-2 vaccinations are not allowed.

- f. Radiotherapy within 14 days prior to first GEN1046 administration. If a subject received radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
- g. Chronic systemic immunosuppressive corticosteroid doses, i.e., prednisone >10 mg daily or a cumulative dose >150 mg prednisone within 14 days before the first GEN1046 administration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.
- h. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support 4 weeks prior to first GEN1046 administration or being chronically transfusion dependent.
3. Subject has used an invasive investigational medical device within 28 days before the planned first dose of GEN1046 or is currently enrolled in an interventional trial.
4. Subject discontinued treatment due to disease progression within the first 6 weeks of an immune CPI containing treatment.
5. Subject received their last dose of anti-PD-1/PD-L1 mAb >250 days prior to enrollment in this trial.
6. Subject has known past or current malignancy other than inclusion diagnosis, except for non-melanoma skin cancers; in situ cancers of bladder, gastric, colon, cervical/dysplasia, endometrial, melanoma, or breast; and any curable cancer with a complete response of >2 years duration that does not require or is not anticipated to require any additional therapy.
7. All subjects should undergo a CT scan or MRI of the brain to document new or existing central nervous system (CNS) lesions. Subjects with history of intracerebral arteriovenous malformation, cerebral aneurysm, progressive brain metastases, spinal cord compression (from disease), or stroke will be excluded.
8. Subjects with known unstable CNS metastases and any active or history of carcinomatous meningitis will be excluded. Subjects with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 28 days by repeat imaging (note that the repeat imaging should be performed during trial screening). Subjects should be clinically stable and should not be undergoing acute corticosteroid therapy or steroid taper or have received stereotactic radiation or whole-brain radiation within 14 days prior to C1D1. Chronic steroid therapy is acceptable provided that the dose is stable for the last 14 days prior to C1D1 (≤ 10 mg prednisone daily or equivalent).
9. Subject has known allergies, hypersensitivity, or intolerance to GEN1046 or its excipients.

10. Subject has contraindications to the use of pembrolizumab per local prescribing information.
11. Subject is a female who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this trial or within 6 months after the last dose of GEN1046.
12. Subject is a male who plans to conceive a child while enrolled in this trial or within 6 months after the last dose of GEN1046.
13. Subject has evidence of active interstitial lung disease or active non-infectious pneumonitis.
14. Subject has any of the following:
 - a. Ongoing or active infection requiring intravenous treatment with anti-infective therapy that has been administered <2 weeks prior to first dose.
 - 10 b. Symptomatic congestive heart failure (grade III or IV as classified by the New York Heart Association), unstable angina pectoris, or cardiac arrhythmia.
 - c. Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management.
 - 15 d. Ongoing or recent (within 6 months) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs.
 - e. Ongoing grade ≥ 2 sensory or motor neuropathy.
 - a. Serious, non-healing wound, skin ulcer, or bone fracture.
 - f. Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the trial or evaluation of the trial result.
 - 20
15. Subject has a known history of any of the following:
 - a. Grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment.
 - b. Myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
 - 25 c. Liver disease (e.g., alcoholic hepatitis or non-alcoholic steatohepatitis, drug-related or autoimmune hepatitis, or evidence of hepatic cirrhosis).
 - d. Organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of GEN1046.
 - e. Grade 3 or higher allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.
 - 30

- f. Ongoing $\geq$ grade 2 toxicities (with the exception of alopecia), related to prior treatments, unless AEs are clinically non-significant and/or stable on supportive therapy in the opinion of the investigator.
- 5 16. Subject has had major surgery (e.g., requiring extended recovery period) and will not have fully recovered to their prior baseline status prior to participation in this trial.
17. Subject has a known history of seropositivity for human immunodeficiency virus HIV.
18. Subject has a history/positive serology for hepatitis B virus (HBV) (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy):
- 10 a. Positive test for antibodies to the hepatitis B core antigen (anti-HBc) and
- b. Negative test for antibodies to the hepatitis B surface antigen (anti-HBs).
19. Subject has medical history of ongoing hepatitis C virus (HCV) infection that has not been cured.
- 15 20. Subject has medical history of HBV (defined as positive for hepatitis B surface antigen [HBsAg] or HBV DNA) or known active HCV virus (defined as HCV RNA [qualitative] is detected) infection.
- 20 21. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

Trial treatments administered

Trial treatments are administered as described in Table 13, until 1 or more of the discontinuation criteria below are met.

25 GEN1046 and pembrolizumab will be administered as IV infusions by qualified site personnel. During drug product preparation and handling, vigorous mixing or shaking is to be avoided. Care must be taken to assure sterility of the prepared solution as the product does not contain any antimicrobial preservative or bacteriostatic agent.

Table 13: Treatment Administration

Arm	Treatment	Dose (mg)	Dosage Formulation	Route	Dosing Instructions	Schedule	Cycle Length
A	GEN1046	100	Concentrate for solution	IV	30-minute infusion	Once	3 weeks
A	GEN1046	500	Concentrate for solution	IV	30-minute infusion	Once	6 weeks
B	GEN1046	100	Concentrate for solution	IV	30-minute infusion	Once	3 weeks
B	Pembrolizumab	200	Solution	IV	30-minute infusion per prescribing information	Once	3 weeks
C	GEN1046	100	Concentrate for solution	IV	30-minute infusion	Once	6 weeks
C	Pembrolizumab	400	Solution	IV	30-minute infusion per prescribing information	Once	6 weeks

GEN1046 Monotherapy

In Arm A, GEN1046 100 mg Q3W is administered as a 30-minute IV infusion on Day 1 for the first 2 treatment cycles; thereafter, GEN1046 500 mg Q6W is administered as a 30-minute IV infusion on Day 1 of the subsequent 6-week treatment cycles. No dose reduction is allowed for GEN1046.

GEN1046 and Pembrolizumab

In Arm B, GEN1046 100 mg and pembrolizumab 200 mg will be administered on Day 1 of every 3-week cycle.

In Arm C, GEN1046 100 mg and pembrolizumab 400 mg will be administered on Day 1 of every 6-week cycle.

Pembrolizumab is administered first followed by GEN1046. Pembrolizumab is promptly followed by a saline flush to clear the line before starting the infusion of GEN1046. The time in between infusions is approximately 30 minutes or longer depending on the situation. Dose reductions for GEN1046 and/or pembrolizumab are not allowed.

Description of Trial Treatment

GEN1046 – 20 mg/mL formulated in 20 mM histidine, 250 mM Sucrose, 0.02% Polysorbate-80, pH 5.5 – is a clear to opalescent, colorless to slightly yellow solution supplied as a concentrate for solution for infusion to be diluted (at site) in 0.9% NaCl (saline).

Pembrolizumab (Keytruda®) infusion is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for IV infusion.

Discontinuation of Trial Treatment

A subject's trial treatment must be discontinued in the event of:

- Unacceptable AE requiring treatment discontinuation*
- Subject non-compliance
- Subject request to discontinue trial treatment*

- Pregnancy
- Clinical progression*
- Disease progression (according to response criteria)

Survival Status

- 5 Survival status is assessed every 12 weeks (± 14 days), beginning from the day of last GEN1046 dose and continuing until the subject dies or withdraws from the trial. Subjects who are not available, or whose designated family members are not available, for this assessment are entered as “lost to follow up”.

Subject withdrawal from the trial

- 10 A subject will be withdrawn from the trial for any of the following reasons:
- Death
 - Lost to follow up
 - Subject withdrawal of consent
 - Trial closure
- 15 • Sponsor terminates the trial

If a subject discontinues trial treatment and withdraws from the trial before demonstrating PD, the end-of-treatment assessments should be obtained.

Efficacy Assessment

- 20 Tumor response is assessed locally according to the RECIST v1.1 criteria (Eisenhauer et al., 2009). The imaging assessment collection plan is presented below. In addition, prior tumor scan images are collected if feasible.

Imaging data are centrally collected and checked for quality by an imaging contract research organization (CRO) designated by the sponsor. The local investigator’s assessment will be used for the primary endpoint analysis and for treatment decision-making.

- 25 Table 14: Imaging Assessment Collection Plan

Procedure	Screening/Baseline	During Treatment/Follow up
Chest, abdomen, and pelvis CT or MRI (with IV contrast enhancement)	Mandated	Mandated
Brain CT or MRI	If clinically indicated	If lesions were documented at baseline, follow same schedule as CT/MRI of chest, abdomen, and pelvis
Whole body bone scan (per institutional standard of care [eg, Tc-99 bone scan, whole body bone MRI, FDG-PET or NaF PET])	If clinically indicated	If clinically indicated
Localized bone CT, MRI, or X-ray	For any lesions identified on the whole-body bone scan that are not visible on the chest, abdomen, and pelvis CT or MRI	If lesions were documented at baseline, follow same schedule as CT/MRI of chest, abdomen, and pelvis
CT or MRI of other metastatic sites (eg, neck)	If clinically indicated	If lesions were documented at baseline, follow same schedule as CT/MRI of chest, abdomen, and pelvis

Abbreviations: CT=computed tomography; MRI=magnetic resonance imaging; PET=positron emission tomography.

For subjects who continue trial treatment beyond initial RECIST-defined disease progression, efficacy assessment must continue.

- 5 For subjects who discontinue trial treatment without RECIST-defined disease progression as assessed by the investigator, on-trial imaging must continue until RECIST-defined disease progression, start of subsequent anti-cancer therapy, withdrawal of consent, death, or loss to follow up, whichever occurs first.

Baseline Imaging Assessments

- 10 Imaging assessments are performed at screening/baseline within 21 days of administration of the first dose of trial treatment (Day -21 to Day -1 prior to C1D1). All sites of metastatic disease are reported as target or non-target lesions at baseline and followed throughout the trial.

Any imaging assessments already completed during the regular evaluation of the subject within 21 days prior to start of treatment, including before signing the main trial ICF, can be considered as the baseline images for this trial only if they fulfill the technical imaging requirements for the trial. Any imaging assessments obtained after randomization cannot be considered baseline images.

- 20 All scheduled tumor imaging, including screening, must include complete imaging of the chest, abdomen, and pelvis. Tumor imaging is strongly preferred to be acquired by CT with iodinated contrast. For the abdomen and pelvis, MRI may be used when CT with iodinated contrast is contraindicated, or when local practice mandates it. Chest imaging must be done by CT, but may be done without contrast when iodinated contrast is contraindicated.

MRI is the strongly preferred modality for imaging the brain. In case of known or suspected brain metastases, brain MRI is completed at baseline. Contrast-enhanced brain MRI is preferred; however, if MRI contrast is contraindicated, then MRI without contrast or CT with/without contrast is acceptable.

Any potentially measurable lesion that has been previously treated with radiotherapy should be considered as a non-measurable lesion. However, if a lesion previously treated with radiotherapy has clearly progressed since the radiotherapy, it can be considered as a measurable lesion.

Post-baseline Imaging Assessments

Imaging assessments as described in Table 14 are performed using the same imaging modality used at baseline, irrespective of trial treatment interruption or actual dosing. On-trial imaging is performed every 6 weeks (± 7 days) for the first 24 weeks, and every 9 weeks (± 7 days) thereafter from the date of first dose until disease progression (as assessed by the investigator), start of subsequent anti-cancer therapy, withdrawal of consent, death, or loss to follow up, whichever occurs first. Imaging assessments are scheduled using the date of first dose of trial treatment as the reference, and are respected regardless of whether treatment with trial drug is temporarily withheld or unscheduled assessments performed.

Additional imaging assessments may be performed at any time during the trial at the investigator's discretion to support the efficacy evaluations for a subject, as necessary. Clinical suspicion of disease progression at any time requires a physical examination and imaging assessments to be performed promptly rather than waiting for the next scheduled imaging assessment.

Each lesion that is assessed at baseline must be assessed by the imaging method and when possible, the same local radiologist/physician throughout the trial so that the comparison is consistent. If an off-schedule imaging assessment is performed because progression is suspected, subsequent imaging assessments should be performed in accordance with the original imaging schedule.

Combined positron emission tomography (PET)-CT may be used only if the CT is of similar diagnostic quality as a CT performed without PET, including the utilization of IV contrast media. At the discretion of the investigators, FDG-PET scans may be performed to document PD as per RECIST 1.1.

Progression-Free Survival 2

Progression-free survival 2 (PFS2) is defined as time from first infusion to objective tumor progression on next-line treatment or death from any cause. For PFS2, objective tumor progression will be determined based on investigator assessment of progression on next-line therapy. For this purpose, subsequent anti-neoplastic therapies including start/end date, reason for discontinuation, and date of disease progression will be captured.

iRECIST Assessment of Disease

iRECIST disease progression should be confirmed at least 4-7 weeks after the first radiologic evidence of PD in clinically stable participants. Subjects who have unconfirmed disease progression may continue on trial treatment until progression is confirmed as long as the subject is clinically stable.

Subjects who are clinically stable must meet the following criteria:

- 5 • Subject must have clinical benefit from continuation of GEN1046 or GEN1046 combination regimen (as assessed by the investigator) and must not have rapid disease progression.
- Subject is tolerating the trial treatment.
- Subject must have a stable ECOG status.
- 10 • Treatment beyond progression will not delay an imminent intervention to prevent serious complications for disease progression (eg, central nervous system metastases requiring immediate treatment).

Any clinically unstable subjects are discontinued from trial treatment at the first occurrence of radiographic disease progression. Subjects that are clinically unstable are not required to have repeated imaging to confirm PD by iRECIST; however, a confirmation of progression scan may be obtained at
15 the investigator's discretion after consultation with the sponsor.

If repeat imaging shows iRECIST-confirmed disease progression (iCPD), subjects will discontinue trial treatment. However, if the subject is deriving benefit after iCPD is observed, an exception to continue trial treatment must be approved by the sponsor medical monitor. If repeat imaging shows iRECIST stable disease (iSD), iRECIST partial response (iPR), or iRECIST complete response (iCR), imaging
20 should be continued every 6 weeks (± 7 days) and the subject should continue on trial treatment.

Preliminary results

As of 10-Aug-2022, 4 patients have been enrolled in the safety run-in part of the Arm C and DLT period of the 4th patient has been completed. No DLTs has been reported in the evaluable subjects, and none of the reported SAEs were related to study drug (GEN1046 or Pembrolizumab). 1 subject experienced
25 partial response and 1 subject has stable disease.

Example 9: Pharmacokinetic/Pharmacodynamic model

An integrated quantitative systems pharmacology (QSP) model was developed that combines a multi-compartment physiologically-based pharmacokinetic (PBPK) model with a mechanistic systems
30 biology model representing the tumor/immune processes and interactions that occur in the tumor micro-environment and draining lymph nodes. The PBPK model describes FcRn-mediated GNE1046 transport and distribution to healthy tissue spaces and tumor spaces, with return to plasma mediated by lymphatic flow. The mechanistic systems biology model is designed to recapitulate the known biology involved in tumor proliferation, the cancer/immunity cycle, and the mechanisms directly related to the

activity of GEN1046 and an anti-PD1 drug Pembrolizumab. The model leveraged a wide range of literature, preclinical, pharmacokinetic, and pharmacodynamic data for parameterization of these pathways. The model was used to generate a population of virtual patients spanning observed variability in key markers (e.g., PD-1 and PD-L1 expression at baseline) and was used to predict objective response rate (ORR) when GEN1046 and Pembrolizumab given as monotherapy or in combination. Model was validated based on objective response rate (ORR) observed for Pembrolizumab (data from literature) and GEN1046 monotherapy clinical trials. Evaluation was done for GEN1046 at 100 mg Q3W or 100 mg Q6W given as monotherapy or in combination with Pembrolizumab at an approved dose of 200 mg Q3W or 400 mg Q6W.

A weak dose-dependent relationship was observed in both partial response (PR) and complete (CR) rates for GEN1046 given as 100 mg Q3W or Q6W in combination with Pembrolizumab. Prediction for PR and CR rates shows maximum response between GEN1046 100mg and 300mg Q3W. Additionally, predictions show minimal differences between GEN1046 and Pembrolizumab when given Q3W or Q6W (Figure 11).

Example 10: Effect of GEN1046 in combination with pembrolizumab on cytokine secretion in an allogeneic MLR assay of LPS-matured dendritic cells and *in vitro* exhausted T cells

Objective: To analyze if the combination of GEN1046 with pembrolizumab could reverse T-cell exhaustion in a mixed lymphocyte reaction (MLR) assay, four unique, allogeneic pairs of human mature dendritic cells (mDCs) and *in vitro* exhausted T cells (Tex) were co-cultured in the presence of GEN1046 alone, pembrolizumab alone, or a combination of both antibodies. Expression of inhibitory receptors on Tex was determined by flow cytometry and secretion of interferon (IFN) γ was assessed in the supernatants of the co-cultures.

Methods

Monocytes and T cells from healthy donors

CD14⁺ monocytes and purified CD3⁺ T cells were obtained from BioIVT. Four unique allogeneic donor pairs were used for the MLR assay.

Differentiation of monocytes to immature dendritic cells

Human CD14⁺ monocytes were obtained from healthy donors. For differentiation into immature dendritic cells (iDCs), 1 - 1.5 $\times 10^6$ monocytes/mL were cultured for six days in Roswell Park Memorial Institute (RPMI) 1640 complete medium (ATCC modification formula; ThermoFisher, cat. no. A1049101) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco, cat. no. 16140071), 100 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF; BioLegend, cat. no. 766106) and 300 ng/mL interleukin (IL)-4 (BioLegend, cat. no. 766206) in T25 culture flasks

(Falcon, cat. no. 353108) at 37°C. After four days, the medium was replaced with fresh medium and supplements.

Differentiation of iDCs to mDCs

5 Prior to start of the MLR assay, iDCs were harvested by collecting non-adherent cells and differentiated to mDCs by incubating $1 - 1.5 \times 10^6$ cells/mL in RPMI 1640 complete medium supplemented with 10% FBS, 100 ng/mL GM-CSF, 300 ng/mL IL-4 and 5 µg/mL lipopolysaccharide (LPS; ThermoFisher, cat. no. 00-4976-93) for 24 h at 37°C.

Exhaustion of T cells

10 Purified CD3⁺ T cells obtained from healthy donors were thawed and resuspended at 1×10^6 cells/mL in AIM-V medium (ThermoFisher, cat. no. 12055091) supplemented with 5% FBS and 10 ng/mL IL-2 (BioLegend, cat. no. 589106). To generate T cells with an exhausted-like phenotype, the cells were stimulated for two rounds with of Dynabeads™ Human T Activator CD3/CD28 (Gibco, cat. No. 11161D) at a bead:cell ratio of 1:1 for 48 h at 37°C and 5% CO₂. The exhausted phenotype of the T cells was confirmed by hyporesponsiveness to CD3/CD28 restimulation (lack of IFNγ secretion), as described below. High expression of the inhibitory receptors TIM3, LAG3 and PD-1 was consistent with an exhausted phenotype. After two rounds of stimulation, the exhausted CD3⁺ T cells (Tex) were rested for 24 h.

20 As a naïve control, purified CD3⁺ T cells obtained from healthy donors were thawed one day prior to the start of the MLR assay, resuspended at 1×10^6 cells/mL in RPMI 1640 complete medium supplemented with 10% FBS and 10 ng/mL IL-2 and incubated O/N at 37°C. Prior to the MLR assay, aliquots of naïve T cells and Tex were collected for flow cytometry.

Flow cytometry

25 For flow cytometry analysis of inhibitory receptors on Tex, cells were pelleted at 400 × g for 5 min, washed in phosphate-buffered saline (PBS), pelleted again, resuspended in 1 mL PBS supplemented with LIVE/DEAD™ Fixable Near-IR Dead Cell Stain (ThermoFisher Scientific, cat. no. L10119, diluted 1:500) or Viability Live/Dead Blue (ThermoFisher Scientific, cat. no. L2305, diluted 1:500) and
30 incubated for 20 min at 4°C in the dark. Next, cells were washed, pelleted, resuspended to 8×10^6 cells/mL in FACS buffer (Dulbecco's phosphate-buffered saline [DPBS, Gibco, cat. no. 14190136] supplemented with 0.5% bovine serum albumin [BSA, Sigma, cat. no. A9576] and 2 mM ethylenediaminetetraacetic acid [EDTA, Invitrogen, cat. no. 15575-038]) containing 5% human serum (Sigma, cat. no. H4522), and incubated for 15 min at 4°C. Then 25 µL containing 2×10^5 cells was
35 transferred to a new 96-well plate containing 150 µL staining mix with fluorescently-labeled antibodies shown in Table 15 diluted in FACS buffer supplemented with Brilliant Stain Buffer Plus (BD Horizon, cat. no. 566385) and incubated for 20 min at RT in the dark. Cells were pelleted, washed using FACS buffer, resuspended in 100 µL Fixation Buffer (Biolegend, cat. no. 420801) and incubated for 15 min at

4°C in the dark. Cells were pelleted again, washed and resuspended in 100 µL FACS buffer. Samples were analyzed on a Cytex® Aurora flow cytometer (Cytex Biosciences).

Table 15: Antibodies used for flow cytometry

Marker	Fluorochrome	Clone	Vendor	Cat#	Titer
TIM3	BV421	7D3	BD	565562	1:60
PD-1	PerCP-eFluor 710	J105	Thermofisher	46-2799-42	1:15
Lag3	PE	11C3C65	Biolegend	369306	1:30
4-1BB	PE-Cy5	4B4-1	Biolegend	309808	1:30
Ki67	BV786	B56	BD	563756	1:150

5

MLR assay

The mDCs (see Differentiation of iDCs to mDCs) were harvested and resuspended in AIM-V medium at 4×10^5 cells/mL. Tex and naïve CD3⁺ T cells (see Exhaustion of T cells) were harvested and resuspended in AIM-V medium at 4×10^6 cells/mL. Co-cultures of mDC and Tex were seeded at a DC:T cell ratio of 1:4 or 1:10, corresponding to 2×10^4 mDCs incubated with 8×10^4 or 2×10^5 Tex, and cultured in the presence of pembrolizumab (1 µg/mL; non-clinical/research-grade version of the clinical product pembrolizumab; Selleckchem, cat. no. A2005) or GEN1046 (0.001 - 30 µg/mL) as single agent, or both agents combined in AIM-V medium in a 96-well round-bottom plate (Falcon, cat. no. 353227) at 37°C for 5 days. Co-cultures treated with bsIgG1-PD-L1×ctrl (30 µg/mL), bsIgG1-ctrl×4-1BB (30 µg/mL), IgG1-ctrl-FEAL (30 µg/mL) or IgG4 isotype control (1 µg/mL) were included as controls (Table 16). In parallel, co-cultures of mDC and naïve CD3⁺ T cells at a DC:T cell ratio of 1:10, corresponding to 2×10^4 mDCs incubated with 2×10^5 T cells, were cultured with and without 1 µg/mL pembrolizumab. After 5 days, the plates were centrifuged at 500 ×g for 5 min and the supernatant was carefully transferred from each well to a new 96-well round bottom plate.

The collected supernatants were analyzed for IFN γ levels by enzyme-linked immunosorbent assay (ELISA) using an AlphaLISA IFN γ kit (Perkin Elmer, cat. no. AL217) on an Envision instrument, according to the manufacturer's instructions.

Table 16: Antibodies

Test compound	Supplier, cat. no.	Comprising SEQ ID NOs
GEN1046	N/A	CD137 binding arm: SEQ ID NOs: 1, 5, 35, 29 PD-L1 binding arm: SEQ ID NOs: 11, 15, 36, 30
bsIgG1-PD-L1×ctrl ¹	N/A	SEQ ID NO: 11, 15, 53, 54, 35, 36, 29, 30

bslgG1-ctrl×4-1BB ¹	N/A	SEQ ID NO: 35, 36, 1, 5, 53, 54, 29, 30
IgG1-ctrl-FEAL ¹	N/A	SEQ ID NO: 53, 54, 30, 35
Pembrolizumab	Selleckchem, cat. no. A2005, Lot no. A200504 (non-clinical/research-grade version of the clinical product pembrolizumab)	N/A
IgG4 isotype control	Biolegend, cat. no. 403702 (isotype control antibody for pembrolizumab)	N/A

¹Control binding moiety based on anti-HIV gp120 antibody IgG1-b12 (Barbas et al., J Mol Biol 1993, 230: 812-823)

Highest single agent (HSA) synergy analysis

- 5 The cytokine concentration values in each treatment condition were normalized by subtracting the background control values (no treatment control wells) and expressed as a percentage of the maximal value in the assay. The combination effect was quantified by comparing the observed response against the expected response using the Highest Single Agent (HSA) reference model, which is defined as the maximum single drug response at corresponding concentrations.

10

Results & conclusion

After two rounds of stimulation with CD3/CD28 beads, the T cells became hyporesponsive to dual anti-CD3 and anti-CD28 stimulation, consistent with an exhausted phenotype as demonstrated by reduced secretion of IFN γ (Figure 12A). Furthermore, the T cells showed an increased expression of the inhibitory receptors TIM3, LAG3 and PD-1 (Figure 12B) and reduced expression of the proliferation marker Ki67 (Figure 12C) compared to naïve T cells, consistent with an exhausted-like phenotype.

15

Reduced IFN γ secretion was also evident in MLR assays of mDCs and Tex as compared to MLR assays of mDCs and naïve CD3⁺ T cells (Figure 13). Treatment with pembrolizumab or GEN1046 as single agents partially rescued IFN γ secretion. Combination of ≥ 0.1 μ g/mL GEN1046 with 1 μ g/mL pembrolizumab further potentiated secretion of IFN γ compared to single-agent activity in these mDC:Tex MLR assays (Figure 13), and showed synergy based on the HSA model (Figure 14). These data suggest that loss of cytokine secretion by exhausted T cells can be partially reversed through GEN1046 in combination with pembrolizumab.

20

Example 11: Anti-tumor activity in MC38 mouse colon cancer tumor outgrowth upon treatment with a combination of mbsIgG2a-PD-L1×4-1BB with anti-mPD-1

Objective: To investigate the anti-tumor activity of mbsIgG2a-PD-L1×4-1BB antibody either alone or in combination with anti-mPD-1 in the MC38 colon cancer model in C57BL/6 mice.

30

Methods

MC38 mouse colon cancer cells were cultured in Dulbecco's Modified Eagle Medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C, 5% CO₂. MC38 cells were harvested from a cell culture growing in log-phase and quantified.

MC38 cells (1×10^6 tumor cells in 100 μ L PBS) were injected subcutaneously in the right lower flank of female C57BL/6 mice (obtained from Shanghai Lingchang Biotechnology Co., Ltd and Services; age 6-8 weeks at start of experiment).

Tumor growth was evaluated three times per week using a caliper. Tumor volumes (mm³) were calculated from caliper measurements as $([\text{length}] \times [\text{width}]^2) / 2$, where the length is the longest tumor dimension and the width is the longest tumor dimension perpendicular to the length.

Treatment was initiated when tumors had reached a mean volume of 60 mm³. Mice were randomized into groups (n = 10/group) with equal mean tumor volume prior to treatment. On treatment days (two doses weekly for three weeks [2QW $\times$ 3]), the mice were injected intraperitoneally with the antibodies indicated in Table 17 in an injection volume of 10 μ L/g body weight. For combination treatments, antibodies were injected in two separate injections with 20 min in between (Table 17). Dose levels were based on previous experience with these antibodies in the MC38 mouse model.

The mice were monitored daily for clinical signs of illness. Body weight measurements were performed three times a week after randomization. The antibodies and combinations thereof were well tolerated, as mice showed minimal body weight loss (<20%) upon treatment, rather an increase in body weight. The experiment ended for the individual mice when the tumor volume exceeded 1500 mm³ or when the animals reached humane endpoints (e.g. when mice showed body weight loss > 20%, when tumors showed ulceration [$> 75\%$], when serious clinical signs were observed and/or when the tumor growth blocked the physical activity of the mouse).

Table 17. Treatment groups and dosing regimen

Treatment group	N per group	Treatment	Dose	Dosing regimen	Seq ids/ Supplier, cat. no.
1	10	mIgG2a-ctrl-AAKR	5 mg/kg	2QW $\times$ 3	Seq ids: 53, 54, 58, 59
2	10	Anti-mPD-1	10 mg/kg	2QW $\times$ 3	clone RMP1-14, Leinco Technologies, cat. no. P372
3	10	mbsIgG2a-PD-L1 $\times$ 4-1BB	5 mg/kg	2QW $\times$ 3	Seq ids: 55, 56, 57, 58, 59, 60, 61
4	10	mbsIgG2a-PD-L1 $\times$ 4-1BB ^a + Anti-mPD-1	5 mg/kg + 10 mg/kg	2QW $\times$ 3	See above: group 2 and 3

^a mbsIgG2a-PD-L1 $\times$ 4-1BB was injected first and the second antibody was injected after 20 min

Mice that showed complete regression of tumors after antibody treatment were rechallenged with MC38 tumor cells 121 days after treatment initiation. Mice were inoculated with 1×10^6 fresh MC38 tumor cells on the opposite flank of the original tumor cell inoculation. As control treatment of tumor outgrowth, a group of age matched naïve C57BL/6 mice (n = 6) was inoculated with MC38 tumor cells from the same cell culture.

Results

Rapid tumor outgrowth was observed in MC38-bearing mice treated with nonbinding control antibody mIgG2a-ctrl-AAKR (5 mg/kg; Figure 15A). In mice treated with anti-mouse PD-1 antibody (anti-mPD-1; 10 mg/kg) or mbsIgG2a-PD-L1×4-1BB (5 mg/kg; Figure 15A) as single agents, delayed tumor outgrowth was observed, with a more pronounced delay in tumor outgrowth induced by mbsIgG2a-PD-L1×4-1BB. In mice treated with mbsIgG2a-PD-L1×4-1BB (5 mg/kg) combined with anti-mPD-1 (10 mg/kg; both 2QW×3) tumor outgrowth was further delayed compared to each agent alone (Figure 15A) and complete tumor regressions were observed in 4/10 mice at day 23 post-treatment initiation (compared to complete tumor regressions in 1/10 and 0/10 mice observed for mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 alone, respectively; Table 18). Kaplan-Meier analysis showed that treatment with the combination of mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 led to a significant increase in progression-free survival, defined as the percentage of mice with tumor volume smaller than 500 mm³, when compared to the control antibody-treated group ($p<0.001$) and compared to either antibody alone ($p<0.05$; Mantel-Cox; Figure 15B, Table 19). Hence, therapeutic synergy was observed with this combination, defined as superior ($p<0.05$) antitumor efficacy relative to the activity shown by each agent as monotherapy.

Mice with complete tumor regression, eg, where the tumors disappeared completely for the duration of the observation period (Table 18), and a control group of six age-matched tumor-naïve mice, were (re)challenged with MC38 tumor cells that were SC injected on Day 121 after the treatment with antibodies was initiated. A control group of six age-matched tumor-naïve mice was SC injected with MC38 tumor cells at the same time. In all naïve mice, the MC38 tumor grew out to 1,500 mm³ at Day 24 after tumor inoculation, whereas there was no tumor outgrowth observed in the rechallenged mice during the entire follow-up period of 35 days after the rechallenge (156 days after the original inoculation with MC38 tumor cells), consistent with the development of immune memory (Figure 16).

These results provide rationale for evaluating the combination of GEN1046 with an anti-PD-1 antibody to further amplify the anti-tumor immune response in cancer patients to produce durable and deep clinical responses and enhance survival.

Table 18. Complete tumor regressions upon treatment of MC38-tumor bearing mice.

Treatment group	Treatment	Dose	Complete tumor regressions (no. of mice with CR/ total no. of mice per group)
1	mIgG2a-ctrl-AAKR	5 mg/kg	0/10
2	Anti-mPD-1	10 mg/kg	0/10
3	mbsIgG2a-PD-L1×4-1BB	5 mg/kg	1/10
4	mbsIgG2a-PD-L1×4-1BB + Anti-mPD-1	5 mg/kg + 10 mg/kg	4/10

Table 19. Mantel-Cox analysis of the progression-free survival induced by mbsIgG2a-PD-L1×4-1BB, anti-mPD-1, or combinations thereof in the MC38 model in C57BL/6 mice

Treatment groups compared			Progression-free survival ¹
			Mantel-Cox P value
mIgG2a-ctrl-AAKR	vs	Anti-mPD-1	0.008
mIgG2a-ctrl-AAKR	vs	mbsIgG2a-PD-L1×4-1BB	0.002
mIgG2a-ctrl-AAKR	vs	mbsIgG2a-PD-L1×4-1BB + anti-mPD-1	<0.001
Anti-mPD-1	vs	mbsIgG2a-PD-L1×4-1BB	0.070
Anti-mPD-1	vs	mbsIgG2a-PD-L1×4-1BB + anti-mPD-1	<0.001
mbsIgG2a-PD-L1×4-1BB	vs	mbsIgG2a-PD-L1×4-1BB + anti-mPD-1	0.043

¹Tumor volume < 500mm³ was used as the cut-off for progression-free survival. Mantel-Cox analysis was performed at Day 69.

²A p-value <0.05 was considered significant

Example 12: The combination of mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 potentiates anti-tumor immunity in the MC38 mouse colon cancer tumor model via distinct and complementary immune modulatory effects

Objective: As described in Example 2 and 11, mbsIgG2a-PD-L1×4-1BB combined with anti-mPD-1 showed potent anti-tumor activity with a durable response in the MC38 colon cancer model in C57BL/6 mice. Therefore, this model was used to further study the mechanism of action of the combination of mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 *in vivo*. MC38-bearing mice were treated with mbsIgG2a-PD-L1×4-1BB, anti-mPD-1 or the combination thereof.

Methods

MC38 colon cancer model

MC38 mouse colon carcinoma tumors from two independent studies were collected for immunohistochemistry and flow cytometry assessments to characterize the *in vivo* activity of mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 as monotherapy and in combination.

The MC38 tumor model was established as described in Examples 2 and 11. Treatment of mice bearing MC38 SC tumors was initiated when tumors had reached a tumor volume of 50-70 mm³. Mice were randomized into groups with equal mean tumor volume prior to treatment. On treatment days (two doses weekly for two weeks [2QW×2]), the mice were injected intraperitoneally with the antibodies indicated in Table 20 in an injection volume of 10 µL/g body weight. For combination treatments, antibodies were injected in two separate injections with 20 min in between (Table 20).

The mice were monitored daily for clinical signs of illness. Body weight measurements were performed three times a week after randomization. On Day 7 or 14 after initiation of treatment, mice (n=5 per group) were euthanized for resection of the tumors.

Table 20. Treatment groups and dosing regimen

Treatment group	Treatment	Dose	Dosing regimen	Seq ids/ Supplier, cat. no.
1	PBS	N/a	2QW×2	n/a
2	Anti-mPD-1	10 mg/kg	2QW×2	clone RMP1-14, Leinco Technologies, cat. no. P372
3	mbsIgG2a-PD-L1×4-1BB	5 mg/kg	2QW×2	Seq ids: 55, 56, 57, 58, 59, 60, 61
4	mbsIgG2a-PD-L1×4-1BB ^a + Anti-mPD-1	5 mg/kg + 10 mg/kg	2QW×2	See above: group 2 and 3

^a mbsIgG2a-PD-L1×4-1BB was injected first and the second antibody was injected after 20 min

Immunohistochemistry and in situ hybridization of tumor tissue

- 5 Tumors were dissected, fixed in formalin, paraffin embedded and sectioned (4 μm). For histologic assessment, tumor sections were deparaffinized and stained with the Tissue-Tek Prisma H&E Stain Kit (Sakura [Torrance, CA], 6190) using the Tissue-Tek Prisma Plus Automated Slide Stainer (Sakura). For evaluation of CD3⁺, CD4⁺ and CD8⁺ cells within the tumor, sections were deparaffinized and antigens were retrieved using CC1 buffer (Roche, 950-124), followed by quenching of endogenous peroxidase (Dako Agilent, S2003) and blocking of aspecific binding sites with blocking buffer (Roche, 05268869001) using the Roche Ventana Discovery (DISC) autostainer platform. Sections were incubated with primary antibodies (listed in Table 21), which were detected using anti-rabbit immunohistochemistry detection kits: for CD3 and CD4 with only anti-rabbit DISC, Omnimap (Roche, 05269679001) for CD8 sequentially with DISC anti-rabbit HQ (Roche, 07017812001) and DISC, and amplification for anti-HQ HRP Multimer (Roche, 06442544001). HRP was visualized using 3,3'-diaminobenzidine (ChromoMap DAB; Roche, 05266645001) according to manufacturer instructions. For evaluation of PD-L1⁺ cells within the tumor, sections were deparaffinized and antigens were retrieved using ER2 buffer (Leica Biosystems, AR9640), followed by quenching of endogenous peroxidase (Dako Agilent, S2003) and blocking aspecific binding sites with blocking buffer (Leica Biosystems, DS9800) using the Leica Bond Rx autostainer platform. Sections were incubated with the primary antibody (listed in Table 21), which were detected using anti-rabbit immunohistochemistry detection kit (Leica Biosystems, DS9800) according to manufacturer instructions. For evaluation of 4-1BB⁺ and PD-L2⁺ cells within the tumor, RNAscope assays have been performed on Leica Bond Rx with corresponding RNAscope probes (ACDBio, 493658 and 447788, respectively) and RNAscope detection kits (ACDBio, 322150) for detection of gene-specific mRNA molecules. In all assays, nuclei were counterstained by incubation with Mayer hematoxylin. Staining specificity was controlled by incorporating isotype, positive and negative control staining on consecutive tissue sections. Stained slides were subjected to whole slide imaging (Zeiss, Axioscan) and whole slide images were uploaded to and analyzed with Halo software (Indica Labs, Albuquerque, NM) using preprogrammed software analysis tools to determine CD3⁺, CD4⁺, CD8⁺ and PD-L1⁺ cells (CytoNuclear v2.0.9) and to determine 4-1BB⁺ and PD-L2⁺ cells (ISH v4.1.3). Quantitative data on CD3⁺, CD4⁺, CD8⁺, and PD-L1⁺ cells were

subsequently expressed as percentage of marker-positive cells in relation to total cell numbers. Quantitative data on 4-1BB⁺ and PD-L2⁺ cells were expressed as RNAscope H-scores by creating four RNAscope intensity buckets and calculating H-scores with the formula: H-score = [(0 x % cells with 0 dots/cell) + (1 x % cells with 1-3 dots/cell) + (2 x % cells with 4-9 dots/cell) + (3 x % cells with 10-15 dots/cell) + (4 x % cells with >15 dots/cell)].

Table 21. Antibodies used for immunohistochemistry

Target	Label	Clone	Supplier	Catalog no.
CD3	unconjugated	2GV6	Ventana	790-4341
CD4	unconjugated	EPR19514	Abcam	Ab183685
CD8α	unconjugated	D4W2Z	Cell Signaling Technology	98941
PD-L1	unconjugated	D5V3B	Cell Signalling Technology	64988

Flow cytometry of tumor tissue

Dissociated tumor cells were blocked with 1 µg/mL Mouse BD Fc Block™ (Fc blocking buffer; BD, cat. no. 553141) at 4°C in the dark for 10 min. For staining of cell surface markers, the fluorescently-labeled antibody mixture described in Tables 22 (except Ki67 and GzmB) diluted in Fc blocking buffer were added to the cells, and incubated at 4°C for 30 min, protected from light. For intracellular staining (Ki67 and GzmB), the cells were permeabilized by incubation with 200 µL Fix/Perm concentrate (eBioscience, cat. no. 00-5123) diluted in Fix/Perm dilution buffer (1:4; eBioscience, cat. no. 00-5223) at RT for 30 min, protected from light. After washing twice in Permeabilization buffer (eBioscience, cat. no. 00-8333), cells were incubated with Ki67 and GzmB antibodies (Tables 22) diluted in Permeabilization buffer at RT for 30 min, protected from light. Finally, cells were resuspended in 250 µL FACS buffer (PBS supplemented with 10% FBS [Gibco, cat. no. 10099-141] and 40 mM EDTA [Boston BioProducts, cat. no. BM-711-K]) and measured at the BD LSRFortessa™ X20 cell analyzer (BD Biosciences, San Jose, CA, USA). Data were analyzed using Kaluza Analysis Software.

Table 22. Antibodies used for flow cytometry

Target	Label ¹	Clone	Supplier	Cat. no.
CD45	BV785	30-F11	Biolegend	103149
CD3	BUV395	17A2	BD	740268
CD4	BV510	GK1.5	Biolegend	100449
CD8	PE-eFluor610	53-6.7	eBiosciences	61-0081-82
Ki67	PerCP/Cy5.5	SolA15	eBioscience	46-5698-82
GzmB	AF700	QA16A02	Biolegend	372222
Live/dead	eFluor780	N/A	eBioscience	65-0865

Results & conclusion

Tumor tissue sections were evaluated for T cell subsets and target expression by immunohistochemistry (IHC) and in situ hybridization (ISH) on day 7 and day 14 following treatment initiation (Figure 17) and dissociated tumor tissues were evaluated for Ki.67⁺ proliferating and GzmB⁺ cytotoxic intratumoral CD8⁺ T cells by flow cytometry on day 7 post treatment initiation (Figure 18).

Treatment with mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 as single agents enhanced the percentage of CD3⁺ cells within the tumor on Day 7 and Day 14 post-treatment. The combination of mbsIgG2a-PD-L1×4-1BB with anti-mPD-1 further increased the percentage of CD3⁺ cells on Day 14 (Figure 17A).

No differences in the percentage of CD4⁺ cells were observed between treatment groups on Day 7. In contrast, the percentage of CD4⁺ cells were increased by treatment with mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 as single agents compared to the PBS-treated group on Day 14 and even further enhanced by the combination of mbsIgG2a-PD-L1×4-1BB with anti-mPD-1 (Figure 17B).

The percentage of CD8⁺ cells was increased by mbsIgG2a-PD-L1×4-1BB compared to the PBS group on both Day 7 and Day 14, but not by anti-mPD-1. The combination mbsIgG2a-PD-L1×4-1BB with anti-mPD-1 showed similar levels of CD8⁺ cells compared to mbsIgG2a-PD-L1×4-1BB alone, suggesting that the increase in CD8⁺ cells was driven by mbsIgG2a-PD-L1×4-1BB (Figure 17C).

On Day 7 and/or Day 14, intratumoral PD-L1 and PD-L2 expression was increased by mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 as single agents compared to the PBS-treated mice. By contrast, the combination of mbsIgG2a-PD-L1×4-1BB with anti-mPD-1 did not show such an increase, as the levels of intratumoral PD-L1 and PD-L2 were comparable to the levels in PBS-treated mice (Figure 17D-E).

Finally, tumoral expression of 4-1BB was increased by mbsIgG2a-PD-L1×4-1BB on Day 7. By contrast, expression of 4-1BB was decreased by anti-mPD-1 as single agent and by the combination of mbsIgG2a-PD-L1×4-1BB with anti-mPD-1 on Day 14 (Figure 17F).

In dissociated tumor tissues, it was found that the percentage of GzmB⁺ within the total intratumoral CD8⁺ T cell population was significantly enhanced by the combination of mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 compared to each single agent (Figure 18A), suggesting increased CD8 T-cell cytotoxicity. Similarly, the percentage of Ki67⁺ within the total tumor-infiltrating CD8⁺ T cell population was enhanced by the combination of mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 compared to each single agent alone, suggesting increased CD8 T-cell proliferation (Figure 18B).

Together, these results suggest that the combination of mbsIgG2a-PD-L1×4-1BB and anti-mPD-1 leads to distinct and complementary modulation of the tumor immune contexture compared to treatment with mbsIgG2a-PD-L1×4-1BB or anti-mPD-1 as single agents. In particular, the greater frequency of proliferating and cytotoxic CD8⁺ TILs in the mbsIgG2a-PD-L1×4-1BB with anti-PD1 combination treated group indicates enhanced functional and effector functions of TILs likely associated with improved antitumor activity.

Example 13: Cytokine analysis in peripheral blood of MC38-tumor bearing mice treated with combinations of mbsIgG2a-PD-L1×4-1BB with an anti-mPD-1 antibody

Objective: To investigate cytokine levels in peripheral blood of MC38-tumor bearing C57BL/6 mice treated with mbsIgG2a-PD-L1×4-1BB either alone or in combination with an anti-mPD-1 antibody.

Methods

In the experiment described in Example 11, blood samples were collected from the MC38-tumor bearing C57BL/6 mice at the following time points: Day -1 (baseline; one day before treatment with the first dose), Day 2 (2 days after first dose) and Day 5 (2 days after second dose) after initiation of treatment.

Cytokines were analyzed in plasma samples by electrochemiluminescence (ECLIA) using the V-PLEX Proinflammatory Panel 1 mouse Kit (MSD LLC, cat. no. K15048D-2) and the V-PLEX Cytokine Panel 1 mouse Kit (MSD LLC, cat. no. K15245D-2) on a MESO QuickPlex SQ 120 instrument (MSD, LLC. R31QQ-3), according to the manufacturer's instructions.

Results

In mice treated with mIgG2a-ctrl-AAKR (5 mg/kg) or anti-mouse PD-1 antibody (anti-mPD-1; 10 mg/kg) as single agent, no or minor changes in the levels of IFN γ , TNF α , IL-2 and IP-10 were observed on Day 2 or Day 5 compared to Day -1 (Figure 19). In mice treated with mbsIgG2a-PD-L1 $\times$ 4-1BB (5 mg/kg), plasma levels of IFN γ , TNF α , IL-2 and IP-10 were increased at Day 2 and further enhanced at Day 5. In mice treated with the combination of mbsIgG2a-PD-L1 $\times$ 4-1BB (5 mg/kg) and anti-mPD-1 (10 mg/kg), the increase in the levels of IFN γ , TNF α , IL-2 and IP-10 was potentiated on Day 2 and/or Day 5 relative to each single agent (Figure 19). On Day 5 levels of IFN γ , TNF α and IP-10 were >3-fold higher in mice treated with the combination of mbsIgG2a-PD-L1 $\times$ 4-1BB and anti-mPD-1 compared to both mIgG2a-ctrl-AAKR and the anti-PD-1 treated groups, and levels of TNF α and IP-10 were >1.48-fold higher compared to the mbsIgG2-PD-L1 $\times$ 4-1BB treated groups (Table 23).

These results provide rationale for evaluating the combination of GEN1046 with an anti-PD-1 antibody to further amplify the anti-tumor immune response in cancer patients.

Table 23. Fold change in cytokine levels in response to the combination of mbsIgG2a-PD-L1 $\times$ 4-1BB with anti-mPD-1 compared to single agents

Cytokine	Treatment groups compared			Ratio of median fold changes	
				Day 2	Day 5
IFN γ	mbsIgG2a-PD-L1 $\times$ 4-1BB + anti-mPD-1	vs	mIgG2a-ctrl-AAKR	1.77	3.39
IFN γ	mbsIgG2a-PD-L1 $\times$ 4-1BB + anti-mPD-1	vs	Anti-mPD-1	1.93	3.42
IFN γ	mbsIgG2a-PD-L1 $\times$ 4-1BB + anti-mPD-1	vs	mbsIgG2a-PD-L1 $\times$ 4-1BB	0.98	0.99
TNF α	mbsIgG2a-PD-L1 $\times$ 4-1BB + anti-mPD-1	vs	mIgG2a-ctrl-AAKR	3.07	3.56
TNF α	mbsIgG2a-PD-L1 $\times$ 4-1BB + anti-mPD-1	vs	Anti-mPD-1	2.59	3.44
TNF α	mbsIgG2a-PD-L1 $\times$ 4-1BB + anti-mPD-1	vs	mbsIgG2a-PD-L1 $\times$ 4-1BB	1.97	1.87
IL-2	mbsIgG2a-PD-L1 $\times$ 4-1BB + anti-mPD-1	vs	mIgG2a-ctrl-AAKR	2.66	1.85

IL-2	mbslgG2a-PD-L1×4-1BB + anti-mPD-1	vs	Anti-mPD-1	2.87	2.87
IL-2	mbslgG2a-PD-L1×4-1BB + anti-mPD-1	vs	mbslgG2a-PD-L1×4-1BB	1.39	1.17
IP-10	mbslgG2a-PD-L1×4-1BB + anti-mPD-1	vs	mIgG2a-ctrl-AAKR	3.54	6.41
IP-10	mbslgG2a-PD-L1×4-1BB + anti-mPD-1	vs	Anti-mPD-1	4.70	4.94
IP-10	mbslgG2a-PD-L1×4-1BB + anti-mPD-1	vs	mbslgG2a-PD-L1×4-1BB	1.41	1.48

CLAIMS

1. A binding agent for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject the binding agent prior to, simultaneously with, or after administration of an antibody binding to Programmed Death-1 (PD-1), or an antigen-binding fragment thereof,
 5 wherein
 the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1;
 10 a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively;
 and
 15 b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively
 and
 20 the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively; or the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ
 25 ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.
2. The binding agent for use according to claim 1, wherein the antibody binding to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable region comprising an
 30 amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 50.
3. The binding agent for use of anyone of the preceding claims, wherein the antibody binding to
 35 PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 50.

4. The binding agent for use of any one of the preceding claims, wherein the antibody binding to PD-1 or the antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 51 and a light chain comprising the amino acid sequence of SEQ ID NO: 52.
5. The binding agent for use of any one of the preceding claims, wherein the antibody binding to PD-1 is pembrolizumab or a biosimilar thereof.
6. The binding agent for use of any one of the preceding claims, wherein PD-L1 is human PD-L1, in particular human PD-L1 comprising the sequence set forth in SEQ ID NO: 40, and/or CD137 is human CD137, in particular human CD137 comprising the sequence set forth in SEQ ID NO: 38.
7. The binding agent for use of any one of the preceding claims, wherein the first binding region of the binding agent comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 or 9 and a light chain variable region (VL) region and comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 5 or 10.
8. The binding agent for use of any one of the preceding claims, wherein the second binding region of the binding agent comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 11 and a light chain variable region (VL) region comprising an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to SEQ ID NO: 15.
9. The binding agent for use of any one of the preceding claims, wherein the first binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 1 or 9 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 5 or 10.
10. The binding agent for use of any one of the preceding claims, wherein the second binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 11 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 15.

11. The binding agent for use of any one of the preceding claims, wherein
- 5 a) the first binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 5;
- and
- 10 b) the second binding region of the binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 11 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 15.
12. The binding agent for use of any one of the preceding claims, wherein the binding agent is a multispecific antibody, such as a bispecific antibody.
- 15 13. The binding agent for use of any one of the preceding claims, wherein the binding agent is in the format of a full-length antibody or an antibody fragment.
14. The binding agent for use of any one of the preceding claims, wherein each variable region comprises three complementarity determining regions (CDR1, CDR2, and CDR3) and four
20 framework regions (FR1, FR2, FR3, and FR4).
15. The binding agent for use of claim 13, wherein said complementarity determining regions and said framework regions are arranged from amino-terminus to carboxy-terminus in the following
25 order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
16. The binding agent for use of any one of the preceding claims, wherein the binding agent comprises
- 30 i) a polypeptide comprising, consisting of or consisting essentially of, said first heavy chain variable region (VH) and a first heavy chain constant region (CH), and
- ii) a polypeptide comprising, consisting of or consisting essentially of, said second heavy chain variable region (VH) and a second heavy chain constant region (CH).
17. The binding agent for use of any one of the preceding claims, wherein the binding agent comprises
- 35 i) a polypeptide comprising said first light chain variable region (VL) and further comprising a first light chain constant region (CL), and

- ii) a polypeptide comprising said second light chain variable region (VL) and further comprising a second light chain constant region (CL).

18. The binding agent for use of any one of the preceding claims, wherein the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises

- i) a polypeptide comprising said first heavy chain variable region (VH) and a first heavy chain constant region (CH), and
- ii) a polypeptide comprising said first light chain variable region (VL) and a first light chain constant region (CL);

and the second binding arm comprises

- iii) a polypeptide comprising said second heavy chain variable region (VH) and a second heavy chain constant region (CH), and
- iv) a polypeptide comprising said second light chain variable region (VL) and a second light chain constant region (CL).

19. The binding agent for use of any one of the preceding claims, wherein the binding agent comprises

- i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, and
- ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1.

20. The binding agent for use of any one of the preceding claims, wherein said binding agent comprises

- i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, the first heavy chain comprising a first heavy chain constant region and the first light chain comprising a first light chain constant region; and
- ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1, the second heavy chain comprising a second heavy chain constant region and the second light chain comprising a second light chain constant region.

21. The binding agent for use of any one of claims 16-20, wherein each of the first and second heavy chain constant regions (CH) comprises one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region and a CH3 region.

22. The binding agent for use of any one of claims 16-21, wherein each of the first and second heavy chain constant regions (CHs) comprises a CH3 region and wherein the two CH3 regions comprise asymmetrical mutations.
- 5 23. The binding agent for use of any one of claims 16-21, wherein in said first heavy chain constant region (CH) at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and in said second heavy chain constant region (CH) at least one of the amino acids in a position corresponding to a position
10 selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein said first and said second heavy chains are not substituted in the same positions.
- 15 24. The binding agent for use of claim 23, wherein (i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first heavy chain constant region (CH), and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second heavy chain constant region (CH), or (ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first heavy chain, and the amino acid in the position
20 corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second heavy chain.
25. The binding agent for use of any of the preceding claims, wherein said binding agent induces Fc-mediated effector function to a lesser extent compared to another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CHs) comprising human IgG1 hinge, CH2 and CH3 regions.
25
26. The binding agent for use of claim 25, wherein said first and second heavy chain constant regions (CHs) are modified so that the antibody induces Fc-mediated effector function to a lesser
30 extent compared to an antibody which is identical except for comprising non-modified first and second heavy chain constant regions (CHs).
27. The binding agent for use of claim 26, wherein each of said non-modified first and second heavy chain constant regions (CHs) comprises the amino acid sequence set forth in SEQ ID NO: 19 or
35 25.

28. The binding agent for use of claim 26 or 27, wherein said Fc-mediated effector function is measured by binding to Fc γ receptors, binding to C1q, or induction of Fc-mediated crosslinking of Fc γ receptors.
- 5 29. The binding agent for use of claim 28, wherein said Fc-mediated effector function is measured by binding to C1q.
30. The binding agent for use of any one of claims 25-29, wherein said first and second heavy chain constant regions have been modified so that binding of C1q to said antibody is reduced
10 compared to a wild-type antibody, preferably reduced by at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100%, wherein C1q binding is preferably determined by ELISA.
31. The binding agent for use of any one of the preceding claims, wherein in at least one of said
15 first and second heavy chain constant regions (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.
32. The binding agent for use of claim 31, wherein the positions corresponding to positions L234
20 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively, in said first and second heavy chains.
33. The binding agent for use of claim 31 or 32, wherein the positions corresponding to positions
25 L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first and second heavy chain constant regions (HCs).
34. The binding agent for use of any one of claims 31-33, wherein the positions corresponding to
30 positions L234 and L235 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F and E, respectively, and wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is R, or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is R, and the position corresponding to F405 in a human IgG1 heavy
35 chain according to EU numbering of the second heavy chain is L.

35. The binding agent for use of any one of claims 31-34, wherein the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F, E, and A, respectively, and wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain constant region is R, or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.
36. The binding agent for use of any one of claims 16-35, wherein the constant region of said first and/or second heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
- a) the sequence set forth in SEQ ID NO: 19 or 25 [IgG1-FC];
 - b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
 - c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).
37. The binding agent for use of any one of claims 16-36, wherein the constant region of said first or second heavy chain, such as the second heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
- a) the sequence set forth in SEQ ID NO: 20 or 26 [IgG1-F405L];
 - b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
 - c) a sequence having at most 9 substitutions, such as at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).
38. The binding agent for use of any one of claims 16-36, wherein the constant region of said first or second heavy chain, such as the first heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
- a) the sequence set forth in SEQ ID NO: 21 or 27 [IgG1-K409R];

- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

39. The binding agent for use of any one of claims 16-15, wherein the constant region of said first and/or second heavy chain comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 22 or 28 [IgG1-Fc_FEA];
- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 7 substitutions, such as at most 6 substitutions, at most 5, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

40. The binding agent for use of any one of claims 16-39, wherein the constant region of said first and/or second heavy chain, such as the second heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 24 or 30 [IgG1-Fc_FEAL];
- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 6 substitutions, such as at most 5 substitutions, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

41. The binding agent for use of any one of claims 16-40, wherein the constant region of said first and/or second heavy chain, such as the first heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 23 or 29 [IgG1-Fc_FEAR];
- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and

- c) a sequence having at most 6 substitutions, such as at most 5 substitutions, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

5 42. The binding agent for use of any one of the preceding claims, wherein said binding agent comprises a kappa (κ) light chain constant region.

43. The binding agent for use of any one of the preceding claims, wherein said binding agent comprises a lambda (λ) light chain constant region.

10

44. The binding agent for use of any one of the preceding claims, wherein said first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

15 45. The binding agent for use of any one of the preceding claims, wherein said second light chain constant region is a lambda (λ) light chain constant region or a kappa (κ) light chain constant region.

20 46. The binding agent for use of any one of the preceding claims, wherein said first light chain constant region is a kappa (κ) light chain constant region and said second light chain constant region is a lambda (λ) light chain constant region or said first light chain constant region is a lambda (λ) light chain constant region and said second light chain constant region is a kappa (κ) light chain constant region.

25 47. The binding agent for use of any one of claims 42-46, wherein the kappa (κ) light chain comprises an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO:35,
- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

30

35 48. The binding agent for use of any one of claims 43-47, wherein the lambda (λ) light chain comprises an amino acid sequence selected from the group consisting of

- a) the sequence set forth in SEQ ID NO: 36,

- b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
- c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

49. The binding agent for use of any one of the preceding claims, wherein the binding agent is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

50. The binding agent for use of any one of the preceding claims, wherein the binding agent is a full-length IgG1 antibody.

51. The binding agent for use of any one of the preceding claims, wherein the binding agent is an antibody of the IgG1m(f) allotype.

52. The binding agent for use of any one of the preceding claims, wherein the binding agent comprises

- i) a first heavy chain and light chain comprising said antigen-binding region capable of binding to CD137, wherein the first heavy chain comprising the sequence set forth in SEQ ID NO: 31, and the first light chain comprising the sequence set forth in SEQ ID NO: 32;
- ii) a second heavy chain and light chain comprising said antigen-binding region capable of binding PD-L1, wherein the second heavy chain comprising the sequence set forth in SEQ ID NO: 33, and the second light chain comprising the sequence set forth in SEQ ID NO: 34.

53. The binding agent for use according to any one of the preceding claims, wherein the binding agent is acasunlimab or a biosimilar thereof.

54. The binding agent for use according to any one of the preceding claims, wherein the binding agent is in a composition or formulation comprising histidine, sucrose and Polysorbate-80, and has a pH from 5 to 6.

55. The binding agent for use according to any one of the preceding claims, wherein the binding agent is in a composition or formulation comprising about 20 mM histidine, about 250 mM Sucrose, about 0.02% Polysorbate-80, and having a pH of about 5.5.

56. The binding agent for use according to any one of the preceding claims, wherein the binding agent is in a composition or formulation comprising 10-30 mg binding agent/mL, such as 20 mg binding agent/mL.
57. The binding agent for use according to any one of the preceding claims, wherein the binding agent is in a composition as defined in any one of claims 54 to 56 and is diluted in 0.9% NaCl (saline) prior to administration.
58. The binding agent for use of any one of the preceding claims, wherein the subject is a human subject.
59. The binding agent for use of any one of the preceding claims, wherein the tumor or cancer is a solid tumor or cancer.
60. The binding agent for use according to any one of the preceding claims, wherein said tumor is a PD-L1 positive tumor.
61. The binding agent for use of any one of the preceding claims, wherein the tumor or cancer is selected from the group consisting of melanoma, ovarian cancer, lung cancer (*e.g.*, non-small cell lung cancer (NSCLC)), colorectal cancer, head and neck cancer, gastric cancer, breast cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, pancreatic cancer, hepatic cancer, thymoma and thymic carcinoma, brain cancer, glioma, adrenocortical carcinoma, thyroid cancer, other skin cancers, sarcoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes, endometrial cancer, prostate cancer, penile cancer, cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Merkel cell carcinoma and mesothelioma.
62. The binding agent for use according to any one of the preceding claims, wherein the tumor or cancer is selected from the group consisting of lung cancer (*e.g.* non-small cell lung cancer (NSCLC), urothelial cancer (cancer of the bladder, ureter, urethra, or renal pelvis), endometrial cancer (EC), breast cancer (*e.g.* triple negative breast cancer (TNBC)) and squamous cell carcinoma of the head and neck (SCCHN) (*e.g.* cancer of the oral cavity, pharynx or larynx)..
63. The binding agent for use of claim 61 or 62, wherein the tumor or cancer is lung cancer, in particular a non-small cell lung cancer (NSCLC), such as a squamous or non-squamous NSCLC.

64. The binding agent for use of any one of claims 61 to 63, wherein the tumor or cancer is metastatic, such as metastatic NSCLC.
- 5 65. The binding agent for use of claim 61 to 64, wherein the lung cancer, in particular NSCLC, does not have an epidermal growth factor (EGFR)-sensitizing mutation and/or anaplastic lymphoma (ALK) translocation / ROS1 rearrangement.
- 10 66. The binding agent for use of any one of claims 61 to 65, wherein the lung cancer, in particular NSCLC, comprises cancer cells and PD-L1 is expressed in $\geq 1\%$ of the cancer cells or tumor cells e.g. as assessed by immunohistochemistry (IHC).
- 15 67. The binding agent for use of claim 66, wherein the lung cancer, in particular NSCLC, comprises cancer cells and PD-L1 is expressed in 1% to 49% of the cancer cells or tumor cells e.g. as assessed by immunohistochemistry (IHC).
68. The binding agent for use of claim 66, wherein the lung cancer, in particular NSCLC, comprises cancer cells and PD-L1 is expressed in $\geq 50\%$ of the cancer cells or tumor cells e.g. as assessed by immunohistochemistry (IHC).
- 20 69. The binding agent for use of the preceding claims, wherein the subject has not received prior systemic treatment of metastatic disease.
- 25 70. The binding agent for use of any one of the preceding claims, wherein the subject has not received prior treatment with a checkpoint inhibitor; e.g., a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti- PD-1 antibody or an anti-PD-L1 antibody.
- 30 71. The binding agent for use of any one of the preceding claims, wherein the subject has not received prior treatment with a 4-1BB (CD137) targeted agent, such as an anti-4-1BB (CD137) antibody, with an antitumor vaccine, or with autologous cell immunotherapy.
72. The binding agent for use of any one of claims 1 to 68, wherein the tumor or cancer has relapsed and/or is refractory after treatment, such as systemic treatment with a checkpoint inhibitor.
- 35 73. The binding agent for use of any one of claims 1 to 68 and 72, wherein the subject has received at least 1 prior line of systemic therapy, such as systemic therapy comprising a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody.

74. The binding agent for use of any one of claims 1 to 68, 72 and 73, wherein the cancer or tumor has relapsed and/or is refractory, or the subject has progressed after treatment with a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy.
75. The binding agent for use of any one of claims 1 to 68 and 72 to 74, wherein last prior treatment was with a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy.
76. The binding agent for use of any one of claims 1 to 68 and 72 to 74, wherein the time from progression on last treatment with a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody is 8 months or less, such as 7 months or less, 6 months or less, 5 months or less, 4 months or less, 3 months or less, 2 months or less, 1 month or less, 3 weeks or less or such as 2 weeks or less.
77. The binding agent for use of any one of claims 1 to 68 and 72 to 74, wherein the time from last dosing of a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody as part of last prior treatment is 8 months or less, such as 7 months or less, 6 months or less, 5 months or less, 4 months or less, 3 months or less, 2 months or less, 1 month or less, 3 weeks or less or such as 2 weeks or less.
78. The binding agent for use of any one of claims 1 to 68 and 72 to 74, wherein the cancer or tumor has relapsed and/or is refractory, or the subject has progressed during or after
- i) platinum doublet chemotherapy following treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody, or
 - ii) treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody following platinum doublet chemotherapy.
79. The binding agent for use of any one of the preceding claims, wherein the subject has not received prior treatment with a taxane chemotherapeutic agent e.g., docetaxel, such as prior treatment of NSCLC with a taxane chemotherapeutic agent e.g., docetaxel.
80. The binding agent for use of any one of the preceding claims, wherein the binding agent and the antibody binding to PD-1, or the antigen-binding fragment thereof are administered in at least one treatment cycle, each treatment cycle being three weeks (21 days) or six weeks (42 days).

- 5
81. The binding agent for use of any one of the preceding claims, wherein one dose of the binding agent and one dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every third week (1Q3W).
82. The binding agent for use of any one of the preceding claims, wherein one dose of the binding agent and one dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every six weeks (1Q6W).
- 10 83. The binding agent for use of any one of the preceding claims, wherein one dose of the binding agent and one dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered on day 1 of each treatment cycle.
- 15 84. The binding agent for use of any one of the preceding claims, wherein the amount of said binding agent administered in each dose and/or in each treatment cycle is 100 mg.
85. The binding agent for use of any one of the preceding claims, wherein the amount of said antibody binding to PD-1, or the antigen-binding fragment thereof administered in each dose and/or in each treatment cycle is 200 mg.
- 20 86. The binding agent for use of any one of the preceding claims, wherein the amount of said antibody binding to PD-1, or the antigen-binding fragment thereof administered in each dose and/or in each treatment cycle is 400 mg.
- 25 87. The binding agent for use of any one of the preceding claims, wherein a 100 mg dose of the binding agent and a 200 mg dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every three weeks (1Q3W).
- 30 88. The binding agent for use of any one of the preceding claims, wherein a 100 mg dose of the binding agent and a 400 mg dose of the antibody binding to PD-1, or the antigen-binding fragment thereof are administered every six weeks (1Q6W).
- 35 89. The binding agent for use of any one of the preceding claims, wherein the tumor or cancer is NSCLC; and wherein a 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 200 mg dose of the antibody binding to PD-1, which is pembolizumab, are administered every three weeks (1Q3W), such as on day one of each three-week treatment cycle.

90. The binding agent for use of any one of claims 1-88, wherein the tumor or cancer is NSCLC; and wherein a 100 mg dose of the binding agent, which is acasunlimab or a biosimilar thereof and a 400 mg dose of the antibody binding to PD-1, which is pembolizumab, are administered every six weeks (1Q6W), such as on day one of every six-week treatment cycle.

5

91. The binding agent for use of any one of the preceding claims, wherein the antibody binding to PD-1, or the antigen-binding fragment thereof is administered first, followed by the binding agent.

10 92. The binding agent for use of any one of the preceding claims, wherein the binding agent is administered by using intravenous (IV) infusion over a minimum of 30 minutes, such as over a minimum of 60 minutes.

15 93. The binding agent for use of any one of the preceding claims, wherein the binding agent is administered by using intravenous (IV) infusion over 30 minutes.

94. The binding agent for use of any one of the preceding claims, wherein the PD-1 inhibitor is administered as an intravenous infusion over 30 minutes.

20 95. A kit comprising
(i) a binding agent comprising a first binding region binding to CD137 and a second binding region binding to PD-L1

25 a) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively,

30 b) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively,

and

35 (ii) an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 62, 63 and 64, respectively, and a

light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

96. The kit according to claim 95, wherein the binding agent and/or the antibody binding to PD-1, or the antigen-binding fragment thereof is as defined in any one of claims 1 to 94.

97. The kit according to claim 95 or 96, wherein the binding agent, and the antibody binding to PD-1, or the antigen-binding fragment thereof are for systemic administration, in particular for injection or infusion, such as intravenous injection or infusion.

98. The kit according to any one of claims 95-97 for use in a method for reducing or preventing progression of a tumor or treating cancer in a subject.

99. The kit for use according to claim 98, wherein the tumor or cancer and/or the subject and/or the method is/are as defined in any one of claims 1-94.

100. A method for reducing or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject a binding agent prior to, simultaneously with, or after administration of an antibody binding to PD-1, or an antigen-binding fragment thereof, wherein the binding agent comprises a first binding region binding to CD137 and a second binding region binding to PD-L1

c) the first binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 6, 7, and 8, respectively;

and

d) the second antigen-binding region comprising a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 12, 13, and 14, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 16, 17, and 18, respectively

and

wherein the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NO: 43, 44 and 45, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 46, 47 and 48, respectively, or the antibody binding to PD-1 comprises a heavy chain variable region (VH) comprising the CDR1, CDR2 and CDR3 sequences set forth

in SEQ ID NO: 62, 63 and 64, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 65, 66 and 67, respectively.

101. The method of claim 100, wherein the tumor or cancer and/or the subject and/or the method
5 and/or the binding agent and/or the PD-1 inhibitor is/are as defined in any one of claims 1-94.



Figure 1**A. PD1-mediated T cell inhibition****B. PD-L1-blockade + T cell co-stimulation**

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11






Figure 12**A. CD3/CD28 stimulation**

Figure 12 continued

C.




Figure 13




Figure 14




Figure 15





Figure 16

○ naive mice (n=6)

■ rechallenge CR mice (n=4): mbslgG2a-PD-L1×4-1BB (5 mg/kg) + anti-mPD-1 (10 mg/kg)


Figure 17

Figure 18





Figure 19



INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2022/077749

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61P35/00 C07K16/28
ADD. A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61P A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MELERO IGNACIO ET AL: "MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody -PD-L1x4-1BB (GEN1046) in advanced solid tumors", ANNALS OF ONCOLOGY, vol. 32, 1 July 2021 (2021-07-01), page S313, XP93008861, NL ISSN: 0923-7534, DOI: 10.1016/j.annonc.2021.05.625 the whole document ----- -/--	1-101



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 January 2023

Date of mailing of the international search report

06/02/2023

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Siaterli, Maria

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2022/077749

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	AIX SANTIAGO PONCE ET AL: "516?Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody -PD-L1x4-1BB (GEN1046) trial", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. Suppl 2, 1 November 2021 (2021-11-01), pages A546-A546, XP093007997, DOI: 10.1136/jitc-2021-SITC2021.516 Retrieved from the Internet: URL:https://jitc.bmj.com/content/jitc/9/Suppl_2/A546.full.pdf> the whole document -----	1-101
X	GARRALDA ELENA ET AL: "412?First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody -PD-L1x4-1BB (GEN1046) in patients with advanced solid tumors", REGULAR AND YOUNG INVESTIGATOR AWARD ABSTRACTS, 1 November 2020 (2020-11-01), pages A250-A251, XP055949469, DOI: 10.1136/jitc-2020-SITC2020.0412 the whole document -----	1-101
X	WO 2021/156326 A1 (GENMAB AS [DK]; BIONTECH SE [DE]) 12 August 2021 (2021-08-12) page 33, line 11 - line 21; examples 6-12 -----	1-101
X	Anonymous: "Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor", EU Clinical Trials Register, 9 July 2021 (2021-07-09), pages 1-7, XP093007858, Retrieved from the Internet: URL:https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001928-17/ES [retrieved on 2022-12-13] paragraph [2.1.1.1] paragraph [03.8] ----- -/--	1-101

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2022/077749

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Hanmi Beijing ET AL: "Total WBC Lymphocyte Count Platelet Count BH3120: A Novel Bispecific Antibody Targeting 4-1BB and PD-L1 with Well Balanced Efficacy and Safety Profiles", Clin Cancer Res Apr Cell Death Differ, 1 January 2017 (2017-01-01), pages 1929-19361187, XP093006444, Retrieved from the Internet: URL:https://www.hanmipharm.com/ehanmi/img/rnd/pipeline/2022_AACR_BH3120_Poster_Final.pdf [retrieved on 2022-12-09] the whole document middle column -----	1-101
X,P	Anonymous: "Study NCT05117242 Submitted Date: December 22, 2021 (v4)", clinicaltrials.gov, 23 December 2021 (2021-12-23), pages 1-5, XP055955439, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history/NCT05117242?V_4=View#StudyPageTop [retrieved on 2022-08-26] page 3 the whole document -----	1-101

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2022/077749

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed.
 - b. ☐ furnished subsequent to the international filing date for the purposes of international search (Rule 13*ter*.1(a)).

☐ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.
2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/077749

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2021156326 A1	12-08-2021	AU 2021215332 A1	18-08-2022
		BR 112022015151 A2	20-12-2022
		CA 3169963 A1	12-08-2021
		CN 115135344 A	30-09-2022
		EP 4100059 A1	14-12-2022
		IL 294967 A	01-09-2022
		KR 20220137054 A	11-10-2022
		WO 2021156326 A1	12-08-2021
